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mitochondrial insults. A large proportion of this work is based on the generation of stable isotope labelled
metabolites to allow for the rigorous quantification of intracellular metabolites by liquid chromatographymass spectrometry. Once developed, this methodology was employed in cell culture models initially to
characterize an unidentified acyl-CoA thioester induced by propionate metabolism. This novel pathway
was identified as the direct formation of 2-methyl-2-pentenoyl-CoA, and using isotopic labeling by
metabolic precursors served as a critical component to this pathway elucidation. These same techniques
were then applied to studying rotenone, a mitochondrial complex I inhibitor associated with
Parkinsonâ??s disease. Previous work by our group has shown that rotenone inhibits components of
glucose metabolism. As demonstrated in this thesis, lipid oxidation and glutamine anaplerosis serve as
important compensatory mechanisms in this setting. Furthermore, chiral analysis of 2-hydroxyglutarate, a
metabolite linked to glutamine metabolism, revealed stereospecific alterations in response to rotenone.
These previously unknown metabolic adaptations induced by rotenone may contribute to neurological
phenotypes resulting from diminished complex I activity. Finally, a collaborative effort was initiated to
study metabolic defects in Friedreichâ??s ataxia, a genetic disease suspected to occur, in part, due to
deficiencies in mitochondrial complex I. Utilizing isolated platelets in combination with isotopic labeling it
was shown that Friedreichâ??s ataxia patients exhibit diminished glucose metabolism with a concomitant
increase in lipid oxidation. Taken together these findings suggest adaptations to glucose and lipid
metabolism are metabolic characteristics resulting from disrupted mitochondrial function across multiple
models, and description of these disruptions gives insight into basic metabolic biotransformation,
toxicology, and etiology of poorly understood diseases.
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ABSTRACT

LIQUID CHROMATOGRAPHY- MASS SPECTROMETRY ANALYSIS OF
MITOCHONDRIAL DYSFUNCTION: IMPLICATIONS FOR ROTENONE
TOXICITY AND FRIEDREICH’S ATAXIA
Andrew J. Worth
Ian A. Blair, PhD
Mitochondrial dysfunction plays a role in a wide range of diseases resulting in an
enormous public health burden. The goal of this thesis is to identify metabolic pathways
that are disrupted in response to mitochondrial insults. A large proportion of this work is
based on the generation of stable isotope labelled metabolites to allow for the rigorous
quantification of intracellular metabolites by liquid chromatography-mass spectrometry.
Once developed, this methodology was employed in cell culture models initially to
characterize an unidentified acyl-CoA thioester induced by propionate metabolism. This
novel pathway was identified as the direct formation of 2-methyl-2-pentenoyl-CoA, and
using isotopic labeling by metabolic precursors served as a critical component to this
pathway elucidation. These same techniques were then applied to studying rotenone, a
mitochondrial complex I inhibitor associated with Parkinson’s disease. Previous work by
our group has shown that rotenone inhibits components of glucose metabolism. As
demonstrated in this thesis, lipid oxidation and glutamine anaplerosis serve as important
compensatory mechanisms in this setting. Furthermore, chiral analysis of 2hydroxyglutarate, a metabolite linked to glutamine metabolism, revealed stereospecific
alterations in response to rotenone. These previously unknown metabolic adaptations
v

induced by rotenone may contribute to neurological phenotypes resulting from
diminished complex I activity. Finally, a collaborative effort was initiated to study
metabolic defects in Friedreich’s ataxia, a genetic disease suspected to occur, in part, due
to deficiencies in mitochondrial complex I. Utilizing isolated platelets in combination
with isotopic labeling it was shown that Friedreich’s ataxia patients exhibit diminished
glucose metabolism with a concomitant increase in lipid oxidation. Taken together these
findings suggest adaptations to glucose and lipid metabolism are metabolic characteristics
resulting from disrupted mitochondrial function across multiple models, and description
of these disruptions gives insight into basic metabolic biotransformation, toxicology, and
etiology of poorly understood diseases.
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Chapter 1: Introduction

1.1 Mitochondrial metabolism and Coenzyme A
Mitochondrial dysfunction is a well-established factor in many different diseases
(1). Specifically, neurodegenerative diseases (2), cancer (3), cardiovascular disease (4),
and aging (5) are all thought to be initiated or propagated in part through mitochondrial
dysfunction. This association affords the opportunity to interrogate cellular processes
specific to mitochondria in hopes of further characterizing pathological factors. Of note,
the mitochondrial matrix is the primary cellular site of oxidative metabolism. As a result
oxidative has received significant attention as playing an important role in these diseases.
Although commonly attributed to oxidative insults, the underlying pathology
could result in part from perturbed mitochondrial metabolic processes (2). This means
that there is a continuing need to further our understanding of the relationship between
mitochondrial metabolism and disease pathogenesis. By expanding our understanding of
the metabolic adaptations arising from disrupted mitochondrial metabolism, we are likely
to shed light on unknown factors that may play a role in the development of a wide range
of diseases. Specifically, this approach will likely offer a synergistic approach with
conventional antioxidant approaches to disease prevention (6).
Mitochondria are cellular organelles that serve as the main site of ATP production
(1). Given this important role in sustaining energy-dependent functions, mitochondria are
often referred to as the “powerhouse” of the cell. The processes by which ATP is
1

produced are complex, involving an intricate network of metabolic pathways that is
adaptable to different sources of carbon (Figure 1.1). Glucose, glutamine, and fatty acids
are among the major carbon-providing nutrients, which are ultimately shuttled to the
mitochondrial matrix to sustain the required energy production. The catabolic processing
of these nutrients and others like them result in the production of reducing equivalents,
primarily NADH and FADH2. The electrons derived from these reduced cofactors are
subsequently shuttled down a series of electron transferring protein complexes, which, as
a whole, make up the electron transport chain (ETC). In aerobic respiration, this process
ultimately leads to the reduction of oxygen, forming water. Importantly, the energy
released throughout this process is converted into an electrochemical gradient across the
inner-mitochondrial membrane. This gradient is utilized for mitochondrial ATP
synthesis. This entire process is known as oxidative phosphorylation or OX-PHOS and is
essential to sustaining the vast majority of life as we know it.
The metabolic processes by which NADH and FADH2 can be produced are numerous but
intricately connected. As a result, cellular metabolic pathways are often depicted as an
intertwined roadmap. The diversity and complicated nature of the catabolic processing of
these nutrients is balanced by the evolutionarily conserved ubiquitous requirement of
Coenzyme A (CoA) as an activated acyl-carrier (Figure 1.1) (7). Derived from the
vitamin B5 pantothenic acid, CoA thioesters act as acyl-carriers of activated carboxylic
acids. Vitamin B5 is an essential nutrient to mammals, but can be synthesized from
precursors in lower organisms (8), thus emphasizing the importance of this carrier to
biochemical processes. Produced from the condensation of carboxylic acids with free
2

Figure 1.1: Schematic of the Krebs cycle, electron transport chain, and related
mitochondrial metabolic pathways.
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thiol groups such as the one present on free CoA (CoASH), thioester bonds have
inherently high bond energies, making them relatively unstable. This high potential
energy facilitates the transfer of the acyl group from acyl-CoA species to substrates,
making it an energetically favorable process. For example, protein acetylation is an
important regulatory post-translational modification and is understood to be dependent
almost entirely on acetyl-CoA as a substrate as opposed to free acetate (9). In addition to
protein modifications, acyl-CoAs are ubiquitous in cellular metabolism and are directly
utilized by metabolic enzymes (Figure 1.1).
CoA thioesters are required for the Krebs cycle, fatty acid metabolism (βoxidation and synthesis), cholesterol metabolism, as well as many amino acid
degradation pathways (Figure 1.1). Of particular interest for this work, acetyl- and
succinyl-CoA are metabolites within the Krebs cycle in the mitochondrial matrix. AcetylCoA serves as a major entry point into the Krebs cycle, as citrate synthase catalyzes the
combination of acetyl-CoA and oxaloacetate to form citrate. Succinyl-CoA also plays an
important role in Krebs cycle anaplerosis (10). For example, odd chain fatty acid
oxidation results in the production of propionyl-CoA (11), which can then be
carboxylated to form (S)-methylmalonyl-CoA, an isomer and precursor to succinyl-CoA
through the intermediate formation of (R)-methylmalonyl-CoA. Thus, by interrogating
metabolic defects through analysis the analysis of acetyl- and succinyl-CoA, catabolism
of glucose, odd and even chain fatty acids, and many amino acids can be assessed.
Expanding the analysis to a wider range of acyl-CoA species sheds additional light on
pathways such as these.
4

In addition to playing an essential role in the synthesis and breakdown of a wide
range of metabolites, free non-acylated CoA (CoASH) is important for the detoxification
of xenobiotics and other potentially harmful moieties (12,13). For example, thiolcontaining compounds such as glutathione and CoASH are critical to combatting
oxidative insults to cells and tissues (14). Furthermore, CoASH is largely localized to
mitochondria and thus is necessary to balancing the mitochondrial redox state. This dual
role of CoA species in both mitochondrial energy metabolism and maintaining redox
state makes their analysis a powerful tool in understanding cellular responses to
pathological factors ultimately leading to disease. Thus assessing acyl-CoA profiles
serves as a powerful technique in determining adaptations in cellular metabolism.
Unfortunately, due to instability as well as analytical difficulties, quantification of CoA
species has proved difficult in the past (15). Development and employment of
methodology capable of quantifying these analytes is necessary to expanding our
understanding of mitochondrial metabolism.
As noted above, mitochondrial dysfunction is clearly associated with a wide range
of diseases (1). In particular, neurodegenerative diseases with characteristic protein
aggregates such as Alzheimer’s and Parkinson’s disease (PD) have received extensive
attention and seem to be initiated in part by mitochondrial dysfunction (6). Furthermore,
oxidative damage has been implicated as a prerequisite to the formation of these
aggregates (2). For this reason great effort has been placed on understanding the role of
mitochondrial oxidative damage leading to cell death. The highly oxidative environment
of the mitochondrial matrix and the electron transferring components of the ETC make it
5

a leading intracellular site of reactive oxygen species (ROS) generation. Impairment of
the ETC and related components are known to increase the production of ROS which can
be harmful to the cell if they overrun endogenous protective antioxidant responses.
Antioxidants have been tested as a therapeutic approach for preventing the
initiation and development of neurodegenerative diseases. Unfortunately, to date these
approaches have not proved beneficial in a significant way (16) and to date, there is no
anti-oxidant driven approach to preventing neurodegenerative diseases. The lack of effect
from antioxidant supplementation is likely a result of insufficient delivery and efficacy.
Put simply, if built in antioxidant defense systems that are already at remarkably high
levels (4 mM for glutathione) are overrun within cells, it is not likely an external source
capable of combatting oxidative damage will lend much aid. One novel approach to
circumventing this issue is up-regulating cellular antioxidant defenses through chronic
administration of so called “soft” electrophilic compounds. Dimethylfumarate, a recently
approved FDA drug for multiple sclerosis, is one such example (17).
Neurodegeneration is a multifaceted phenomenon in which many factor are likely
to lead to cell death (2). In addition to oxidative stress resulting from mitochondrial
dysfunction, it is likely that mitochondrial metabolism can be a target for preventing or
diminishing the effects of neurodegeneration. Targeting of the mitochondria is not unique
to neurodegeneration, and lessons from other fields may be informative as to successful
approaches. As an example, cancer metabolism has received renewed interest as a target
for specific therapeutics (18). Once thought to arise from defective mitochondria, the
unique metabolic profiles of cancer cells are now understood to be a reprogramming to
6

provide a growth advantage (3). While the goal for cancer is to inhibit cell proliferation,
the opposite approach may be beneficial for preventing neuronal cell death. Genetic or
external factors leading to neuronal cell death may modulate specific metabolic
pathways. For example, one finding reported from our group is that increased lipid
breakdown is a result of impaired mitochondrial function (19). Targeting lipid catabolism
may therefore be a novel approach to preventing neuronal cell death. Furthermore,
targeting cellular metabolism through approaches such as dietary supplementation in
combination with antioxidant approaches may have a positive synergistic effect.
Given the central role mitochondrial function plays in the development of
neurodegenerative diseases it is imperative to expand our understanding of the metabolic
adaptations arising from disrupted mitochondrial metabolism. Doing so is likely to shed
light on unknown factors that may play a role in the development of a wide range of
diseases and thus will provide novel therapeutic targets.
1.2 Liquid chromatography – mass spectrometry
Identification of perturbations to mitochondrial metabolism requires a platform
with high sensitivity and specificity. Liquid chromatography coupled with mass
spectrometry (LC-MS) is often considered the predominant technique for quantitative
analysis of low abundance compounds from complex biological matrices (20).
Development and application of a full LC-MS workflow entails many steps beginning
with the extraction. Whether working from serum, urine, tissue, or cell samples, the goal
of the extraction is to isolate the analytes of interest while removing as much unwanted
7

material that could interfere with measurement as possible. A more thorough sample
extraction and clean-up is likely to result in a more robust and reproducible LC-MS
method. A few examples of sample preparation methods include protein precipitations, as
well as extractions based in both the liquid and solid phase. The optimal approach to
sample preparation is based largely on the physiochemical properties of the metabolites
of interest.
LC-MS is a powerful method for the analysis of endogenous analytes because the
initial chromatographic separation enables time-resolution, which further isolates the
analyte of interest from other interfering compounds that are co-extracted from biological
matrices. LC operates by pumping mobile phase through the column under high
pressures. Samples are injected into the flow of the system to be loaded onto the column.
Based on the chemistry of analyte and stationary phase within the column compounds
interact and are retained. As the composition of the mobile phase being run through the
column is modified metabolites begin to move down the column. The time and rate at
which this occurs is specific to a given compounds, thus some analytes are retained
longer than others. In this manner time-based separations can be achieved prior to MS
analysis.
There is a wide range of MS instrumentation, but for the current thesis studies, the
primary platform was a triple quadrupole (QqQ) mass spectrometer, which will be briefly
described here (Figure 1.2). At its most fundamental level, MS operates by detecting
ions. Once extracted and run through the LC column, solvents are evaporated and
analytes are converted to gas phase ions by one of several mechanisms. The ions are then
8

Figure 1.2: Depiction of a triple quadrupole mass spectrometer operating in selected reaction
monitoring mode.
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introduced into the mass spectrometer at which point they can be selected based on their
mass to charge ratio (m/z). The quadrupole within a mass spectrometer consists of
hyperbolic rods capable of alternating currents, which modulates the flight path of ions
passing between the rods. The physics of ions traveling in high vacuum are understood
and predictable, and for this reason modulating the applied current can be done in a way
that particular m/z values are selected for and allowed to pass through, while all other
ions are filtered out.
The majority of analyses on a triple quadruple mass spectrometer are performed
in the selected reaction monitoring (SRM) mode (Figure 1.2). This approach utilizes the
ion filtering capabilities of 2 separate quadrupoles (Q1 and Q3) fitted with a Rf only
collision cell (Q2) between them. In this manner as a complex array of ions is introduced
into the mass spec a single precursor ion m/z can be selected for by Q1. Q2 allows the
selected ion to interact with collisions gases that fragment the ionized molecule. Q3 is
then able to select for a specific product ion m/z resulting from from the precursor ion m/z
allowed to pass through Q1. This Q1 to Q3 passage is known as a transition (precursor
ion to product ion), thus each analyte of interest is required to have at least 1 selected
reaction monitoring (SRM) transition with which it can be detected. The stringent
requirements for an analyte to be selected for by extraction and correct LC retention time,
as well as a specific precursor and product ion combination makes LC-SRM/MS a highly
specific bioanalytical platform.
By combining the selectivity and sensitivity afforded by the described LC-MS
methodology, a sensitive and specific analysis can be carried out on compounds of
10

interest. However, although powerful, LC-MS by itself it not a quantitative technique.
The ionization that occurs in the source of the mass spectrometer is a highly variable
process that is easily influenced by the environment in which it is occurring. One of the
greatest sources of variability is known as suppression of ionization. This phenomenon
occurs when an analyte of interest is passing through the source of the MS with other
compounds present. Competition for charge can lead to decreased analyte ionization,
which could be interpreted as the analyte being present at lower levels by the mass
spectrometer. This artifactual decrease in analyte abundance can lead to erroneous
experimental data if not properly controlled for. In rare cases, the inverse of suppression
can be observed, resulting in higher ionization efficiency due to source conditions. Ion
suppression, variability in chromatography, stability of analytes, and other often
unmeasurable variables can confound LC-MS analysis without additional controls.
To account for suppression and other factors that can cause variation in MS
analysis internal standards can be used to normalize the response across samples (20). For
LC-MS the ideal internal standard is a stable isotope labeled version of a given
compound. For example, the ideal internal standard for succinic acid is [13C4]-succinic
acid, differing only by 1 neutron in each of the 4 carbon atoms (Figure 1.3). In this
instance the internal standard is chemically identical with a 4 Da mass shift. Once added
at the beginning of the workflow, these chemically identical compounds go through all
steps of sample extraction, preparation, storage and analysis accounting for any losses or
modifications that may occur due to chemical instability or human error. While the
analyte and internal standard are chemically identical in all aspects of workflow and
11

clean up, they are completely distinct to a mass spectrometer, in which stable isotopes are
readily differentiable by virtue of mass selective detection. For this reason all quantitative
LC-MS outputs are expressed as a ratio to the representative stable isotope analog
internal standard. In this manner, reliable and robust quantification of intracellular
metabolites can be achieved, as any losses will track exactly with the internal standard,
leaving the ratio between the compounds unaltered. Of note, by running a calibration
curve with stock compounds in vary ratios to the internal standard, a plot of ratio against
known amount can be generated, enabling absolute quantification (Figure 1.2).
It is important to note that the closer an internal standard is chemically related to
an analyte of interest the better quantification can be performed. An exact match in
physiochemical characteristics relevant to the modes of separation used results in coelution of analyte and internal standard, as the two are indistinguishable on the LC
column. This is an ideal scenario ensuring any suppression that may be occurring will be
perfectly accounted for. While some compounds, such as succinic acid (Figure 1.3A), are
commercially available in isotopically labeled forms (Figure 1.3B), many are not. In
addition, the wide range of intracellular metabolites capable of being analyzed by MS
makes purchasing all of them financially impractical. CoA thioesters are among classes
of metabolites in which isotopically labeled forms are available for some, but not all. For
this reason great effort in this thesis has been placed on biosynthetically generating
heavy-isotope labeled acyl-CoA species, allowing for proper quantification in subsequent
experiments.

12

Figure 1.3: (A) Unlabeled succinic acid and (B) [13C4]-succinic acid. These structures differ
only in their isotopic composition.
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Another critical component to understanding cellular metabolisms and
compensatory metabolic actions is assessing the extent to which metabolic precursors are
utilized (21). MS enables probing metabolic pathways by following the incorporation of
labeled metabolic precursors into downstream metabolites. As opposed to absolute
quantification, in which we address the question of whether a metabolite pool is going up
or down, stable isotope tracers enable the assessment of from where and to what extent a
metabolite is being derived. The most complete understanding of cellular metabolism can
be achieved by combining mass isotopologue distribution (MID) analysis with absolute
quantification. Isotopologues are isotopic analogs, whereby the exact same chemical
structure differs only in the number of heavy isotopes present. Although often confused
in the literature, isotopomers are isotopic isomers in which the same number of isotopes
are present, though they differ in positions within the chemical structure. An example of
isotopomers is 1-[13C1]- and 2-[13C1]-succinic acid, whereas an example of isotopologues
is 1-[13C1]- and 1,2-[13C2]-succinic acid (Figure 1.4). All work presented in this thesis is
based on isotopologue analysis, in which differing mass shifts are assessed. Isotopomer
analysis is sometimes possible with MS, depending upon the fragmentation pattern of a
given analyte, but is compound and platform specific.
1.3 Overview
I would like to conclude this introduction by giving a brief overview of the
following chapters. In particular I want to emphasize the relationship and flow between
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Figure 1.4: Representation of isotopologues and isotopomers.
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each component of this project. My approach has been to first develop the methodology
required to address alterations in mitochondrial metabolism that have never before been
identified. Once developed, these methods were then applied to cell culture models in
which the environment could be controlled such that the source of compensatory
metabolic adaptations could be elucidated. Finally we went to a novel clinical model of
mitochondrial dysfunction with the intention of validating our findings from cell culture
in a model more directly relevant to human health.
Chapters 2-4 of this thesis describe the development and implementation of the
tools required to interrogate chemical and genetic insults to mitochondrial function. In
particular, this includes development of an LC-MS method and a corresponding
extraction capable of analyzing a wide range of acyl-CoA species. In addition, a more
efficient and practical system than had been used previously for the generation acyl-CoA
internal standards was developed, allowing a much greater production of the needed
enriched metabolites.
Chapters 5 and 6 focus on the pesticide rotenone, a well-documented inhibitor of
mitochondrial complex I. Rotenone has received particular interest recently as
environmental exposures have been linked with an increased risk of PD. Animal studies
have also shown that rotenone is able to recapitulate Parkinsonian characteristics in
animal models and is used widely as a tool for studying the disease. A strong body of
literature indicates that inhibition of complex I by rotenone results in oxidative stress
which is largely responsible for the neurological manifestations of rotenone exposure. In
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addition to these concepts, we thought it likely that rotenone disrupts components of
mitochondrial metabolism and sought to identify these abnormalities.
The work described in chapter 7 was initiated in hopes of expanding cell culture
studies of mitochondrial dysfunction to a more clinically relevant system. To pursue this
concept, a collaboration was initiated with the Lynch lab at the Children’s Hospital of
Philadelphia. Dr. Lynch studies Friedreich’s ataxia, a genetic disease in which affected
individuals are deficient in a protein called frataxin. Frataxin is a mitochondrial enzyme
involved in the assembly of iron-sulfur clusters which are critical in many mitochondrial
processes such as the electron transport chain. For this reason mitochondrial dysfunction
is thought to play an important role in FRDA. In particular, diminished complex I activity
has been implicated in FRDA, thus we sought to identify similarities with my studies on
rotenone.
More specifically, chapter 2 of this thesis describes the development of LC-MS
methodology, which was critical for addressing the points raised previously. In particular,
there was a large unmet need for an LC-MS method capable of analyzing a wide range of
acyl-CoA species. The technology described in this chapter enables analysis of a panel of
analytes by LC-MS, which has never before been achieved. In particular, the method
allows for analysis of short, medium, and long-chain acyl-CoA species. Previous methods
developed in our lab were limited to acyl-CoA species of 6 carbons or less. Thus this new
method enables a much greater level of information. In addition to the LC-MS method
itself, this work also involved expanding the generation of isotopically labeled CoAs
beyond what had been previously achieved by our group.
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Chapter 3 expands upon the utilization of isotopically labeled acyl-CoA thioesters
by implementing a genetically engineered yeast line, which is auxotrophic for
pantothenic acid. In this manner the yeast cell line parallels mammalian systems that are
dependent on an external source of pantothenic acid for survival. By introducing labeled
pantothenic acid into the growth media the yeast cells generate isotopically enriched acylCoAs. This adaptation of earlier work within our group allows the internal standards to
be made with increased labeling efficiency and in vastly greater quantities. Essentially all
work involving CoASH and acyl-CoA internal standards in our group now uses the CoA
species generated by this method. Furthermore, the technology developed in this chapter
may be useful for generating other classes of internal standards from biological yeast
systems. Doing so, in theory, will only require various yeast strains to make them
dependent on an external supply of nutrients which can be administered in an isotopically
labeled form.
Chapter 4 describes a new metabolic pathway discovered by our group, which
required the use of the methodology described in chapters 2 and 3, as well as pathway
elucidation via the incorporation of isotopically labeled metabolic substrates. Although
not directly related to mitochondrial dysfunction, this pathway is relevant to
mitochondrial metabolism. Importantly, this work demonstrates the utility of the methods
developed by our group and how together they can be used to not only identify, but also
characterize previously unknown metabolites and pathways. In both human cell lines and
freshly isolated platelets we show that propionic acid is metabolized to a novel
monounsaturated 6-cabon acyl-CoA. This pathway was previously unrecognized in
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mammals, and represents a potentially large error in existing metabolic models.
Characterization of this acyl-CoA required inducing the heavy labeled form in the models
utilized in chapters 2 and 3. In this way co-elution studies and quantification was
possible. In addition, utilizing labeled propionate as a precursor, we were able to track
specific carbon labeling and devise the metabolic scheme in which the product is formed.
Doing so employed both
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C and

2

H labeling techniques. Thus the induction,

quantification, and characterization of this novel metabolic pathway was a result of the
culmination of the methodology developed in our lab. Importantly, these same
approaches were then used to characterize metabolic defects likely to have impacts on
human health in subsequent chapters. This work is an excellent example of how absolute
quantification and labeling can be used in combination to characterize metabolic
pathways more comprehensively than is possible with either approach alone. This
principle was employed in chapters 5 and 6.
Chapter 5 is based largely on previously published work from our group in which
rotenone was shown to diminish glycolytic incorporation into acetyl-CoA, and yet
paradoxically acetyl-CoA levels are maintained, indicating some type of compensatory
metabolic adaptation must be occurring. By employing the techniques developed in
chapters 2 and 3, I found that medium-chain acyl-CoAs were reduced dramatically in
response to rotenone while the levels of both short and long chain CoA species were
maintained. Furthermore, utilizing isotopic tracers we found that up-regulation of fatty
acid β-oxidation of various fatty acids helped maintain acetyl-CoA pools. In addition to
fatty acids, glutamine was also found to be an important metabolic substrate for
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supporting acetyl-CoA levels. Rotenone treatment was found to induce a paradoxical
cycling of lipids in which increased breakdown was supported by both fatty acid import,
as indicated by palmitoylcarnitine levels, and lipogenesis via acetyl-CoA derived from
reductive glutamine metabolism. Once proposed mechanism for this seemingly futile
cycle is the generation of FADH2, which may be utilized by mitochondrial complex II as
a compensatory mechanism. Literature suggests that alterations to lipid metabolism may
be an important and thus far underappreciated component to the development of PD. The
findings in this chapter therefore lend insight into an adaptation critical for maintaining
energy production in times of impaired complex I capacity.
Chapter 6 employs the same model as chapter 5 but focuses on a different set of
metabolites. In addition to acyl-CoA analysis, quantification of the organic acids within
and related to the Krebs cycle proved very informative. In particular, the α-ketoglutarate
metabolite 2-hydroxyglutarate (2-HG) was found to be upregulated in response to
rotenone. 2-HG is a chiral metabolite, making distinguishing the enantiomers critical for
understanding of the observed increase. To address this issue an LC-MS method was
developed in which 2-HG was derivatized in order improve its LC-MS characteristics and
analyzed by normal phase chiral chromatography. Importantly, this chiral separation
revealed the observed increase was only in (S)-2-HG, (R)-2-HG levels were not affected
by rotenone. Tracer studies also found that glutamine was a major metabolic source of
the increased (S)-2-HG. This finding is the first example of a stereospecific increase in 2HG levels by pharmacological intervention. Furthermore, the developed methodology is
likely to hold utility for investigating subsets of cancers with aberrant 2-HG metabolism.
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Other methods have been used for chiral analysis of 2-HG, though the chiral
derivatization reactions employed are likely to induce enatioselective artifacts, whereas
my method poses no such risk because achiral derivatization remote from the chiral
center was employed.
As addressed in chapter 7, to interrogate metabolic abnormalities in Friedreich’s
ataxia I developed a novel assay in which platelets are isolated from whole blood and
subsequently treated with isotopic tracers. In contrast to absolute quantification, this
approach circumvents the need for external normalization typically required for
determining changes in metabolite levels. My findings show a trend toward decreased
glucose labeling and increased palmitate labeling in FRDA patients when compared to
controls. This result was particularly exciting given the similarity with metabolic
adaptations resulting from rotenone treatment in cell culture models. Furthermore, for
multiple markers the degree of variation within the patient cohort correlated with known
genetic markers of disease severity. Thus we propose that our assay may be useful in
determining the therapeutic efficacy of treatments for the disease. For example, any
successful attempt at increasing frataxin levels would be met with the requirement of
showing the protein is functional. My assay may hold utility in addressing such a
concern. Current work involves collaborating with an ongoing clinical trial to track
differences in platelet metabolism before and after a 12-week trial of a promising
compounds for ameliorating FRDA symptoms.
This thesis aims to address the point that mitochondrial metabolism plays a role in
the pathogenesis of neurodegenerative diseases and may afford the opportunity for
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synergistic therapeutic approaches. Oxidative damage is a real factor and undoubtedly
imparts detrimental damage to cells, leading to diseases that have brought on negative
impacts on society. Directly combatting oxidative damage can be done by either direct
administration of antioxidants or up-regulation of cellular defense systems. However,
impacting cells through oxidative load undoubtedly imparts adaptive changes to energyproducing metabolic processes. By characterizing compensatory metabolic adaptations
we hope to identify metabolic substrates that are consumed at a higher rate than normal.
Supplementation of these precursors or modulation of their related metabolic pathways
seems likely to soften the overall burden to cells and may have an overall beneficial
effect. It is with this thought in mind that we have developed the necessary tools and
employed them in a manner to characterize potential targets for this strategy.
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Chapter 2: Stable isotope dilution liquid chromatography-mass spectrometry
analysis of cellular and tissue medium- and long-chain acyl-coenzyme A thioesters
2.1 Abstract
Acyl-Coenzyme A (CoA) thioesters are the principal form of activated
carboxylates in cells and tissues. They are employed as acyl carriers that facilitate the
transfer of acyl groups to lipids and proteins. Quantification of medium-chain and longchain acyl-CoAs represents a significant bioanalytical challenge because of their
instability. Stable isotope dilution-liquid chromatography-selected reaction monitoringmass spectrometry (LC-SRM/MS) provides the most specific and sensitive method for
the analysis of CoA species. However, relevant heavy isotope standards are not available
and they are challenging to prepare by chemical synthesis. Stable isotope labeling by
essential nutrients in cell culture (SILEC) developed originally for the preparation of
stable isotope labeled short-chain acyl-CoA thioester standards has now been extended to
medium-chain and long-chain acyl-CoAs and used for LC-SRM/MS analyses.
Customized SILEC standards with > 98 % isotopic purity were prepared using mouse
Hepa 1c1c7 cells cultured in pantothenic-free media fortified with [13C315N1]-pantothenic
acid and selected fatty acids. A SILEC standard in combination with LC-SRM/MS was
employed to quantify cellular concentrations of arachidonoyl-CoA (a representative longchain acyl-CoA) in two human colon cancer cell lines. A panel of SILEC standards was
also employed in combination LC-SRM/MS to quantify medium- and long-chain acylCoAs in mouse liver. This new SILEC-based method in combination with LC-SRM/MS
will make it possible to rigorously quantify medium- and long-chain acyl-CoAs in cells
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and tissues. The method will facilitate studies of medium- and long-chain acyl-CoA
dehydrogenase deficiencies as well as studies on the role of medium- and long-chain
acyl-CoAs in cellular metabolism.

24

2.2 Introduction
In prokaryotes and eukaryotes, coenzyme A (CoA) is an essential cofactor for
biosynthetic and energetic metabolic pathways (22). Fatty acyl-CoAs are the precursors
of sphingolipids, a major form of stored fatty acids (23,24). They are also involved in
nuclear signaling (25), mitochondrial dysfunction (26), fatty acid catabolism (27),
xenobiotic and biotransformations (28), post-translational protein modifications and gene
regulation (24,25,29). Because of these diverse functions, fatty acyl-CoAs have been
implicated in obesity (23,25), cardiovascular disease (30), diabetes mellitus (31-33),
cancer (25), and a spectrum of genetic short, medium, and long-chain acyl-CoA disorders
(27,34-37). Paradoxically, mammals are incapable of synthesizing the essential acyl-CoA
precursor, pantothenic acid, which is also known as vitamin B5 (38). Previously, we have
taken advantage of the essential requirement for pantothenate by replacing it in cell
media with a [13C315N1]-pantothenic acid heavy isotope labeled analog, which is then
incorporated into CoASH, and thus into any acyl-CoAs that are formed (Figure 2.1) (15).
We termed this methodology SILEC (39), after the similarity to the stable isotope
labeling by amino acids in cell culture (SILAC) methods employed for proteins (40). For
CoASH and acyl-CoA thioesters, this imparts a +4 m/z shift to the internal standard,
allowing distinction between the analyte and the internal standard in a mass spectrometer,
without significant isotopic overlap or interference from biological matrices (39). The
thioester bond in acyl-CoAs, is relatively energy-rich when compared with ordinary
esters, due primarily to the lack of resonance stabilization. As a result, thioesters are
destabilized relative to the corresponding esters, making them more susceptible to
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Figure 2.1: Biosynthesis of isotopically labeled medium- and long-chain acyl-CoAs
and constant neutral loss of 507.1 Da from protonated acyl-CoA molecules.
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hydrolysis. This means that CoA thioesters readily decompose in aqueous solutions and
they are particularly labile under basic conditions (41). These issues raise the concern that
selective losses can occur during complex bioanalytical procedures. The use of stable
isotope analogs as internal standards corrects for such losses (20). The analogs also act as
carriers for trace amounts of acyl-CoAs by preventing selective losses that can occur
through binding active sites present on glassware and LC equipment (20). Therefore,
stable isotope acyl-CoA analogs significantly improve the accuracy of assays for their
corresponding endogenous isomers present in biofluids particularly when only trace
amounts are present.
A major limitation of our earlier SILEC studies was that the method was
primarily targeted to short-chain acyl-CoAs relevant to the Krebs cycle. Therefore, the
previous method failed to include or extract naturally transient medium chain acyl-CoAs
and more hydrophobic longer chain acyl-CoA species that are important for monitoring
aberrant cellular metabolism. Our original SILEC method has now been modified so that
a wider range of acyl-CoA species can be analyzed. In addition, the utility of the method
has been established by quantifying the absolute levels of acyl-CoA species in mouse
liver tissue and induction of long-chain arachidonoyl-CoA in cell culture.
2.3 Materials and methods
2.3.1 Reagents
Arachidonoyl-CoA, 5-sulfosalicilic acid (SSA), ammonium formate solution,
glacial acetic acid, and dimethyl sulfoxide (DMSO) were purchased from Sigma-Aldrich
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(St. Louis, MO). Optima LC-MS grade methanol, acetonitrile (ACN), 2-propanol (IPA)
and water were purchased from Fisher Scientific (Pittsburgh, PA). 2-(2-pyridyl) ethyl
functionalized silica gel 100 mg/1 mL tubes were obtained from Supelco Analytical
(Bellefonte, PA). F-12K media, DMEM, medium 200, low serum growth supplement
(LSGS) kit, streptomycin, and penicillin were purchased from Invitrogen (Carlsbad, CA).
Charcoal stripped fetal bovine serum (csFBS) was from Gemini Bioproducts (West
Sacramento, CA). [13C315N1] calcium pantothenate was purchased from Isosciences (King
of Prussia, PA). Peroxide free arachidonic acid (AA) was purchased from Cayman
Chemical (Ann Arbor, MI). Human colorectal adenocarcinoma (LoVo) cells and human
colon adenocarcinoma (HCA7) cells were obtained from ATCC (Manassas, VA). Livers
from C57BL/6 mice were taken under University of Pennsylvania IACUC protocol #
803875.
2.3.2 Cell culture
For SILEC labeling, Hepa1c1c7 cells were passaged at least 7 times in custom
RPMI 1640 media without calcium pantothenate (AthenaES, Baltimore, MD) and
containing 10% csFBS, 100 units/mL penicillin, 100 mg/L streptomycin, and 2 mg/L
[13C315N1]-calcium pantothenate. 24 hours before extraction, “ultra-labeling” with media
as above, but omitting csFBS, was performed in order to ensure optimal acyl-CoA stable
isotope labeling. For unlabeled cell culture, HCA7 cells were grown in DMEM media
with 2% FBS and 100 units/mL penicillin and 100 mg/L streptomycin. LoVo cells were
grown in F-12K media with 2% FBS and 100 units/mL penicillin and 100 mg/L
streptomycin.
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2.3.3 Isolation of SILEC standards
Upon completion of labeling, Hepa1c1c7 cells were gently lifted, centrifuged at
500 x g for 5 minutes and resuspended in 750 µL/10cm2 plate of ACN:IPA (3:1; v/v).
Samples were sonicated with a probe tip sonicator on ice 30 times for 0.5 s. 250 µL of
100 mM KH2PO4 (pH= 6.7) were added to the samples, then vortex-mixed and spun
down for 10 min at 16,000 x g at 4°C. The supernatant was pooled and stored in -80°C
until use.
2.3.4 Acyl-CoA analysis
Cells were gently lifted with a cell scraper, centrifuged at 500 x g for 5 min and
resuspended in 550 µL/10 cm2 plate of ACN:IPA (3:1; v/v) for extraction as described
previously (42). The SILEC standard was added (200 µL) and samples were pulse
sonicated with a probe tip sonicator on ice 30 times for 0.5 s. 250 µL of 100 mM KH2PO4
(pH= 6.7) were added to the samples, then vortex-mixed and spun down for 10 min at
16,000 x g at 4°C. The supernatant was transferred to a glass tube and acidified with 125
µL of glacial acetic acid. SPE columns were equilibrated with 1 mL of
ACN:IPA:H2O:acetic acid (9:3:4:4; v/v) washing solvent. Samples were transferred to
the columns, which were washed two times with 1 mL of the washing solvent. The acylCoAs were then eluted by washing the columns twice with 500 µL methanol/250 mM
ammonium formate (4:1; v/v) into glass tubes. After evaporation to dryness under
nitrogen gas, the eluates were re-dissolved in 50 µL of H2O/ACN (70:30; v/v) containing
5 % SSA (w/v) and transferred to HPLC vials ready for LC-MS analysis.
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2.3.5 Formation of arachidonyl-CoA in cell culture
HCA7 and LoVo cells were grown until 80% confluence as above. 25 µM
arachidonic acid with 0.25% DMSO in DMEM media was added and at 30 min, 60 min,
90 min and 4 hours, the cells were gently scraped and collected in plastic tubes. Tubes
were centrifuged for 5 min at 500 x g. Media was removed and the cell pellet was
dissolved in 550 µL 3:1 ACN:IPA and 200 µL of the internal standard mix was added to
each sample. The samples were then extracted and prepared as above.
2.3.6 Extraction of mixed length acyl-CoAs from mouse liver
Approximately 10 mg samples of frozen mouse liver were cut on a cold tile with a
cold blade and exact dry weight was determined for each liver. 750 µL of internal
standard mix in 3:1 ACN:IPA was added to the liver samples. Samples were sonicated
with a probe tip sonicator on ice 60 times for 0.5 s. Sonication produced a visually
homogeneous mixture. Extraction proceeded as for the cells samples above, except that
final liver acyl-CoAs were adjusted by weight of liver used for analysis.
2.3.7 Quantification of arachidonoyl-CoA
Six standard solutions of arachidonyl-CoA in methanol were made corresponding
to 20 pmol, 2 pmol, 0.2 pmol, 20 fmol, 2 fmol and 0 fmol on column. The standards were
dried and then re-dissolved and spiked with internal standard as above. Samples were
extracted using SPE columns as described for the mouse liver homogenate. Regression
analyses of the standard curve and calculations of concentrations of arachidonoyl-CoA
were performed with Excel.
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2.3.8 LC-MS/MS
Samples were kept at 4°C in a Leap CTC autosampler (CTC Analytics,
Switzerland) with 20 μL injections used for LC-MS analysis. Chromatographic
separation was performed using a reverse phase Waters XBridge C18 column (2.1 x 150
mm, pore size 3 μm) on an Agilent 1100 HPLC system using a three solvent system: (A)
5 mM ammonium acetate in water, (B) 5 mM ammonium acetate in 95/5 ACN/water
(v/v), and (C) 80/20/0.1 (v/v/v) ACN/water/formic acid, with a constant flow rate of 0.2
mL/min. Gradient elution was performed as follows: 2% B (isocratic) for 1.5 min, 2% to
20% (linear gradient) over 3.5 min, 20% to 100% B (linear gradient) B over 0.5 min,
100% B (isocratic) for 8 min, 100% C for 5 min, before equilibration at initial conditions
for 5 min.
Samples were analyzed using an API 4000 triple quadrupole mass spectrometer
(Applied Biosystems, Foster City, CA) in positive electrospray ionization (ESI) mode
and data was analyzed using Analyst software as described previously (39). The mass
spectrometer operating conditions were as follows: ion spray voltage (5.0 kV),
compressed air as curtain gas (15 psi) and nitrogen as nebulizing gas (8 psi), heater (15
psi), and collision-induced dissociation (CID) gas (5 psi). The ESI probe temperature was
450°C, the declustering potential was 105 V, the entrance potential was 10 V, the
collision energy was 45 eV, and the collision exit potential was 15 V. CoA thioesters
were monitored using the selected reaction monitoring (SRM) transitions described in
Table 1, which employed the major product ion resulting from the loss of the
phosphoadenosine diphosphate moiety (507.1 Da) as shown in Figure 2.1.
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2.4 Results
2.4.1 Mixed Acyl-CoA Extraction
Extracts of LoVo cells at 80% confluence were analyzed by the LC-MS method
described above. The neutral loss scans of 507.1 m/z are shown in Figure 2.2 for the
mixed acyl-CoA solid phase extraction (Figure 2.2A), the short-chain acyl-CoA solid
phase extraction (Figure 2.2B), and a biphasic liquid-liquid Folch extraction (Figure
2.2C). In our hands, the mixed extraction recovered the broadest range of acyl-CoA
species as evidenced by the peaks corresponding to acyl-CoA species in the short,
medium, and long chain range. The short-chain acyl-CoA extraction we have previously
used gave intense CoASH and acetyl-CoA peaks, and overall higher signal intensity, but
did not recover significant middle or long chain acyl-CoA species. Recovered species
appeared less abundant in the Folch extract versus the mixed acyl-CoA SPE (Figure
2.2A, 2.2C).
2.4.2 Generation of a SILEC standard
Hepa1c1c7 mouse hepatocellular carcinoma cells were grown for 7 passages in
SILEC media then “ultra-labeled” for 24 h in the same media with 0% FBS. The cells
were harvested using the mixed acyl-CoA SPE method. Labeling for oleoyl-CoA was
determined using integration of the peak area for the m/z 1032 → m/z 525 and m/z 1036
→ m/z 529 transitions corresponding respectively to the unlabeled and labeled oleoylCoA (Figure 2.3), where labeling was over 98%. Commercial standards were analyzed
together with SILEC internal standards for tetradecanoyl-, palmitoleoyl-, linoleolyl-,
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Figure 2.2: Neutral loss 507.1 Da scans of LoVo cells
extracted by (A) mixed acyl-CoA SPE (B) Folch
extraction (C) short-chain acyl-CoA SPE.
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Figure 2.3: LC-SRM/MS chromatogram showing labeling efficiency of [13C315N1]-oleoyl-CoA
extracted from Hepa1c1c7 SILEC extracts.
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Table 2.1: Medium– and long-chain acyl-CoAs with corresponding SILEC internal
standards showing protonated molecules and product ions used for LC-SRM/MS
analysis.
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stearoyl-, and oleoyl-CoA (Table 2.1). A typical chromatogram for the long chain-fatty
acyl-CoAs is shown in Figure 2.4. Importantly, the M+2 isotopologues for overlapping
isobaric species, such as oleoyl-CoA (C18:1) M+2 and stearoyl-CoA (C18:0), are shown
to achieve baseline separation with the new LC method (Figure 2.4). Consistent with
previous studies on short-chain acyl-CoAs (15,39), the distribution of acyl-CoA species
was unequal, such that certain labeled molecules of interest might be of low abundance in
the SILEC internal standard mixture for analytical use. To address this problem, the
biosynthesis of acyl-CoAs in Hepa1c1c7 cells with various doses of fatty acid mixtures
was conducted. A fatty acid mixture of sodiumbutanoate, sodium hexanoate, sodium
octanoate, sodium decanoate, and sodium dodecanoate at 100 µM was found to be ideal,
where above that concentration cellular toxicity was observed. A time course study
revealed that a 3 h incubation produced the broadest distribution of acyl-CoA species
(Figure 2.5).
2.4.3 Time course for formation arachidonoyl-CoA in colon cancer cells
A special SILEC standard was generated by treating the SILEC Hepa1c1c7 cells
with 25 µM arachidonic acid for one hour before extraction. This provided an enriched
arachidonoyl-CoA internal standard, which made it possible to quantify endogenous
arachidonoyl-CoA (Figure 2.6A) and illustrated the applicability of the SILEC method
for targeted long chain acyl-CoA quantitation. LoVo and HCA-7 colon adenocarcinoma
cells were treated with 25 µM arachidonic acid, and the cells were extracted and analyzed
by our method at various time points. The resulting standard curve was linear over 4
orders of magnitude from 20 fmol to 20 pmol (y=1.3555x + 0.1267, R2=0.9978). The
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Figure 2.4: LC-SRM/MS chromatograms of SILEC-derived long-chain acyl-CoAs analyzed with
corresponding unlabeled authentic standard long-chain acyl-CoAs. Where overlap of isobaric ions
was possible, clear chromatographic resolution was obtained.
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Figure 2.5: Constant neutral loss of 507.2 Da in m/z scans of [13C315N1]-pantothenic acid
derivatives. Hepa1c1c7 cells extracted at (A) baseline, (B) 30 min, (C) 3 h, (D) 6 h, (E) 12
h, (F) 24 h after fatty acid induction.
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Figure 2.6: (A) LC-SRM/MS analysis of endogenous arachidonoyl-CoA using the
[13C315N1]-arachidonyl-CoA SILEC internal standard. (B) Absolute quantitation of
the arachidonoyl-CoA in two different colon carcinoma cells lines from 0.5 to 4 h
after the addition of 25 mM arachidonic acid. Analyses were performed in
duplicate.
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precisions for analysis of low (0.60 fmol), middle (5 pmol) and high (15 pmol) quality
control samples (n=5) were better than 15 %. Accuracies for analysis ranged were in the
acceptable of between 85 % and 115 %. This made it possible to rigorously quantify the
concentration range of arachidonoyl-CoA in the arachidonate-treated colon cancer cells.
Interestingly, initial concentrations of arachidonoyl-CoA in the HCA-7 cells were almost
two-fold higher (14. 9 pmol/106 cells) than the LoVo cells (8.9 pmol/106 cells). However,
after the addition of arachidonic acid concentrations of arachidonyl-CoA increased to a
maximum of 22.4 pmol/106 cells in both cell lines after 4 h (Figure 2.6B).
2.4.4 Tissue acyl-CoA quantification
A set of three mouse liver tissue samples was analyzed by the new SILEC
method, and absolute quantification of select acyl-CoA species was conducted. Standard
curves were generated from 0.02 to 20 pmol for the acyl-CoAs. Regression lines for
selected CoAs were as follows: butanoyl (y=1.77x+9.89e-5, R2=0.9907), octanoyl
(4.07x+1.1e-5, R2=0.9974), decanoyl (7.44x+0.000226, R2=0.9994), dodecanoyl
(12.1x+0.00171, R2=0.9919), tetradecanoyl (y=1.12x+0.000102, R2=0.9961), and
palmitoleoyl (y=0.996x+8.82e-5, R2=0.9955). Precision for analysis of low (0.04 pmol),
middle (5 pmol) and high (15 pmol) quality control samples (n=5) were better than 15 %.
Accuracies for analysis were in the acceptable range from 85 % to 115 %. The relative
abundance of the acyl-CoAs in the mouse liver samples ranged from 0.04 pmol/mg tissue
for dodecanoyl-CoA to 0.52 pmol/mg tissue for butanoyl-CoA (Figure 2.7). This
demonstrates the utility of the method for quantitative analysis of the medium- and longchain acyl-CoA species that are present in tissue samples.
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Figure 2.7: Absolute quantitation of medium-chain
acyl-CoA species from three mouse liver samples
taken from different animals. Results are shown as
means ± standard error of the mean.
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2.5 Discussion
Acyl-CoAs are important to cell bioenergetics and metabolism, and they also play
critical roles in lipid biosynthesis, cell signaling, post-translational modification of
proteins, and metabolism of xenobiotics (26,28). Accurate and precise quantification of
medium and long-chain acyl-CoAs has specific utility for the interrogation of a wide
variety of inherited and acquired disorders of metabolism including medium- and longchain acyl-coenzyme A dehydrogenase deficiencies (43-45), as well as for elucidating
their critical role in numerous important biochemical pathways (12,30,46-48). Longchain acyl-CoAs act as a feedback regulators in bioenergetics and cellular carbon
metabolism (49), as well as regulating cardiac function at the level of ATP channels (50).
Clearly, in order to establish the physiological relevance of altered levels of acyl-CoAs,
the bioanalytical methodology that is employed must unequivocally determine the
specific concentrations of these relatively unstable, structurally diverse molecules. The
variety of individual chemical entities making up the acyl-CoA family poses a significant
challenge to the analyst (51). LC-UV strategies for analysis of acyl-CoA species are
insufficiently specific due to co-eluting peaks (52). Excellent LC-MS/MS strategies for
the analysis of acyl-CoAs have been employed by other groups, including validated
methods by Haynes et al. (24), Magnes, et al. (53), and Mauriala et al. (54). However,
these methods do not employ stable isotope internal standards, which limits their
specificity, accuracy, and precision especially for complex biological matrices where
interfering ion-suppressing molecules are likely to be present. Heavy isotope analog
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internal standards overcome this problem by preventing selective suppression of the
analyte signal (20).
2.6 Conclusion
In this study, our previous SILEC method for short-chain acyl-CoAs was
expanded to include medium- and long-chain acyl-CoAs. It was possible to generate
stable isotopically labeled standards for low abundance endogenous acyl-CoA species by
adding suitable fatty acid precursors. The utility of the method for medium-chain acylCoAs was demonstrated by quantifying medium-chain acyl-CoAs present in mouse liver
tissue. Long-chain acyl-CoAs could also be quantified as was demonstrated by
monitoring the formation of arachidonyl-CoA in two human colon cancer cell lines in
response to the addition of arachidonic acid. The SILEC method will be particularly
useful for future studies on the quantification of acyl-CoAs derived from bioactive
arachidonic acid metabolites such as 11- and 15-oxo-eicosatetraenoic acid (55-57), to be
conducted so that their role in intracellular signaling as well as the effects of nonsteroidal anti-inflammatory drugs on acyl-CoA biosynthesis (58,59), can be further
elucidated, as these drugs should diminish the cyclooxygenase-mediated formation of
these intermediates.
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Chapter 3: Production of stable isotope labeled acyl-coenzyme A thioesters by yeast
SILEC
3.1 Abstract
Acyl-coenzyme A (CoA) thioesters are key metabolites in numerous anabolic and
catabolic pathways, including fatty acid biosynthesis and β-oxidation, the Krebs cycle,
and cholesterol and isoprenoid biosynthesis. Stable isotope dilution-based methodology is
the gold standard for quantitative analyses by mass spectrometry. However, chemical
synthesis of families of stable isotope labeled metabolites such as acyl-coenzyme A
thioesters is impractical. Previously, we biosynthetically generated a library of stable
isotope internal standard analogs of acyl-CoA thioesters by exploiting the essential
requirement in mammals and insects for pantothenic acid (vitamin B5) as a metabolic
precursor for the CoA backbone. By replacing pantothenic acid in the cell media with
commercially available [13C315N1]-pantothenic acid, mammalian cells exclusively
incorporated [13C315N1]-pantothenate into the biosynthesis of acyl-CoA and acyl-CoA
thioesters. We have now developed a much more efficient method for generating stable
isotope labeled CoA and acyl-CoAs from [13C315N1]-pantothenate using SILEC in Pan6
deficient yeast cells. Efficiency and consistency of labeling were also increased, likely
due to the stringently defined and reproducible conditions used for yeast culture. The
yeast SILEC method greatly enhances the ease of use and accessibility of labeled CoA
thioesters and also provides proof-of-concept for generating other labeled metabolites in
yeast mutants.

44

3.2 Introduction
Liquid chromatography (LC) coupled with selected reaction monitoring mass
spectrometry (SRM/MS) is a highly sensitive and specific platform for quantifying a
wide range of analytes from complex biological samples. To control for the effects of
complex analytical workflows including, analyte stability, extraction efficiencies, and
ionization suppression, internal standards are required. The ideal internal standard is a
stable isotope labeled analog that reproduces the exact chemical properties of the analyte
of interest with no overlap in detection of the relevant analyte by MS. This methodology,
which is termed stable isotope dilution LC-SRM/MS, represents the current gold standard
for quantitation of a variety of endogenous analytical targets. However, with gains in
instrument performance allowing increasingly multiplexed analyses, affordable and
efficient generation of diverse sets of stable isotope labeled internal standards remains
challenging.
Acyl-coenzyme A (CoA) thioesters are key metabolites in numerous anabolic and
catabolic pathways, including fatty acid biosynthesis and β-oxidation, the Krebs cycle,
and cholesterol and isoprenoid biosynthesis (15,22). Previously, we biosynthetically
generated a library of stable isotope internal standard analogs of acyl-CoA thioesters by
exploiting the essential requirement in mammals and insects for pantothenic acid
(vitamin B5) as a metabolic precursor for the CoA backbone (39) (Figure 3.1). By
replacing pantothenic acid in the cell media with commercially available [13C315N1]pantothenic acid, mammalian cells exclusively incorporated [13C315N1]-pantothenate into
the biosynthesis of acyl-CoA and acyl-CoA thioesters (Figure 3.2). We termed this
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Figure 3.1: Pantothenate is an essential nutrient in organisms lacking
pantothenate synthetase, encoded for by the pan6Δ gene in S. cerevisiae.
Enzymes are shown in bold: Valine-pyruvate transaminase (VPT);
ketopantoate hydroxymethyl transferase (KPHMT); ketopantoate reductase
(KPR); aspartate alpha-decarboxylase (ADC); pantothenate synthetase
(PS); pantothenate kinase (PanK); phosphopantothenoylcysteine
synthetase
(PPCS);
phosphopantothenoylcysteine
decarboxylase
(PPCDC); phosphopantetheine adenylyltransferase (PPAT); dephosphoCoA kinase (DPCK).
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Figure 3.2: Incorporation of [13C315N1]-isotopic label into CoA via biosynthesis of CoA
from pantothenate. Chemical structures for conversion of pantothenate to 4’phosphopantothenate
(1),
(R)-4’-phosphopantothenoyl-L-cysteine
(2),
4’phosphopantotheine (3), 3’-dephosphocoenzyme A (4), and coenzyme A (5).
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methodology SILEC, after the similarity to SILAC methods employed for proteins (40).
Since the labeling efficiency of CoA thioesters in this method was found to be over 98%,
the resulting stable isotope analogs can be used as internal standards in LC-SRM/MS
analysis while maintaining a low limit of detection and high analytical precision.
Labeling efficiency is critical as this parameter scales inversely with the sensitivity of the
LC-MS/MS method, as unlabeled contamination increases the signal in the blank and
introduces an additional source of variability into the analysis.
Despite the utility of this method, mammalian cell culture is relatively time
consuming, expensive, and requires appropriate cell culturing facilities. Additionally,
mammalian cell culture requires either defined media or fetal bovine serum (FBS), which
may introduce variability in labeling as well as residual unlabeled pantothenate. In our
hands, various lots of charcoal stripped (cs) FBS) have produced labeling efficiencies
ranging from 68%-99%, and dialyzed (d) FBS can result in only 95% labeling (15).
Furthermore, mammalian cells require multiple media changes and passages to achieve a
high labeling purity, as well as time consuming expansions to scale the culture to
generate the required amount of internal standard.
3.3 Materials and Methods
3.3.1 Materials
Biotin, folic acid, inositol, niacin, p-aminobenzoic acid, pyridoxine-HCl,
riboflavin, dextrose, sodium propanoate, sodium butanoate, sodium hexanoate, sodium
octanoate, sodium decanoate, sodium dodecanoate, sodium myristate, sodium palmitate,
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trichloroacetic acid (TCA), 5-sulfosalicyilic acid (SSA), ammonium formate, and
potassium dihydrogen phosphate were purchased from Sigma-Aldrich (St. Louis, MO).
FBS, csFBS, and dFBS were obtained from Gemini Bio-Products (West Sacramento,
CA). Ammonium acetate and Optima LC-MS grade water, methanol, acetonitrile (ACN),
2-propanol (IPA), and formic acid were purchased from Fisher Scientific (Pittsburgh,
PA). Thiamine HCl, Yeast Nitrogen Base w/o AA & w/o AS, w/o Vitamins, and Dropout Mix Complete w/o Yeast Nitrogen Base were purchased from United States
Biological (Salem, MA). Granulated agar was purchased from Becton Dickinson and
Company (Franklin Lakes, NJ). Ammonium sulfate was purchased from Mallinckrodt
Pharmaceuticals (St. Louis, MO). Nitrogen gas was purchased from Airgas (Radnor
Township, PA). Oasis solid phase extraction (SPE) cartridges were purchased from
Waters (Milford, MA). 2-(2-Pyridyl) ethyl silica gel solid phase extraction cartridges
were purchased from Supelco (Bellefonte, PA). Calcium [13C315N1]-pantothenate was
purchased from Isosciences (King of Prussia, PA). The pan6Δ S. cerevisiae strain was
obtained from the Yeast Knockout Collection library (GE Healthcare Bio-Sciences,
Piscataway, NJ). Hepa 1c1c7 murine hepatoma cells were obtained from ATCC
(Manassas, VA; # CRL-2026)
3.3.2 Yeast cell culture
Yeast growth media was prepared with 200 µg biotin, 200 µg folic acid, 200 mg
inositol, 40 mg niacin, 20 mg p-aminobenzoic acid, 40 mg pyridoxine-HCl, 20 mg
riboflavin, 40 mg thiamine HCl, 20 g dextrose, 400 µg [13C315N1]-pantothenate, 2.0 g
Drop-out Mix Complete w/o Yeast Nitrogen Base, 1.7 g Yeast Nitrogen Base w/o AA &
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w/o AS, w/o Vitamins, and 5.0 g ammonium sulfate dissolved in 1.0 L of distilled H2O.
The vitamins and [13C315N1]-pantothenate were filter sterilized and the dextrose, drop-out
mix, yeast nitrogen base mix, and ammonium sulfate were autoclaved. The pan6Δ S.
cerevisiae strain was confirmed by a pantothenate auxotrophy test. Agar plates were
prepared, with one batch omitting pantothenate from the growth media. The plates were
inoculated with pan6Δ yeast, and then incubated at 37 ˚C for 24 h.
1 L of media was inoculated with pan6Δ S. cerevisiae and incubated at 30 ˚C
while agitating overnight with 500 mL in two 2 L Erlenmeyer flasks covered loosely with
aluminum foil. Optional fatty acid induction for some batches was begun the following
day. Induction consisted of adding the sodium salts of propanoate, butanoate, hexanoate,
octanoate, decanoate, dodecanoate, myristate, and palmitate to an equal final
concentration in the media for 1 h prior to harvesting. After approximately 31 h from the
onset of the culture, the yeast cells were removed from the incubator, divided into 50 mL
aliquots, and pelleted at 500 x g. The cells were resuspended in ice-cold 10% TCA or
ACN/IPA (3:1; v/v) for short-chain or mixed-chain extraction, respectively. The cells
were pulse sonicated for 30 half-second pulses, on ice. Samples were spun at 16,000 x g
for 10 min at 4˚C to remove unbroken cells and debris. The final supernatant was
transferred to a separate tube and stored at -80˚C.
3.3.3 Acyl-CoA thioester extraction
Extractions of acyl-CoA thioesters were performed using previously documented
procedures (15,39,42,60). Briefly, after pelleting, supernatant was transferred to 1.5 mL
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microcentrifuge tubes, transferring 1 mL for short-chain or 0.75 mL for short-, mediumand long-chain (mixed-chain) acyl-CoA thioester extractions. 250 µL of 10% KH2PO4
was added to the mixed-chain acyl-CoA thioester extractions. Samples were centrifuged
at 16000g for 10 min at 4 ˚C and supernatants were transferred to fresh tubes. 125 µL of
glacial acetic acid was added to the mixed-chain acyl-CoA thioester supernatant. Samples
were then purified using a solid-phase extraction. For short-chain acyl-CoA thioester
samples, Oasis HLB 1cc (30 mg) SPE columns (Waters) were conditioned with 1 mL
methanol and washed with 1 mL water. Supernatant was loaded, followed by a 1 mL
wash with water, and eluted using 1 mL of 25 mM ammonium acetate in methanol. For
mixed-chain acyl-CoA thioester samples, 2-(2-pyridyl)ethyl functionalized silica gel SPE
tubes (Supelco) were conditioned with 1 mL of ACN/IPA/H2O/AA (9:3:4:4; v/v/v/v).
Supernatants were loaded, followed by a 2 mL wash with ACN/IPA/H2O/AA (9:3:4:4;
v/v/v/v), and then the SPE columns were eluted using 1 mL of 250 mM aqueous
ammonium formate/methanol (1:4; v/v). Eluents were evaporated to dryness under
nitrogen gas. Short-chain acyl-CoA thioester samples were resuspended in 100 µL of 5%
5-sulfosalycic acid, while mixed-chain acyl-CoA thioester samples were resuspended in
100 µL of H2O:ACN (7:3; v/v). Injections of 10 µL were made for analysis by LCelectrospray ionization (ESI)/SRM/MS.
3.3.4 LC-ESI/SRM/MS analysis
Analytes were separated using a reversed-phase Phenomenex HPLC Luna C18
column (2.0 mm x 150 mm, particle size 5 µm) with 5 mM ammonium acetate in water
as solvent A, 5 mM ammonium acetate in acetonitrile/water (95:5. v/v) as solvent B, and
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acetonitrile/water/formic acid (80/20/0.1, v/v/v) as solvent C. Gradient conditions were as
follows: 2% B for 1.5 min, increased to 25% over 3.5 min, increased to 100% B in 0.5
min and held for 8.5 min, washed with 100% C for 5 min, before equilibration for 5 min.
The flow rate was 200 μL/min. Samples were analyzed using an API 4000 triplequadrupole mass spectrometer (Applied Biosystems, Foster City, CA) in the positive ESI
mode. Samples (10 µL) were injected using a Leap CTC auto- sampler (CTC Analytics,
Switzerland) where they were maintained at 4 oC, and data was analyzed with Analyst
1.4.1 software. The column effluent was diverted to the mass spectrometer from 8 to 18
min and to waste for the remainder of the run. The mass spectrometer operating
conditions were as follows: ion spray voltage (5.0 kV), nitrogen as curtain gas (15 units),
ion source gas 1 (8 units), gas 2 (15 units), and collision-induced dissociation (CID) gas
(5 units). The ESI probe temperature was 450 ˚C, the declustering potential was 105 V,
the entrance potential was 10 V, the collision energy was 45 eV, and the collision exit
potential was 15 V. Isotopic labeling using [13C315N1]-pantothenate resulted in labeled
CoA and acyl-CoA thioesters with a 4 Da increase in mass.
3.3.5 Stability of yeast SILEC-derived acyl-CoAs
SILEC derived acyl-CoAs were stored in 10 mL aliquots of 10% TCA at -80˚C and an
aliquot allowed to thaw to room temperature. The aliquot was then re-frozen and stored at
-80 oC for 24 h. The freeze-thawing process was repeated for a total of five times and the
amount of acetyl-CoA determined by LC-MS as described previously (39). The amount
of acetyl-CoA was then compared with the amount determined to be present in the
originally prepared yeast SILEC CoA standard solution.
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3.3.6 Variation in efficiency of acetyl-CoA labeling in mammalian cell culture
SILEC standards were prepared as described previously using Hepa 1c1c7 murine
hepatoma cells and different batches of FBS. Incorporation of labeled pantothenate was
determined as described above using high resolution LC-MS.
3.4 Results
3.4.1 Yeast cell culture
Due to the availability of genetic mutants and the ability to rapidly reproduce in
inexpensive media, the yeast Saccharomyces cerevisiae provides an attractive alternative
for the biosynthesis of a variety of endogenous metabolites. Unlike mammalian cells,
yeast are capable of de novo biosynthesis of pantothenate (Figure 3.1), meaning that
replacement of only [13C315N1]-pantothenic acid is insufficient for generating isotopically
labeled acyl-CoAs with a high labeling efficiency (38). In this method, we tested pan6Δ
yeast as a platform for acyl-CoA SILEC generation. PAN6 encodes the enzyme
pantothenate synthase, which combines pantoic acid and β-alanine to form pantothenate
(Figure 3.1). Pan6Δ cells are incapable of de novo pantothenate synthesis, and are
auxotrophic for pantothenate (61). Therefore, when the pan6Δ yeast cells were cultured
with exogenous [13C315N1]-pantothenic acid as the sole source of pantothenate, CoA and
all the acyl-CoA thioesters were isotopically labeled with the [13C315N1]-pantothenate
moiety (Figure 3.2). Under these conditions, liters of pan6Δ cells could be readily
cultured (Figure 3.3A) and stable isotope-labeled CoA thioesters extracted. Pan6Δ cells
grew only in media supplemented with exogenous pantothenate (Figure 3.3B).
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Figure 3.3: Biosynthesis and incorporation of isotopic labels from pantothenate (vitamin
B5) into Coenzyme A. (A) Comparative workflow for SILEC with mammalian versus
yeast culture. (B) Confirmation of pan6Δ yeast auxotrophy for vitamin B5 (VB5) by
growth on agar with (+) or without (-) pantothenate.
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3.4.2 Optimization of the yeast SILEC method
[13C315N1]-pantothenic-labeled acyl-CoA species were observed with > 99 %
incorporation of label after only 2 days of yeast SILEC culture. The yields of [13C315N1]acetyl-CoA were proportional to cell density, reaching a maximum as the culture
approached stationary phase (Figure 3.4A, B). Cell lysis by sonication or glass beads
gave similar results (Figure 3.4C) so sonication was used as the preferred method due to
its simplicity. Acyl-CoA thioesters are stable in acidic conditions at -80 ˚C and so it was
possible to produce and store a large amount of stable isotope-labeled acyl-CoAs for
future use as internal standards for LC-SRM/MS assays. The stable isotope labeled acylCoAs were stored in 10 mL aliquots of 10% TCA at -80˚C, to avoid freeze-thaw cycles.
We have successfully used batches of stable isotope labeled acyl-CoAs stored in this
manner for over 6 months. The estimated yield from 1 L of yeast culture was 405 µg of
[13C315N1]-acetyl-CoA, approximately the same amount of [13C315N1]-HMG-CoA, and
lesser amounts of other acyl-CoAs.
3.4.3 Abundance and labeling of CoA and acyl-CoA thioesters
The abundance of isotope-labeled acetyl-CoA, 3-hydroxy-3-methylglutaryl
(HMG)-CoA (Figure 3.5A), succinyl-CoA, CoA, and β-hydroxybutyryl (βHB)-CoA
(Figure 3.5B), increased with increasing cell density. Labeling efficiency was calculated
for [13C315N1]-CoASH (99.41%), [13C315N1]-acetyl-CoA (99.88%), [13C315N1]-succinylCoA (99.54%), and [13C315N1]-HMG-CoA (99.82%). Constant neutral loss scans of 507
Da, a fragmentation specific for the CoA backbone, revealed a distribution of protonated
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Figure 3.4: Yeast SILEC rapidly produces efficiently labeled [13C315N1]-acyl-CoAs
from [13C315N1]-pantothenate. Pan6Δ yeast incubated over 31 h at 30˚C show an
increase in (A) optical density and (B) amount of isotopically labeled acetyl-CoA.
(C) Lysis by sonication (black fill) or with glass beads (white fill) did not significantly
alter yields. Maximum yield of [13C315N1]-acetyl-CoA was obtained at 26-29 h,
corresponding to the end of log phase growth.
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Figure 3.5: Formation and stability of labeled acyl-CoAs by yeast SILEC. Pan6Δ
yeast was incubated over 31 h at 30˚C and extracted using the short-chain acylCoA method. (A) Levels of [13C315N1]-labeled acetyl-CoA and HMG-CoA. (B)
Levels of [13C315N1]-labeled succinyl-CoA, CoA, and βHB-CoA. (C) Stability of
yeast SILEC-derived acetyl-CoA through five freeze-thaw cycles.
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Figure 3.6: MH+ signals from constant neutral loss scans of 507 Da for the acyl-CoA extract
from (A) Hepa1c1c7 SILEC (B) yeast SILEC, and mixed chain acyl-CoA extract from (C)
Hepa1c1c7 SILEC (D) yeast SILEC (E) yeast SILEC induced with fatty acid treatment.
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molecules (MH+) from acyl-CoAs in the Hepa 1c1c cells (Figure 3.6A) that was
somewhat different from the yeast SILEC extract (Figure 3.6B). Signals corresponding to
MH+ were observed for [13C315N1]-labeled CoA (m/z 772), acetyl-CoA (m/z 814),
succinyl-CoA (m/z 872), and HMG-CoA (m/z 916). There was a significantly enriched
abundance of HMG-CoA in the yeast extract (Figure 3.5B) when compared with the
Hepa 1c1c cell extract (Figure 3.5A).
3.4.4 Stability of yeast SILEC-derived acyl-CoAs
Multiple freeze-thaw cycles resulted in some degradation of the acyl-CoA content
of the prepared batches with some degradation after the second freeze-thaw and a
significant loss after the fifth cycle. This is reflected in data for acetyl-CoA where there
was a loss of 16 % after five freeze-thaw cycles (Figure 3.5C). This means that
appropriate analytical technique should include standard curves run from the same
aliquot of the same batch for absolute quantitation and comparisons across the same
aliquot of the same batch for relative quantitation.
3.4.5 Customization of the yeast SILEC method
The composition of isotope-labeled acyl-CoA thioesters produced by pan6Δ cells
could be modified by both the extraction used (42) and fortification of the medium with
specific precursors (60). Extraction of acyl-CoAs using a procedure to capture acyl-CoAs
of mixed length resulted in a wider library of [13C315N1]-acyl-CoA internal standards as
reflected by the MH+ signals that were detected from both Hepa1c1c7 SILEC (Figure
3.6C) as well as yeast SILEC (Figure 3.6D) in the constant neutral loss mass spectra.
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Supplementation of the yeast SILEC media with 1 mM sodium propionate, sodium
butyrate, sodium hexanoate, sodium octanoate, sodium decanoate, sodium laurate
(dodecanoate), sodium myristate (tetradecanoate), and sodium palmitate for 1 h before
the acyl-CoA thioester extraction yielded a distribution of isotopically labeled products
enriched in medium- and long-chain acyl-CoAs. Intense peaks corresponding to MH+
from [13C315N1]-labeled CoA (m/z 772), acetyl-CoA (m/z 814) decanoyl-CoA (m/z 926),
lauroyl-CoA (m/z 954), myristoyl-CoA (m/z 982), and palmitoleoyl-CoA (m/z 1008) were
observed in the constant neutral loss mass spectrum (Figure 3.6E).
3.4.6 Variation in efficiency of acetyl-CoA labeling in mammalian cell culture
The efficiency of isotopic purity in mammalian culture differed between types
and batches of FBS (Table 3.1). This is due to presence of residual amounts of unlabeled
pantothenate in the serum. Therefore, labeling efficiency was significantly higher in the
yeast SILEC system (typically 99.9 %) where FBS was not required.
3.5 Discussion
In order to establish the physiological relevance of altered levels of acyl-CoAs,
the bioanalytical methodology that is employed must unequivocally determine the
specific concentrations of these structurally diverse molecules. The variety of individual
chemical entities making up the acyl-CoA family poses a significant challenge to the
analyst. In addition, the energy-rich thioester bond in acyl-CoAs lack resonance
stabilization when compared with the corresponding esters, making them more
susceptible to hydrolysis (60). This means that acyl-CoA thioesters readily decompose in
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aqueous solutions and they are particularly labile under basic conditions. The use of
stable isotope analogs as internal standards can correct for such losses (20). Furthermore,
when using LC-ESI/MS methodology suppression of the analyte signal can occur from
substances that are present in the biological matrix that is being analyzed. Stable isotope
analog internal standards overcome this problem by adjusting for selective suppression of
the ESI signal (20).
Currently, seven high quality individual stable isotope labeled acyl-CoA
derivatives are commercially available from Sigma for use as internal standards in LCMS assays - [13C4]-acetoacetyl-CoA, [13C2]-acetyl-CoA, [13C3]-malonyl-COA, [13C4]octanoyl-CoA, [13C18]-oleoyl-CoA, [13C16]-palmitoyl-CoA, and [13C18]-stearoyl-CoA.
However, considering the wide variety and interconnected metabolism of acyl-CoAs,
these available products are completely inadequate to conduct comprehensive metabolic
profiling. Searching the term “CoA” on the Human Metabolome Database (HMD) (62)
currently produces 268 acyl-CoA species and this value is likely an underestimate of the
true variety of acyl-CoA intermediates considering the diversity of metabolic pathways
featuring a critical acyl-CoA intermediate. The same term searched on MetaCyc (63),
revealed some 524 structurally distinct acyl-CoAs. Chemical synthesis of one or two
isotopically labeled acyl-CoA analogs is practical; but generating a library of relevant
CoA species through synthesis is impractical for most researchers. In contrast, this is a
relatively easy task for the SILEC method when appropriate precursors are added to the
media.
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Table 3.1: Variations in efficiency of acetyl-CoA labeling using
different lots of csFBS or dFBS for seven passages in Hepa
1c1c7 murine hepatoma cells.
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Our previous SILEC methodology employed mammalian cell culture to generate
a library of CoA standards (39). The new yeast SILEC method is much more efficient
because the time required to produce a batch of labeled material is significantly reduced
due to the growth rates of yeast and ease of scalability (Figure 3.3A). In addition, the
efficiency of isotopic labeling is increased versus mammalian culture, which results of
the ability to omit any form of serum (Table 3.1). Considerable variability in SILEC
labeling efficiency exists when using different types and even batches of serum in
mammalian cell culture (Table 3.1). Sensitivity and precision of the stable isotope
dilution LC-MS method relies heavily on highly efficient labeling. The yeast SILEC
method is therefore an important improvement because the high labeling efficiency (>
99.5 %) makes it possible to maximize sensitivity and specificity of CoA analysis by LCMS. The uniform [13C315N1]-labeled standards generated by the yeast SILEC method
provides a consistent label across all acyl-CoAs that imparts a 4 Da increase in mass
resulting in no isotopic overlap, permitting rapid method development coupled with high
sensitivity and precision. The introduction of a [15N]-label also allows neutron encoded
isotope analysis on high-resolution mass spectrometers (64). In addition, the genetic yeast
SILEC method will enable studies of pantothenate synthesis tracing in both normal and
mutant yeast cells to be conducted. Furthermore, the method can be elaborated to other
metabolites and organisms. Finally, the composition of the internal standard stocks can be
quickly modified by providing appropriate metabolic precursors to increase the
abundance of specific acyl-CoAs.
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The availability of a diverse set of stable isotope analogs for use as internal
standards is important because the biological roles of individual acyl-CoA species are
distinct. Acetyl-CoA and succinyl-CoA are important components of the Krebs cycle.
Additionally, acetyl-CoA is used as a metabolically sensitive rheostat in acetylation
reactions, such as in post-translational modifications of histone proteins (9). βHB-CoA is
a key intermediate in both fatty acid oxidation and ketone body metabolism. HMG-CoA
is critical in cholesterol metabolism (or ergosterol for yeast). The capacity to produce
medium- and long-chain acyl-CoA standards such as octanoyl-, decanoyl-, lauroyl-,
myristoyl-, and palmitoyl-CoA greatly adds to the utility of this method, as these
metabolites are conserved metabolic intermediates and precursors for protein posttranslational modifications. The ability to measure panels of acyl-CoAs is crucial because
this multiplexing allows dissection of compensatory metabolic responses, as was
demonstrated for the complex I inhibitor rotenone (19,26).
The capacity to generate high quality internal standards for a panel of acyl-CoA
species using a yeast auxotrophic mutant should be applicable to other biosynthetic
pathways. Stable isotope labeling incorporating [13C]- and [15N]-labeled standards is
superior to the use of [2H]-labeled standards due to the potential for hydrogen exchange
and differences in chromatographic retention times with [2H]-analogs when compared
with the corresponding protium forms. Thus, other synthetic intermediates that
incorporate carbon or nitrogen backbones efficiently from a single metabolic precursor
could be amenable to the SILEC approach. Yeast mutant strains that confer auxotrophy
of key metabolites are available. In these cases, growth in defined media is well64

established, and the only limiting factor may be obtaining a stable isotope analog of the
key metabolite, which can alleviate the auxotrophy.
3.6 Conclusion
In summary, we have reported a simple method for producing relatively large quantities
of stable isotope-labeled acyl-CoA internal standards in yeast for use as internal standards
in LC-SRM/MS assay. These stable isotope analogs could be incorporated into other
published methods for targeted (24,51,53,54) or untargeted quantitative analyses (65,66).
The yeast SILEC method is simpler, less expensive, and more rapid than our previous
approaches. Efficiency and consistency of labeling were also increased, likely due to the
stringently defined and reproducible conditions used for yeast culture. This method
greatly enhances the ease of use and accessibility of the SILEC method for the
preparation of stable isotope labeled acyl-CoA thioesters for use as internal standards in
quantitative LC-MS assays. Furthermore, it provides proof of principle that yeast can be
used for the preparation of stable isotope analogs of other cellular metabolites.
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Chapter 4: Metabolism of propionic acid to a novel acyl-coenzyme A thioester by
mammalian cell lines and platelets
4.1 Abstract
Metabolism of propionate involves the activated acyl-thioester propionyl-CoA
intermediate. We employed liquid chromatography-tandem mass spectrometry (LCMS/MS), LC-selected reaction monitoring (SRM)/MS and LC- high-resolution MS
(HRMS) to investigate metabolism of propionate to acyl-CoA intermediates. We
discovered that propionyl-CoA can serve as a precursor to the direct formation of a new
6-carbon mono-unsaturated acyl-CoA. Time course and dose-response studies in human
hepatocellular carcinoma HepG2 cells demonstrated that the 6-carbon mono-unsaturated
acyl-CoA was propionate-dependent and underwent further metabolism over time.
Studies utilizing [13C1]- and [13C3]-propionate suggested a mechanism of fatty acid
synthesis, which maintained all 6-carbon atoms from two propionate molecules.
Metabolism of 2,2-[2H2] propionate to the new 6-carbon monounsaturated acyl-CoA
resulted in the complete loss of two deuterium atoms, indicating modification at C2 of the
propionyl moiety. Co-elution experiments and isotopic tracer studies confirmed that the
new acyl-CoA was trans-2-methyl-2-pentenoyl-CoA. Acyl-CoA profiles following
treatment of HepG2 cells with mono-unsaturated 6-carbon fatty acids also supported this
conclusion. Similar results were obtained with human platelets, mouse hepatocellular
carcinoma Hepa1c1c7 cells, human bronchoalveolar carcinoma H358 cells, and human
colon adenocarcinoma LoVo cells. Interestingly, trans-2-methyl-2-pentenoyl-CoA would
correspond to a previously described acylcarnitine tentatively described in patients with
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propionic and methylmalonic acidemia. We have proposed a mechanism for this
metabolic route consistent with all of the above findings.
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4.2 Introduction
Coenzyme A (CoA) thioesters, which are members of the fatty acyl class of lipids
(67), are critical for adequate control of cellular bioenergetics (68) as well as the
regulation of important cellular functions (46). Furthermore, anabolic and catabolic
carbon processing is extensively dependent on a pool of acyl-CoA intermediates, which
are available as activated and localized substrates (69). Specifically, synthesis of fatty
acids in mammalian cells is initiated through activation of acetyl- and malonyl-CoA, with
elongation of the nascent chain via addition of the acetyl moiety from acetyl-CoA (46).
This system is in contrast to the ability of certain bacteria, which condense propionate, a
3 carbon precursor, to a 6 carbon product directly (70) Catabolism of diverse molecules
including cholesterol, branched chain amino acids, and odd chain fatty acids is
accomplished through propionyl-CoA (71). Thus, a fundamental understanding of the
acyl-CoA chemical space is relevant to a wide spectrum of cellular biochemical
transformations.
Perturbations of acyl-CoA biosynthesis are associated with diseases that have
high morbidity and mortality, including a spectrum of inborn errors of metabolism. For
example, dysregulated propionyl-CoA metabolism caused by deficiency or aberrant
function of propionyl-CoA carboxylase (PCC) results in metabolic acidosis, coma,
mental developmental delays, and cardiac complications (72). Modulation of levels of
other acyl-CoAs can result in cellular responses such as histone acetylation, which
modulates transcriptional activation (9). In addition, exogenous exposures such as the
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pesticide and complex I inhibitor rotenone disrupt specific acyl-CoA metabolism and
cause PD-like symptoms (26).
Increasing use of liquid chromatography-tandem mass spectrometry (LCMS/MS), LC-selected reaction monitoring (SRM)/MS, and LC-high resolution MS (LCHRMS) provides orthogonal separations and structural information that are ideal for
analysis of complex analytes such as acyl-CoAs that are present in biological matrices
(73). Development of new model systems such as isolated human platelets may provide a
future platform integrating acyl-CoA analysis into quantitative metabolic studies (74).
Furthermore, coupling of stable isotopic labels, including [13C]- and [2H]-labeled
precursors, to metabolic analysis can provide new insight into cellular metabolism in
humans as well as in animal models (21).
When employing LC-MS/MS to examine the utilization of isotopically labeled
precursors including [13C1]-propionate and [13C3]-propionate for acyl-CoA biosynthesis,
we discovered a high abundance unknown chromatographic spectral feature which was
inconsistent with existing mammalian metabolic models. The present study was designed
to test the hypothesis that the unknown feature resulted from propionate metabolism to a
previously unknown acyl-CoA thioester.
4.3 Materials and methods
4.3.1 Materials
5-sulfosalicylic acid (SSA), ammonium formate solution, glacial acetic acid,
formic acid, and dimethyl sulfoxide (DMSO) were purchased from Sigma-Aldrich (St.
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Louis, MO). [13C3]-propionate, [13C1]-propionate, and 2,2-[2H2]-propionate were
purchased from Cambridge Isotopes (Tewksbury, MA). Optima LC-MS grade methanol,
acetonitrile (ACN), 2-propanol (IPA) and water were purchased from Fisher Scientific
(Pittsburgh, PA). DMEM:F12 media, fetal bovine serum (FBS), streptomycin, and
penicillin were purchased from Invitrogen (Carlsbad, CA). Charcoal stripped fetal bovine
serum (csFBS) was from Gemini Bioproducts (West Sacramento, CA). RPMI1640 media
omitting pantothenate was purchased from Athena ES (Baltimore, MD). [13C315N1]calcium pantothenate was purchased from Isosciences (King of Prussia, PA).
4.3.2 Cell line studies
HepG2 cells were grown and maintained in DMEM:F12 with 2% FBS and 2 mM
glutamine with 100,000 units/L penicillin and 100 mg/L streptomycin. For all
experiments, cells were grown to 80% confluence prior to treatment. For dose response
studies solutions of sodium propionate in maintenance media were prepared by serial
dilution from the most concentrated stock after filtration through a 0.2 µm sterile filter
(Corning Inc., Corning, NY). Spent media was aspirated and new media containing 0, 1
µM, 100 µM, 1 mM, 10 mM, or 100 mM propionate was added. After incubations
lasting 1 h, the cells were extracted and analyzed. For time-course studies, cells were
grown as above, and spent media was replaced with 1 mM propionate containing media.
At indicated time-points, cells were taken for extraction and analysis. For all mass
isotopologue distribution (MID) analysis, samples were treated with an equal
concentration to the tracer with unlabeled propionate (as a control) and processed in
parallel. The untreated samples were then analyzed and used for isotope correction as
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previously described (19). Mouse hepatocellular carcinoma Hepa1c1c7 cells, human
bronchoalveolar carcinoma H358 cells, and human colon adenocarcinoma LoVo cells
were cultured in similar conditions to the HepG2 cells, except the base media was
RPMI1640 for the H358 cells and F-12 K for the LoVo cells. Treatment and extraction
conditions were identical to that used for HepG2 cells.
4.3.3 Human platelet studies
Blood was donated by healthy volunteers under the Children’s Hospital of
Pennsylvania protocol # 01-002609. Platelet rich plasma (PRP) was isolated as
previously described (74). Briefly, donor blood was collected into acid-citrate-dextrose
tubes, gently mixed by inversion then transferred to 15 mL conical tubes. Whole blood
was spun at 170 x g for 15 min at 25 °C with no brakes. The resulting upper layer of PRP
was transferred avoiding the buffy coat and red blood cells to a 1.5 mL Eppendorf tube.
The PRP was centrifuged at 400 x g for 10 min to pellet the platelets. The supernatant
was aspirated and the platelets were gently resuspended in Tyrode’s buffer with or
without propionate, [13C3]-propionate, [13C1]-propionate, or 2,2-[2H2]-propionate. The
samples were incubated for 1 h at 37 °C, and then centrifuged at 10,000 x g for 2 min to
pellet the platelets. The resulting pellet was then taken for extraction and analysis.
4.3.4 Extraction of acyl-CoAs from cell lines and platelets
The procedures for cell extraction have been described in detail previously
(15,39,60,66,74). Briefly, cells or platelets were gently lifted and transferred to 15 mL
conical tubes, centrifuged at 500 x g for 5 min and resuspended in 1 mL of ice-cold 10%
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TCA. They were then pulse-sonicated for 30 s on ice using a sonic dismembrator
(Fisher), followed by a 5 min centrifugation at 15,000 x g at 4 °C. The supernatant was
transferred to a fresh tube, and the pellet was discarded. The supernatant was purified by
solid-phase extraction (SPE) as follows: Oasis HLB 1 cm3 (30 mg) SPE columns
(Waters) were conditioned with 1 mL of methanol followed by 1 mL of water. The
collected supernatant was applied, washed with 1 mL of water, and finally eluted using
three subsequent applications of 0.5 mL of methanol containing 25 mM ammonium
acetate. Eluted compounds were dried down under nitrogen and resuspended in 50 μL of
5% 5-SSA. Injections of 10 μL were made for LC-electrospray ionization (ESI)/MS
analysis.
4.3.5 LC-MS/MS and LC-SRM/MS analysis
Acyl-CoAs were separated using a reversed-phase HPLC Phenomenex Luna C18
column (2.0 mm × 150 mm, particle size 5 μm) with 5 mM ammonium acetate in water
as solvent A, 5 mM ammonium acetate in 95/5 ACN/water (v/v) as solvent B, and
80/20/0.1 ACN/water/formic acid (v/v/v) as solvent C. Gradient conditions were as
follows: 2% B for 1.5 min, increased to 25% over 3.5 min, increased to 100% B in 0.5
min and held for 8.5 min, washed with 100% C for 5 min, before equilibration to 2%B
for 5 min. The flow rate was 200 μL/min. Samples were analyzed using an API 4000
triple-quadrupole mass spectrometer (Applied Biosystems, Foster City, CA) in the
positive ESI mode. Samples (10 μL) were injected using a Leap CTC autosampler (CTC
Analytics, Switzerland) where they were maintained at 4 °C, and data was analyzed with
Analyst 1.4.1 software. The column effluent was diverted to the mass spectrometer from
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8 to 23 min and to waste for the remainder of the run. The mass spectrometer operating
conditions were as follows: ion spray voltage (5.0 kV), nitrogen as curtain gas (15 units),
ion source gas 1 (8 units), gas 2 (15 units), and collision-induced dissociation (CID) gas
(5 units). The ESI probe temperature was 450 °C, the declustering potential was 105 V,
the entrance potential was 10 V, the collision energy was 45 eV, and the collision exit
potential was 15 V. A constant neutral loss of 507 Da was monitored for each acyl-CoA.
LC-SRM/MS analysis was conducted using similar instrument parameters and specific
selected ions as noted in the text. LC-HRMS was conducted on a LTQ-Orbitrap XL
operated in positive ion mode at a resolution of 100,000 as previously described (66),
except that an ESI source was used and the mass spectrometer was coupled to the LC
system described above.
4.4 Results
4.4.1 Metabolism of propionate in HepG2 cells
Treatment of HepG2 cells with 10 mM propionate revealed an up-regulation of
certain acyl-CoA species after analysis by the constant neutral loss 507 Da scans to
survey short chain acyl-CoA content (Figure 4.1). The expected increase of propionylCoA with a protonated molecule (MH+) at m/z 824 was coupled to an unexpected
increase in an intense ion at m/z 864 corresponding to MH+ of a new C6 monounsaturated acyl-CoA (Figure 4.1B). Treatment under the same conditions with [13C1]propionate revealed a similar acyl-CoA profile except that MH+ for the new acyl-CoA
appeared at m/z 866 (Figure 4.1C) corresponding to a C6 acyl-CoA isotopologue
containing both [13C]-labeled carbon atoms. Furthermore, [13C3]-propionate treatment
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Figure 4.1 Propionate treatment in HepG2 cells induced distinct acyl-CoA species. MH+
observed from constant neutral loss (507 Da) scans from HepG2 cells extracted with (A)
no treatment, (B) 10 mM propionate, (C) 10 mM [13C1]-propionate, (D) 10 mM [13C3]propionate or (E) 10 mM 2-methyl-2-pentenoic acid. A new acyl-CoA with MH+ at m/z
864 was strongly induced by propionate treatment with a corresponding species at m/z
866.4 (+2 Da) and m/z 870.4 (+6 Da )for the 10 mM [13C1]-propionate and [13C3]propionate treatments, respectively. The pattern of acyl-CoA formation following10 mM
propionate treatment was identical to that observed from treatment with 10 mM trans-2methyl-2-pentenoic acid
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revealed a highly abundant ion at m/z 870, which would correspond to MH+ of a C6
mono-unsaturated acyl-CoA containing all six [13C]-atoms (Figure 4.1D). Finally,
treatment of the cells with trans-2-methyl-2-pentenoic acid resulted in the formation of a
C6 acyl-CoA with an MH+ at m/z 864 and similar constant neutral loss mass spectrum to
that observed with propionate (Figure 4.1E).
Treatment of HepG2 cells with other mono-unsaturated 6-carbon fatty acids for 1
h resulted in the substrate specific acyl-CoA profiles as demonstrated by constant neutral
loss scans of 507 Da (Supplementary figure S4.1). However, the LC-MS chromatograms
observed after treatment of cells with propionate, [13C1]-propionate, or [13C3]-propionate
could only be reproduced by the addition of trans-2-methyl-2-pentenoic acid.
Importantly, the ion at m/z 838 corresponding to MH+ of butyryl -CoA was only
observed after treatment with unbranched hexanoyl fatty acids. This confirmed the
differential metabolism of a 2-methyl-substituted pentanoate when compared with an
unbranched hexanoate (75). Correspondingly, propionate did not increase the formation
of butyryl-CoA, confirming that neither propionyl-CoA nor its metabolites were
catabolized via unbranched fatty acid β-oxidation. Treatment of other cell lines with
propionate, including mouse hepatocellular carcinoma Hepa1c1c7 cells, human
bronchoalveolar carcinoma H358 cells, and human colon adenocarcinoma LoVo cells,
also resulted in generation of the new acyl-CoA with MH+ at m/z 864 (Supplemental
figure S4.2).
4.4.2 Dose-response and time-course experiments with propionate
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Figure S4.1:LC-constant neutral loss/MS analysis of acyl-CoAs resulting from the treatment
HepG2 cells with other 6-carbon, mono-unsaturated fatty acids. The pattern of CoA formation was
clearly different from that observed with trans-2-methyl-2-pentenoic acid or propionate. MH+
observed from constant neutral loss (507 Da) scans of HepG2 cell extracts after treatment with
other 6-carbon, mono-unsaturated fatty acids for 1 h before acyl-CoA extraction and analysis.
Cells were treated with 10mM (A) 4-methyl-pentenoic acid, (B) trans-2- hexenoic acid, (C) trans-3hexenoic acid, (D) 4-hexenoic acid, or (E) 5-hexenoic acid.
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Figure S4.2: Propionate treatment induced formation of 2-methyl2-pentenoyl-CoA in other human and murine cells lines. LC-SRMMS/MS monitoring of the transition m/z 864 to m/z 357 of extracts
from other cell lines including murine hepatocellular carcinoma
Hepa1c1c7 cells, human bronchioavelolar carcinoma H358 cells,
and human colorectal adenocarcinoma LoVo cells, revealed a
strong increase in the chromatographic peak corresponding to 2methyl-2-pentenoyl-CoA.
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Formation of the new acyl-CoA increased in a dose-dependent manner with increasing
propionate treatment over the range of 0-1 mM. Its formation reduced with 10 mM and
100 mM propionate suggesting that this new metabolic pathway could be inhibited at
high propionate concentrations or that the new acyl-CoA underwent further propionatedependent metabolism (Figure 4.2A). An increase of almost an order of magnitude in
concentration of the new acyl-CoA was observed between 1 and 100 µM propionate with
almost another order of magnitude increase between 100 µM and 1 mM. Following
treatment with 1 mM propionate, the MH+ at m/z 864 increased rapidly to a maximum at
1 h, with a stable plateau of levels from 1 h to 12 h, followed by a decrease until 24 h
(Figure 4.2B).
4.4.3 Stable isotope labeling by essential nutrients in cell culture (SILEC)
[13C315N1]-pantothenic acid was used to label all CoA species in mouse
hepatocellular carcinoma Hepa1c1c7 cells as previously described (26). Co-elution
experiments conducted after the addition of unlabeled propionate provided further
support the identification of the new metabolite as trans-2-methyl-2-pentenoyl-CoA. LCSRM/MS monitoring of the transition m/z 864 (MH+) to m/z 357 (MH+-507) as well as
the corresponding [13C315N1]-labeled acyl-CoA transition m/z 868 (MH+) to 361 (MH+507) demonstrated co-elution of the propionate-derived acyl-CoA with MH+ at m/z 864
with the [13C315N1]-labeled acyl-CoA obtained from the SILEC Hepa1c1c7 cells (Figure
4.3A). Likewise, the trans-2-methyl-2-pentenoic acid derived analyte with MH+ at m/z
864 co-eluted with the corresponding [13C315N1]-labeled acyl-CoA (Figure 4.3B). Finally,
LC-SRM/MS analysis of the trans-2-methyl-2-pentenoic acid-derived acyl-CoA (SRM
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Figure 4.2: Formation of the new acyl-CoA was dose- and timedependent following propionate treatment in HepG2 cells. (A)
LC-SRM/MS analysis of the transition m/z 864 (MH+) to m/z
357 (MH+- 507) for the new acyl-CoA following treatment with
indicated doses of sodium propionate for 1 h. (B) Time course
of generation of the new acyl-CoA by LC-SRM/MS analysis
following treatment of HepG2 cells with 1 mM sodium
propionate.
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Figure 4.3: Co-elution experiments confirmed that the new acyl-CoA is 2-methyl-2pentenoyl-CoA. Hepa1c1c7 cells, grown with or without [13C315N1]-pantothenate, were
treated with propionate to generate [13C315N1]-propionyl-CoA, which was then converted
to the new [13C315N1]-acyl-CoA with propionate.
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Table 4.1: Accurate mass and isotope analysis of the putative 2-methyl-2pentenoyl-CoA derived from treatment of HepG2 cells with propionate, [13C1]propionate, and 2,2-[2H2]-propionate.

Predicted Formula
(MH+)

Found
mass

Predicted
mass

delta
(ppm)

C27H45N7O17P3S+

864.1776

864.1800

-2.77

866.1846

866.1867

-2.42

864.1784
865.184
866.1908

864.1800
865.1863
866.1926

-1.85
-2.65
-2.07

Propionate
M0
13

[ C1]-Propionate
M2
2,2-[2H2]-Propionate
M0
M1
M2

13

C212C25H45N7O17P3S+

C27H45N7O17P3S+
C272H11H44N7O17P3S+
C272H21H43N7O17P3S+
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transition m/z 864 to m/z 357), the [13C315N1]-labeled acyl-CoA (SRM transition m/z 868
to m/z 361), and the [13C3]-propionate-derived [13C6]-acyl-CoA (SRM transition m/z 870
to m/z 363) all co-eluted (Figure 4.3C).
LC-HRMS analysis was employed to confirm that the MH+ at m/z 864 arose from
a C6 mono-saturated acyl-CoA (Table 4.1). An intense MH+ was observed at m/z
864.1776 which corresponded to a molecular formula of C27H45N7O17P3S+ (M0, ∆m -2.77
ppm). The acyl-CoA from [13C1]-propionate-treated cells gave an intense MH+ at m/z
866.1846 corresponding to a molecular formula of 13C212C25H45N7O17P3S+ (M2, ∆m -2.42
ppm). Importantly, LC-HRMS was able to distinguish MH+ of the

13

C-istopologue

arising from the natural abundance of 13C - 13C212C25H45N7O17P3S+ (m/z 866.1846) from
the MH+ of hexanoyl-CoA, which had the same nominal mass but different accurate mass
C27H47N7O17P3S+ (m/z 866.1956, ∆m 12.70 ppm). Interestingly, the acyl-CoA derived
from 2,2-[2H2]-propionate, revealed intense MH+ at m/z 865.1840 (M1, ∆m -2.65 ppm)
and m/z 866.1908 (M2, ∆m -2.07 ppm), indicating the incorporation of either 1 or 2
deuterium atoms into the new acyl-CoA.
4.4.4 MID analyses
HepG2 cells treated with 1mM [13C3]-propionate revealed the anticipated M3
enrichment into MH+ of propionyl-CoA (Figure 4.4A). Furthermore, propionyl-CoA
extracted from HepG2 cells treated with 1 mM 2,2-[2H2]-propionate revealed nearly
equal enrichment in M1 and M2 of the MH+, indicating a portion of deuterium was lost
through protium exchange. Similar to the observations in the constant neutral loss
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Figure 4.4: MID analysis revealed the stoichiometry and positional specificity of
incorporation of propionate into 2-methyl-2-pentenoyl-CoA. Labeling % of HepG2
derived acetyl-, propionyl-, succinyl- and the new acyl-CoA. Treatment with [13C3]propionate resulted in enrichment of M3 propionyl-CoA (A) and M+6 in the new acyl-CoA
(B), with virtually no detectable enrichment in acetyl-CoA (C) and minimal M3 labeling in
succinyl-CoA (D). 2,2-[2H2]-propionate treatment yielded nearly equal M1 and M2
labeling in propionyl- CoA (A) as well as the new acyl-CoA (B) with very little enrichment
in acetyl-CoA (C) and succinyl-CoA (D). Taken together these findings suggest direct a
direct condensation of 2 propionyl-CoA molecules to for the new acyl-CoA independently
of anaplerosis into the Krebs cycle.
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experiments, [13C3]-propionate treatment resulted in approximately 80% of the new acylCoA to be enriched in the M6 isotopologue (Figure 4.4B); indicating direct incorporation
of 6 carbon atoms from 2 molecules of propionyl-CoA without any carbon loss.
Deuterium labeling in the new acyl-CoA was almost identical to the labeling in
propionyl-CoA, with nearly equal enrichment of the M1 and M2 of MH+ and virtually no
labeling in M3 or M4 (Figure 4.4C). M3 labeling, which was present in succinyl-CoA
only for the [13C3]-propionate treatment, arose from anaplerosis into the Krebs cycle
(Figure 4.4D).
4.4.5 Human platelet studies
Platelets from healthy volunteers were isolated for isotopic tracer studies using a
previously described procedure (74). Studies were conducted using platelets because
although they are anuclear, they are rich in mitochondria, and produce much higher levels
of mitochondrial metabolites than lymphocytes (74) or neutrophils (data not shown).
Thus, platelets have much higher basal oxygen consumption rate when compared with
lymphocytes or neutrophils (76). In contrast to platelets, lymphocytes primarily only
utilize oxidative phosphorylation under basal conditions and they have a limited capacity
to increase glycolytic flux (76). Neutrophils have little or no dependence on oxidative
phosphorylation and glycolysis is not increased when mitochondrial ATP synthase is
inhibited (76). Furthermore, platelets are amenable to isolation and purification, and do
not require culturing, which could otherwise introduce changes in cellular metabolism.
Finally, alterations in platelet mitochondrial function have been demonstrated in a variety
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Figure 4.5: MID analysis with human platelets confirmed incorporation of
propionate into 2-methyl-2-pentenoyl-CoA. Treatment of platelets with [13C3]propionate resulted in the expected enrichment in MH+ of M3 propionyl-CoA
(A) and in M6 of MH+ in the new acyl-CoA (B) along with a slight enrichment in
M5 (B). This indicated a minor pathway involving a decarboxylation step with
subsequent incorporation of an unlabeled carbon atom. In agreement with this
finding, [13C1]-propionate yielded a major amount of M2 labeling in MH+ in the
new acyl-CoA (B) together with a slight enrichment of M1 in MH+ of the new
acyl-CoA (B), together with the anticipated M1 labeling in MH+ of propionylCoA (A). 2,2-[2H2]-propionate treatment gave similar labeling of M1 and M2 in
propionyl-CoA (A) and the new acyl-CoA (B) resulting from protium/deuterium
exchange of the labile deuterium atoms on the α-carbon atom of propionate.
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Figure 4.6: Schematic showing stable isotope labeling (13C in red closed circles and 2H in blue
open circles) together with a proposed mechanism for conversion of two molecules of
propionate into trans-2-methyl-2-pentenoyl-CoA. The stable isotope labeling pattern was
observed with all mammalian cell lines that were used as well as with human platelets.
Incubations of the cell lines and platelets with [13C3]-propionate resulted in [13C3]-labeling of all
six-carbon atoms.
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of diseases so that they have been proposed to serve as potential markers of systemic
mitochondrial dysfunction (74,77).
The M0 through M3 isotopologues of MH+ from propionyl-CoA, and the M0
through M6 isotopologues of MH+ from the new acyl-CoA were monitored by LCSRM/MS. After adjustment for natural isotopic abundance, treatment with unlabeled
propionate gave essentially 100% M0 isotopologue at MH+ for both propionyl-CoA
(Figure 4.5A) and the new acyl-CoA (Figure 4.5B). [13C1]-propionate treatment resulted
in a predominant M1 isotopologue at MH+ for propionyl-CoA (Figure 4.5A). However
there was a predominant M2 isotopologue at MH+ for the new acyl-CoA (Figure 4.5B).
Similarly, [13C3]-propionate resulted in a predominant M3 isotopologue at MH+ for
propionyl-CoA (Figure 4.5A), whereas there was a predominant M6 isotopologue at MH+
for the new acyl-CoA (Figure 4.5B). In contrast, 2,2-[2H2]-propionate treatment resulted
in a similar mixture of M0, M1 and M2 isotopes in MH+ for both propionyl-CoA (Figure
4.5A) and the new acyl-CoA (Figure 4.5B).
4.4.6 Characterization of the new acyl-CoA as 2-methyl-2-pentenoyl-CoA and
mechanism of formation
The LC-MS/MS properties of the new 6 carbon mono-unsaturated acyl-CoA were
identical with the acyl-CoA that was formed by the addition of trans-2-methyl-2pentenoic acid to human cell lines and platelets. This finding together with the isotope
labeling data provided compelling evidence for the structural assignment of the new acylCoA as trans-2-methyl-2-pentenoyl-CoA (Figure 4.6). Its mechanism of formation must
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account for the results of three isotope-labeling experiments: (1) conservation of the
[13C1]-atom from each precursor propionate. (2) Conservation of all [13C3]-atoms from
precursor propionate. (3) Exchangeable deuterium labeling with a maximum of 2 total
conserved [2H]-atoms from precursor propionate (Figure 4.6). The proposed mechanism
involves initial formation of propionyl-CoA through the action of a short chain CoA
synthetase (Figure 4.6). The limited protium/deuterium exchange observed in the
formation of propionyl-CoA from 2,2-[2H2]-propionate (Figure 4.5A) was consistent with
the lability of the deuterium atoms on the α-carbon atom (C2) during CoA thioester
formation. The propionyl-CoA was then converted to propionyl-acyl carrier protein
(ACP) and 2-methyl-malonyl-CoA through the action of propionyl-CoA:ACP
transacylase or propionyl-CoA carboxylase, respectively (Figure 4.6). Subsequently, 3keto-ACP synthase added an additional propionate moiety from propionyl-ACP with a
concomitant loss of CO2 (containing the carbon added during the formation of 2-methylmalonyl-CoA) and free ACPSH. This conserved the [13C]-atom from 1-[13C]-propionate
and partially conserved one of the deuterium atoms at C2 derived from the first molecule
of 2,2-[2H2]-propionate. Sequential actions of a reductase and dehydratase resulted in the
generation of an olefin, which was converted to the final trans-2-methyl-2-pentenoylCoA molecule by a transacylase (Figure 4.6). All deuterium atoms that were originally on
C2 from the first propionate molecule were lost during the dehydration step (Figure 4.6).
The remaining deuterium atoms at C2 from the second propionate molecule were
partially exchanged for protium (Figure 4.5B) in a similar manner to that observed in
propionyl-CoA (Figure 4.5A).
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4.5 Discussion
Diseases of propionic acid metabolism, most notably, propionic and
methylmalonic acidemias, result in a widely dysregulated metabolome (78-80). This
follows from the diverse metabolic capacity that utilizes propionyl-CoA as an
intermediate, such as catabolism of the branched chain amino acids isoleucine and valine
via propionyl-CoA. Propionyl-CoA can also be formed directly from activation of
propionate with free CoASH. Additionally, catabolism of threonine, methionine,
cholesterol, odd-chain fatty acids, and C5-ketone bodies are precursors in the formation of
propionyl-CoA. Importantly, metabolism via propionyl-CoA provides an anaplerotic
pathway (through D-malonyl-CoA then L-malonyl-CoA) to generate succinyl-CoA as a
precursor to other intermediates in the Krebs cycle (81,82). The effectiveness of
propionyl-CoA as an anaplerotic precursor is driven by a tightly regulated equilibrium,
allowing a diverse pool of substrates to enter the Krebs cycle (83).
Considering this diversity of substrates and products for reactions involving
propionyl-CoA, it is not surprising that many studies have implicated aberrant propionate
metabolism as leading to disruptions in other metabolic pathways. The existence of a
propionyl-CoA to trans-2-methyl-2-pentenoyl-CoA metabolic pathway may explain the
findings of unique acylcarnitines with branched medium chain acyl groups in the urine of
propionic acidemia patients (79). This would occur through fatty acid elongation,
oxidation, or other metabolism from the precursor metabolite identified here as trans-2methyl-2-pentenoyl-CoA. In particular the biochemical relationship between CoAs and
carnitines makes this scenario seem likely. Our study has provided the first identification
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of this metabolite and so there is currently no information on the physiological relevance
of this finding. However, previous untargeted metabolomics surveys have most likely
observed trans-2-methyl-2-pentenoylcarnitine but lacked sufficient depth of experimental
information to characterize the exact structure or propose a mechanism of formation (80).
Clearly, further research is needed to examine the biochemistry of the newly identified
trans-2-methyl-2-pentenoyl-CoA, as we did not investigate the enzymes involved in its
formation or its potential for further metabolism. Although we did not quantify the levels
of propionic acid in the media over the course of the experiments, an understanding of the
utilization of the substrate propionate in terms of kinetics and relative incorporation into
downstream metabolites would be useful in the future.
Relevant to the present study, the normal physiological range of propionic acid in
portal vein blood is reported to range between 0.1-0.3 mM in non-fasting humans, and
lower in fasting individuals (84). Peripheral blood concentrations are much lower at 6
µM, but patients in ketotic hyperglycemia may have 0.1-0.3 mM propionic acid in
peripheral blood (85). Reported incompatibility with life was described at blood
concentrations of 4-6 mM propionic acid in propionic academia patients in crisis (86).
Although we observed no immediate cellular toxicity by light microscopy within the time
frame of treatment at 10 mM and 100 mM, we cannot discount the seemingly likely
conclusion that the decrease in of trans-2-methyl-2-pentenoic acid formation at these
doses was due to cell death. The lack of detection of the intermediate at basal conditions
may relate to the fact that there is no sodium propionate added to DMEM base media.
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Thus, the doses of propionate used in this study range from below to above physiological
relevance.
Understanding of propionate metabolism has been driven not only by human
disease but also by the critical nature of propionate for branched chain hydrocarbons and
hormones in insects (71,87). In fact, 2-methyl-2-pentenoic acid is an aggregation
pheromone of the grain borer, and produced by the grain borer when feeding (88). As
sources of propionate are relatively energetically expensive to a developing insect,
branched chain products are likely to be biologically important (89). Such branched chain
products include 2-methyl branched alkanes, critical components of the cuticular lipids
that compose significant portions of the outer shells of insects.
Absolute quantification of intracellular metabolites serves an indispensable role in
identifying and characterizing new metabolic pathways. For this purpose, LC-SRM/MS is
the gold standard for quantification because it affords high sensitivity and specificity
from complex biological matrices especially when coupled to the isotopic labeled analogs
of target analytes as internal standards to adjust for variation in extraction and analysis
(20). However, it is also useful in combination with stable isotope labeling for examining
alterations that can occur to cellular metabolite pools (19,26). Monitoring the uptake and
conversion of isotopic labeled nutrients into downstream metabolic pathways can shed
light on unknown components of metabolism (21). The utility of stable isotopes for
metabolic elucidation is demonstrated by the findings in this report, where [13C1]-, [13C3], and 2,2-[2H2]-labeled propionate provided complimentary metabolic information in
conjunction with LC-SRM/MS and LC-HRMS. For quantitative studies, stable isotope
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analog internal standards utilizing carbon or nitrogen labels are more desirable than
deuterium, which causes small LC retention time shifts and can potentially undergo
protium/deuterium exchange. However, deuterated analogs may provide insight into
unexpected metabolic pathways as demonstrated in this study and in the recent
elucidation of folate-dependent generation of NADPH (90). Constantly improving
capabilities of LC-SRM/MS and LC-HRMS may warrant re-examination of previously
studied metabolic pathways, and may make identification of previously unrecognized
pathways possible.
4.6 Conclusion
In summary, we have used absolute quantification in combination with MID
analysis to show both the propionate-dependent metabolism and labeling from upstream
metabolic sources of trans-2-methyl-2-pentenoyl-CoA in multiple biological systems.
Future work could elucidate the enzymology of this pathway completely, as well as
assess the contribution of trans-2-methyl-2-pentenoic acid to metabolic crisis in
propionic academia patients.
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Chapter 5: Inhibition of neuronal cell mitochondrial complex I with rotenone
increases lipid β-oxidation, supporting acetyl-coenzyme A levels
5.1 Abstract
Rotenone is a naturally occurring mitochondrial complex I inhibitor with a known
association to Parkinsonian phenotypes in both human populations and rodent models.
Despite these findings, a clear mechanistic link between rotenone exposure and neuronal
damage remains to be determined. Here, we report alterations to lipid and glutamine
metabolism in SH-SY5Y neuroblastoma cells exposed to rotenone. The absolute levels of
acetyl-coenzyme A (CoA) were found to be maintained in spite of a significant decrease
in glucose derived acetyl-CoA. Furthermore, palmitoyl-CoA levels were maintained,
whereas, levels of many of the medium chain acyl-CoA species were significantly
reduced. Additionally, using isotopologue analysis it was found that β-oxidation of fatty
acids of varying chain lengths helped maintain acetyl-CoA levels. Rotenone also induced
increased glutamine utilization for lipogenesis, in part through reductive carboxylation as
has been found previously in other cell types. Finally, palmitoylcarnitine levels were
increased in response to rotenone, indicating an increase in fatty acid import. Taken
together, these findings show alterations to lipid and glutamine metabolism play an
important compensatory role in response to complex I inhibition by rotenone.
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5.2 Introduction
Rotenone is a naturally occurring organic pesticide known to inhibit complex I of
the mitochondrial electron transport chain (91). Epidemiological studies have suggested a
positive correlation between rotenone exposure and PD in human populations (92).
Furthermore, chronic rotenone exposure induces a Parkinsonian phenotype in rodents
(93,94). Despite a known association between rotenone and dopaminergic neuronal
damage, the mechanistic cause of neuronal cell death remains unknown.
There is substantial evidence to suggest that mitochondrial dysfunction plays an
important role in the development of PD (95-98). Mitochondrial abnormalities have been
well documented in PD patients, often coinciding with elevated markers of oxidative
stress (99,100). Rotenone can induce the formation of reactive oxygen species (ROS)
resulting in oxidative stress, indicating a potential mechanistic link between ROS and PD
(101,102). On the other hand, it is unlikely that oxidative stress is the sole factor that
links mitochondrial dysfunction with PD, as multiple studies have shown that antioxidant
supplementation fails to abrogate the progression of PD in humans (16). Therefore,
defects in mitochondrial metabolism apart from ROS production could be important to
the pathogenesis of PD. The present study was initiated in order to further characterize
the metabolic perturbations and expand upon our current understanding of mitochondrial
abnormalities that result from complex I inhibition by rotenone using SH-SY5Y cells.
Although SH-SY5Y cells are derived from a human neuroblastoma, they are widely used
as an in vitro cell model of dopaminergic neurons in PD (103).
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Previous findings from our group revealed that biosynthesis of succinyl-CoA was
inhibited at low concentrations of rotenone (IC50 25 nM), while acetyl-CoA was
maintained at constant levels in SH-SY5Y cells (26). Additionally, studies conducted
with [13C6]-glucose revealed that glycolytically-derived acetyl-CoA was reduced
substantially in response to inhibition of mitochondrial complex I by rotenone (26).
These studies have now been expanded to include both medium and long-chain acyl-CoA
species. Furthermore, potential compensatory metabolic alterations for maintenance of
acetyl-CoA levels in response to rotenone have been investigated by utilizing stable
isotopically-labeled fatty acids and stable isotopically-labeled glutamine in combination
with isotopologue analyses employing mass spectrometry (MS)-based methodology
(21,104,105). Isotopologues are defined as chemical species that differ only in the
isotopic composition of their ions. Thus, an isotopologue has at least one atom with a
different number of neutrons than its major naturally occurring form.
5.3 Materials and methods
5.3.1 Materials
N-(tert-butyldimethylsilyl)-N-methyl-

trifluoroacetamide

(MTBSTFA),

5-

sulfosalicilic acid (SSA), ammonium formate solution, glacial acetic acid, rotenone,
formic acid, [1,2,3,4-13C4]-palmitoylcarnitine, [13C16]-palmitic acid, [13C515N2]-glutamine,
methoxyamine HCl, pyridine, pentafluorobenzyl (PFB) bromide, diisopropylethylamine
(DIPEA) and dimethyl sulfoxide (DMSO) were purchased from Sigma-Aldrich (St.
Louis, MO). [1,2,3,4-13C4]-sodium octanoate was purchased from Cambridge Isotopes
(Tewksbury, MA). Optima LC-MS grade methanol, acetonitrile (ACN), 2-propanol (IPA)
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and water were purchased from Fisher Scientific (Pittsburgh, PA). 2-(2-pyridyl) ethyl
functionalized silica gel 100 mg/1 mL tubes were obtained from Supelco Analytical
(Bellefonte, PA). DMEM:F12 media, fetal bovine serum (FBS), streptomycin, and
penicillin were purchased from Invitrogen (Carlsbad, CA). Charcoal stripped fetal bovine
serum (csFBS) was from Gemini Bioproducts (West Sacramento, CA). RPMI1640 media
omitting pantothenate was purchased from Athena ES (Baltimore, MD). [13C3

15

N1]-

calcium pantothenate was purchased from Isosciences (King of Prussia, PA). Oasis HLB
solid phase extraction (SPE) cartridges were from Waters (Milford, MA). SH-SY5Y cells
were obtained from the laboratory of Dr. David Lynch at the Children’s Hospital of
Philadelphia.
5.3.2 Cell culture and rotenone treatments
SH-SY5Y cells were maintained in 1:1 DMEM:F12 media, supplemented with
10% fetal bovine serum, 2 mM L-glutamine, penicillin and streptomycin. Cells were
incubated at 37 °C and 95% humidity with 5% CO2. Cells were treated with either freshly
prepared rotenone in DMSO (100 nM final concentration) or 1 % DMSO vehicle control
when cells had reached approximately 80% confluence. For isotopic labeling
experiments, cells were treated in the presence of media in which the nutrients or
precursors of interest were substituted for their isotopic analogs.
5.3.3 Liquid chromatography-selected reaction monitoring (LC-SRM)/MS analysis of
acyl-CoA thioesters
All CoAs were separated using a reversed-phase HPLC Phenomenex Luna C18
column (2.0 mm × 150 mm, particle size 5 μm) with 5 mM ammonium acetate in water
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as solvent A, 5 mM ammonium acetate in ACN/water (95:5; v/v) as solvent B, and
ACN/water/formic acid (80:20:0.1; v/v/v) as solvent C as described previously (39). A
linear gradient was run as follows: 2% B for 1.5 min increased to 25% over 3.5 min,
increased to 100% B in 0.5 min and held for 8.5 min, washed with 100% C for 5 min,
before equilibration for 5 min. The flow rate was 200 μL/min. Samples were analyzed
using an API 4000 triple-quadrupole mass spectrometer (Applied Biosystems, Foster
City, CA) in the positive electrospray (ESI) mode. Samples (10 μL) were injected using a
Leap CTC autosampler (CTC Analytics, Switzerland) where they were maintained at 4
°C. Data were analyzed using Analyst 1.4.1 software (AB Sciex). The column effluent
was diverted to the mass spectrometer from 8 to 23 min and to waste for the remainder of
the run. The mass spectrometer operating conditions were as follows: ion spray voltage
(5.0 kV), nitrogen as curtain gas (15 units), ion source gas 1 (8 units), gas 2 (15 units),
and collision-induced dissociation (CID) gas (5 units). The ESI probe temperature was
450 °C, the declustering potential was 105 V, the entrance potential was 10 V, the
collision energy was 45 eV, and the collision exit potential was 15 V. A loss of 507 Da
was monitored for each acyl-CoA.
5.3.4 LC-SRM/MS analysis of citrate, isocitrate, and α-ketoglutarate
The three metabolites were analyzed using a reversed-phase HPLC Xbridge
BEH130 C18 column (2.0 mm × 50 mm, pore size 3.5 μm) with 5 mM ammonium
acetate in water/ACN/formic acid (40:60:0.1; v/v/v) as solvent A, and 100/0.1
ACN/formic acid (100:01; v/v) as solvent B. A linear gradient was run as follows: 0% B
for 1 min, increased to 100% B over 5 min, and held for 5 min, down to 0% B over 1
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min, before equilibration for 4 min. The flow rate was 500 μL/min. Samples were
analyzed using the API 4000 triple-quadrupole mass spectrometer equipped with
autosampler and software described previously. The column effluent was diverted to the
mass spectrometer from 2.5 to 13 min. The mass spectrometer operating conditions were
as follows: ion spray voltage (5.0 kV), nitrogen as curtain gas (15 units), ion source gas 1
(20 units), gas 2 (25 units), and CID gas (6 units). The ESI probe temperature was 400
°C, the declustering potential was 80 V, the entrance potential was 10 V, the collision
energy was 25 eV, and the collision exit potential was 15 V.
5.3.5 LC-SRM/MS analysis of succinate, fumarate, and malate
The three diacids converted to PFB derivatives (see below) were separated using a
Chiralpak AD-H column (250 × 4.6 mm i.d., 5 μm; Daicel Chemical Industries, Ltd.,
Tokyo, Japan) at a flow rate of 1 mL/min. Solvent A was hexanes and solvent B was
IPA/methanol (1:1; v/v). The linear gradient was as follows: 1% B for 3 min, increased to
60% B over 22 min and held for 4 min, down to 1 % B over 1 min prior to a 5 min
equilibration. The separation was performed at 30°C and a post-column addition (0.75
mL/ min methanol) was used. MS analysis was conducted on a Thermo Scientific TSQ
Quantum Ultra AM mass spectrometer (Thermo Scientific, San Jose, CA, USA) equipped
with an atmospheric pressure chemical ionization (APCI) source in the electron capture
(EC) negative ion mode (106). The TSQ Quantum operating conditions were as follows:
vaporizer temperature, 350°C; heated capillary temperature, 300°C; corona discharge
needle, 30 μA. The sheath gas (nitrogen) and auxiliary gas (nitrogen) pressures were 35
and 10 (arbitrary units), respectively. Collision-induced dissociation (CID) used argon as
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the collision gas at 1.5 mTorr.
5.3.6 LC-MS analysis of palmitoylcarnitine
The acylcarnitine was analyzed by LC-high resolution MS as described
previously (66). LC separations were conducted using a Waters nano-ACQUITY UPLC
system (Waters Corp., Milford, MA, USA) with 10 mM ammonium formate in
water/ACN/formic acid (40:60:0.1; v/v/v) as solvent A and 10 mM ammonium formate
in IPA/ACN/formic acid (90:10:0.1; v/v/v) as solvent B. A Waters BEH130 C18 column
(100 µm × 150 mm, 1.7 µm pore size; Waters Corp) was employed for reversed phase
separation. A partial loop injection of 3 μL was made at a flow rate of 1400 nL/min. The
linear gradient was run from 30% B to 95% B over 30 min. The LTQ XL-Orbitrap hybrid
mass spectrometer (Thermo Fisher) was used in positive ion mode at a resolution of
60,000 with a Michrom captive spray ESI source. The operating conditions were: spray
voltage at 4 kV; capillary temperature at 250°C; capillary voltage at 35 V.
5.3.7 Short-chain acyl-CoA extraction
Extractions were performed as described in detail previously (15). Briefly, cells
were lifted manually with a cell scraper, centrifuged at 500 x g for 5 min and resuspended
in 1 mL of ice-cold 10% TCA and pulse-sonicated for 30 s on ice using a sonic
dismembranator (Fisher), followed by a 5 min centrifugation at 15,000 x g. The
supernatant was transferred to a fresh tube, and the pellet was discarded. The supernatant
was purified by solid-phase extraction as follows: Oasis HLB 1 cm3 (30 mg) SPE
columns (Waters) were conditioned with 1 mL of methanol followed by 1 mL of water.
The collected supernatant was applied, washed with 1 mL of water, and finally eluted
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using three subsequent applications of 0.5 mL of methanol containing 25 mM ammonium
acetate. Eluted compounds were dried down under nitrogen and resuspended in 100 μL of
5% 5-SSA. Injections of 10 μL were made for LC-ESI/MS/MS analysis.
5.3.8 Long-chain acyl-CoAs extraction
Cells were lifted manually with a cell scraper, centrifuged at 500 x g for 5 min
and resuspended in 550 µL/10 cm2 plate of ACN:IPA (3:1; v/v). The internal standard
prepared (as described below) using stable isotope labeling by essential nutrients in cell
culture (SILEC) was added (200 µL) and samples were pulse sonicated with a probe tip
sonicator on ice 30 times for 0.5 s. 250 µL of 100 mM KH2PO4 (pH 6.7) was added to the
samples, then vortex-mixed and spun down for 10 min at 16,000 x g at 4°C. The
supernatant was transferred to a glass tube and acidified with 125 µL of glacial acetic
acid. SPE columns were equilibrated with 1 mL of ACN/IPA/water/acetic acid (9:3:4:4;
v/v/v/v) washing solvent. Samples were transferred to the columns, which were washed
two times with 1 mL of the washing solvent. The acyl-CoAs were then eluted by washing
the columns twice with 500 µL methanol/250 mM ammonium formate (4:1; v/v) into
glass tubes. After evaporation to dryness under nitrogen gas, the eluates were redissolved in 50 µL of water/ACN (7:3; v/v) containing 5 % SSA (w/v) and transferred to
HPLC vials for LC-SRM/MS analysis. For isotopologue analysis, the same extraction
was used, except that no internal standard was added.
5.3.9 Organic acid extraction and derivatization
Cells were lifted manually with a cell scraper, centrifuged at 500 x g for 5 min
and resuspended in 750 µL/10 cm2 plate of ice cold methanol/water (4:1; v/v) for
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extraction. Samples were pulse sonicated on ice for 30 s. Sonicated samples were
centrifuged at 16,000 x g for 10 min. The supernatant was then transferred to a clean tube
and dried under nitrogen. For citrate, isocitrate, and α-ketoglutarate dried residues were
derivatized with 150 µL methoxyamine HCl in pyridine (20 mg/mL) at 40°C for 1 hr.
Samples were then spiked with 50 µL MTBSTFA and incubated at 70°C for 1 h. 20 µL
of each samples was then diluted with 980 µL ACN and analyzed by LC-SRM/MS. For
succinate, fumarate, and malate dried samples were derivatized with 100 µL DIPEA in
ACN (2.5/97.5 v/v) and 50 µL PFB-Br in ACN (1:4 v/v) at 37°C for 30 min (107).
Samples were dried under nitrogen and resuspended in hexanes/ethanol (95:5 v/v) prior
to LC-SRM/MS analysis.
5.3.10 Palmitoylcarnitine extraction
Cells were lifted manually with a cell scraper, centrifuged at 500 x g for 5 min
and resuspended in 2 mL/10 cm2 plate of chloroform/methanol (2:1; v/v) and vortex
mixed for 30 s following the addition of internal standard. 500 µL of water was added
followed by vortex mixing for an additional 30 s. Samples were then centrifuged at 2,500
x g for 10 min. Lower phases were transferred and dried under nitrogen. Dried samples
were resuspended in 50 µL ACN/IPA/water (5:3:2; v/v/v). Samples were analyzed by
stable isotope dilution LC-high resolution MS.
5.3.11 Generation of SILEC internal standards
Hepa1c1c7 cells were passaged at least 7 times in custom RPMI 1640 media
without calcium pantothenate and containing 10% csFBS, 100 units/mL penicillin, 100
mg/L streptomycin, and 2 mg/L [13C315N1]-calcium pantothenate as described previously
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(15,39). 24 h before extraction, “ultra-labeling” with media as above, but omitting csFBS,
was performed in order to ensure optimal stable isotope labeling of CoA species. Upon
completion of labeling, Hepa1c1c7 cells were lifted manually with a cell scraper,
centrifuged at 500 x g for 5 min and re-suspended in 750 µL/10cm2 plate of ACN:IPA
(3:1; v/v). Samples were sonicated with a probe tip sonicator on ice 30 times for 0.5 s.
250 µL of 100 mM KH2PO4 (pH 6.7) were added to the samples, then vortex-mixed and
spun down for 10 min at 16,000 x g at 4°C. The supernatant was pooled and stored in 80°C until use.
5.4 Results
5.4.1 Rotenone causes a decrease in medium-chain acyl-CoA levels
Expanding upon our previous findings (26), we used our recently developed acylCoA SILEC methodology to evaluate the impact of rotenone on intracellular levels of
short, medium, and long-chain acyl-CoA species. SH-SY5Y cells were treated with 100
nM rotenone or vehicle control DMSO for 6 h. Harvested cells were spiked with SILEC
internal standards and extracted, followed by LC-SRM/MS analysis. Absolute levels of
each acyl-CoA (Table 5.1) were normalized to control values (Figure 5.1). Acetyl-CoA
levels were maintained in response to rotenone as was observed previously (15).
Interestingly, absolute levels of longer-chain CoA species were also unchanged. In
contrast concentrations of medium-chain acyl-CoAs (C6, C8, C10, C12) were
significantly decreased in response to rotenone (Figure 5.1). The magnitude in reduction
of medium-chain acyl-CoAs ranged from 25% for C12:0 to 80% for C6:0. These findings
showed that rotenone induced metabolic alterations to maintain acetyl- and long-chain
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Figure 5.1: Rotenone causes a decrease in absolute levels of medium
chain acyl-CoA species. SH-SY5Y cells were incubated with 100 nM
rotenone or DMSO for 6 hours. Quenched cells samples were spiked
with SILEC internal standards for absolute quantification. Student's twotailed t-test against the relevant acyl-CoA species from the vehicle
control: * p<0.05, ** p<0.01, *** p<0.001.
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Table 5.1: Absolute levels of acyl-CoAs (pmol/106 cells ± SEM) in SHSY5Y cells after addition of 100 nM rotenone (n=4).
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CoAs, while medium-chain CoAs were reduced. This suggested that they were utilized to
maintain acetyl-CoA levels through β-oxidation. Decreased formation of the borderline
medium-chain/long-chain fatty acid, C-14 CoA was indicative that this also served to
maintain acetyl-CoA levels through β-oxidation. The decrease in levels of the C-4 shortchain CoA was in keeping with our previous observation that there was a significant
increase in its down-stream metabolite, β-hydroxybutyryl (BHB)-CoA after rotenone
treatment (Figure 5.3) (26).
5.4.2 Octanoate and palmitate oxidation are up-regulated in response to rotenone
To investigate the metabolic utilization of acyl-CoA species of varying acyl chain
lengths, isotopologue analysis was performed in cells treated with either 100 µM [13C4]sodium octanoate (Figure 5.2A) or [13C16]-palmitic acid (Figure 5.2B). SH-SY5Y cells
were treated with each tracer separately and either DMSO or 100 nM rotenone for 6 h.
Short-chain acyl-CoA species were extracted and analyzed for isotopic enrichment by
LC-SRM/MS. Both tracers clearly labeled acetyl-CoA in the M+2 isotopologue,
indicating incorporation via β-oxidation (Figure 5.2). Surprisingly, rotenone treatment
approximately doubled the incorporation of both tracers into acetyl-CoA, indicating that
fatty acid catabolism played a compensatory role in maintaining acetyl-CoA levels
(Figure 5.3). This finding indicates that metabolic shifts took place to support acetyl-CoA
production in order to maintain absolute levels despite diminished biosynthesis from
glycolysis.
5.4.3 Glutamine supports acetyl-CoA production by reductive metabolism
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Figure 5.2: Octanoate and palmitate utilization for acetyl-CoA synthesis is increased in
response to rotenone. SH-SY5Y cells were incubated with 100 µM [13C4]-sodium
octanoate or [13C16]-palmitate in combination with either 100 nM rotenone or DMSO for 6
hours and analyzed by LC-SRM/MS. Isotopic enrichment of acetyl-CoA was determined.
Unpaired t-test:** p<0.01.
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Figure 5.3: Scheme showing [13C]-labeling of metabolic intermediates by [13C16]palmitate and [13C515N2]-glutamine during lipid oxidation and oxidative and reductive
glutamine metabolism. Abbreviations: 3-HACD, 3-hydroxybutyryl-CoA dehydrogenase;
αKGD, α-ketoglutarate dehydrogenase; ACAC, acetyl-CoA carboxylase; ACAD, acylCoA dehydrogenase; ACL, ATP-citrate lyase; AST, aspartate aminotransferase; BHBD,
β-hydroxybutyrate dehydrogenase; CS, citrate synthase; CSF, cerebrospinal fluid;
ECAH, enoyl CoA hydratase; FH, fumarate dehydrogenase; GDH, glutamate
dehydrogenase; HMGCAL, 3-hydroxy-3-methylglutaryl-coenzyme A lyase HMGCAS, 3hydroxy-3-methylglutaryl-coenzyme A synthase; IDH, isocitrate dehydrogenase; MD,
malate dehydrogenase; SCAS, succinyl-CoA synthase; SD, succinate dehydrogenase.
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Previous studies have shown that glutamine plays an important role in the maintenance of
acetyl-CoA levels in cancer cells. (105,108-110). Additionally, glutamine is the most
abundant endogenous free amino acid with concentrations of 100 µg/mL (683 µM) in
serum and plasma (111,112) and 50 µg/mL (342 µM) in cerebrospinal fluid (CSF) (111).
This makes it a potentially important metabolic precursor for regulating mitochondrial
function. In order to investigate the utilization of glutamine in SH-SY5Y cells,
incubations were performed in glutamine-free media supplemented with 2 mM
[13C515N2]-glutamine and either DMSO or 100 nM rotenone for 6 h. Isotopologue
analysis of acetyl-CoA showed an approximately 3-fold increase in the relative
incorporation of glutamine into acetyl-CoA in response to rotenone as revealed by
increased labeling in the M+2 isotopologue (Figure 5.4H). Glutamine metabolism is
known to occur by both oxidative and reductive pathways and cellular stress plays in
important role in switching between the two. In particular, mitochondrial impairment and
hypoxic conditions lead to a shift to reductive metabolism, whereby isocitrate
dehydrogenase (IDH) reductively carboxylates α-ketoglutarate to form isocitrate, which
is then converted to citrate (Figure 5.3) (105,113,114). The resulting cytosolic citrate is a
substrate for ATP-citrate lyase (ACL), resulting in the formation of acetyl-CoA and
oxaloacetate. The acetyl-CoA is subsequently converted to malonyl-CoA, the precursor
to lipid biogenesis (Figure 5.3). Although informative, the observed +2 mass shift in
acetyl-CoA does not distinguish the metabolic route by which glutamine is incorporated
into acetyl-CoA. Utilizing [13C515N2]-glutamine, the same experiment was performed
followed by isotopologue analysis of citrate. As expected from the labeling patterns,
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Figure 5.4: Glutamine supports acetyl-CoA production through reductive carboxylation.
SH-SY5Y cells were incubated with 100 µM [13C5 15N2]-glutamine and either 100 nM
rotenone (open bars) or DMSO (closed bars) for 6 hours and analyzed by LC-SRM/MS.
Isotopic enrichment of acetyl-CoA and citrate was determined. Unpaired t-test : * p<0.05,
** p<0.01, *** p<0.001.
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oxidative metabolism of glutamine resulted in a +4 mass shift in citrate, while reductive
metabolism resulted in a +5 mass shift since the glutamine derived carbon was no longer
lost in the formation of succinyl-CoA (Figure 5.3). Rotenone treatment resulted in a large
increase in the M+5 isotopologue of citrate (Figure 5.4A), indicating a significant
proportion of glutamine metabolism occurred via reductive carboxylation of αketoglutarate (Figure 5.3). Furthermore, the observed increase in M+3 isotopologues of
malate (Figure 5.4B) and fumarate (Figure 5.4C) was due to ACL-mediated cleavage of
[13C5]-citrate derived from reductive carboxylation of [13C5]-α-ketoglutarate (Figure
5.4D) with the intermediate formation of [13C5]-isocitrate (Figure 5.4E). However, both
succinyl-CoA (Figure 5.4F) and succinate (Figure 5.4G) showed a marked increase in
M+4 isotopologues (derived from [13C5]-α-ketoglutarate) in response to rotenone (Figure
5.3). This showed that although rotenone induced reductive glutamine metabolism,
oxidative metabolism also persisted. The increase in M+2 labeling of acetyl CoA (Figure
5.4H) could have arisen from either oxidative or reductive glutamine metabolism (Figure
5.3). Taken together, these findings showed that both oxidative and reductive glutamine
metabolism helped to maintain acetyl-CoA levels in response to mitochondrial complex I
inhibition.
5.4.4 Glutamine-derived acetyl-CoA supports lipogenesis
To further understand the metabolic utilization of glutamine-derived acetyl-CoA,
long-chain CoAs were extracted from cells treated with either 100 nM rotenone or
DMSO, grown in the presence of 2 mM [13C515N2]- glutamine. Isotopologue analysis
revealed an increase in the incorporation of glutamine into palmitoyl-CoA, represented
110

[13C5 15N2]- Glutamine %
labeling in palmitoyl-CoA

6

DMSO
Rotenone

***

4

*

2

**

0
M+2

M+4

M+6

Isotopologue

Figure 5.5: Glutamine supports palmitoyl-CoA synthesis
in response to rotenone. SH-SY5Y cells were incubated
with 2 mM [13C515N2]-glutamine and either 100 nM
rotenone or DMSO for 6 hours and analyzed by LCSRM/MS. Isotopic enrichment of palmitoyl-CoA was then
determined. Unpaired t-test: * p<0.05, ** p<0.01, ***
p<0.001.

111

by an increase in the labeling in M+2, M+4, and M+6 (Figure 5.5). This finding indicated
that rotenone also increased the relative contribution of glutamine carbons in lipogenesis.
5.4.5 Palmitoylcarnitine levels increase in response to rotenone
Import of fatty acids for catabolism is important to meeting cellular energy
demand (18). In order to examine the effect that rotenone had on fatty acid utilization,
absolute quantification of palmitoylcarnitine was performed using stable isotope dilution
LC-high resolution-MS. Cells treated with 100 nM rotenone showed a marked 2.5-fold
increase in intracellular levels of palmitoylcarnitine (Figure 5.6). This suggested that in
addition to lipogenesis of glutamine-derived acetyl-CoA, import of palmitate played an
important role in compensating for complex I inhibition.
5.5 Discussion
Mitochondrial defects are thought to play an important role in a wide range of
diseases (115). In particular, the complex I inhibitory effects of rotenone have been tied
to the onset of a Parkinsonian phenotype in both animal models and human studies (9294). While much focus has been placed on oxidative stress and the role it may play in the
pathogenesis of neurodegeneration in PD (99,116-118), there is substantial evidence to
suggest that mitochondrial dysfunction may also contribute to this process (119,120).
Previous studies from our group showed that there was a rotenone-dependent
decrease in the incorporation of glucose-derived carbon into both acetyl- and succinylCoA (26). Furthermore, there was a marked increase in the absolute levels of BHB-CoA
(EC50 = 75 nM) in contrast to the decrease of succinyl-CoA (IC50 = 25 nM). We had
suggested previously this might result from an increase in β-oxidation of fatty acids as a
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Figure 5.6: Rotenone increases absolute levels of
palmitoyl-carnitine. SH-SY5Y cells were treated
with 100 nM rotenone or DMSO for 6 h and
analyzed by untargeted LC-high resolution MS.
Unpaired t-test: ** p<0.01.
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compensatory metabolic alteration (26). The present study has revealed that rotenone
does in fact have profound impacts on lipid metabolism in a neuronal cell culture model.
Absolute quantification of acyl-CoA species showed that while acetyl- and palmitoylCoA levels were maintained, medium-chain acyl-CoA species decreased substantially in
response to rotenone (Figure 5.1). In contrast, isotopologue analysis utilizing isotopically
labeled octanoate and palmitate revealed that incorporation of both fatty acids into acetylCoA was increased significantly in response to rotenone (Figure 5.2). Lipid metabolism
is becoming recognized as an important factor in the pathogenesis of neurodegenerative
disease. For example, parkin, an E3 ubiquitin ligase known to be defective in PD patients,
has recently been identified as a regulator of lipid uptake and metabolism (121). These
findings suggest alterations in lipid metabolism induced by rotenone could be a
mechanistic link to the observed phenotypes of rotenone exposure.
Rotenone-mediated perturbations in lipid metabolism were also accompanied by a
shift in glutamine metabolism to a reductive pathway (Figure 5.3). This enabled
glutamine to help maintain intracellular levels of both acetyl-CoA and palmitoyl-CoA.
Furthermore, glutaminolysis occurred through both oxidative and reductive metabolism.
Rotenone has previously been shown to induce reductive glutamine metabolism in renal
cancer cells (105). Therefore, the present study has provided additional evidence for the
reductive carboxylation pathway (104,105), which has recently become somewhat
controversial (122). It was shown recently that isotopic labeling in citrate can occur from
glutamine through isotopic exchange without net flux through the reductive pathway
(123). This could be due to the reversibility of all the metabolic steps between α114

ketoglutarate and citrate (Figure 5.3). If the labeled citrate were then further processed by
ACL, it would ultimately lead to the formation of isotopically labeled lipids. Although
net reductive flux was not determined in our study, the large increase in M+5 of citrate
from [13C5]-glutamine indicates an up-regulation of reductive glutamine metabolism in
response to rotenone. Despite the possibility of some labeling occurring through isotopic
exchange, rotenone clearly increases the contribution of glutamine to acetyl- and
palmitoyl-CoA pools, likely through a combination of reductive and oxidative
metabolism.
In addition to increased oxidation of lipids and glutaminolysis, complex I
inhibition by rotenone also resulted in increased levels of palmitoylcarnitine. This
increase suggests that import of fatty acids also plays a compensatory metabolic role as
suggested previously by Fan et al. (122). This would help maintain long-chain acyl-CoA
species, which is particularly important for palmitoyl-CoA, a key precursor in
sphingolipid biosynthesis (124).
Complex I inhibition by rotenone appears to induce a seemingly futile cycle of
lipid breakdown and synthesis from glutamine. Ordinarily, regulation of this process by
malonyl-CoA prevents such cycling. Malonyl-CoA generated from the carboxylation of
acetyl-CoA by acetyl-CoA carboxylase (ACAC) (Figure 5.3), inhibits carnitine palmitoyl
transferase I (CPTI) and prevents import of fatty acids into the mitochondria for
oxidation. In addition to regulation of CPTI, malonyl-CoA is a required substrate for the
first and rate limiting step of de novo fatty acid synthesis by fatty acid synthase (FASN).
High levels of malonyl-CoA therefore result in decreased fatty acid breakdown coupled
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with increased fatty acid synthesis. Given the increased levels of lipid synthesis from
glutamine (Figure 5.5), malonyl-CoA would be expected to rise in response to rotenone.
Paradoxically, increased levels of palmitoylcarnitine (Figure 5.6) suggests malonyl-CoA
levels should decrease upon rotenone treatment. Malonyl-CoA levels in SH-SY5Y cells
were below our limit of quantification and so future studies will require the development
of more sensitive quantitative methodology in order to further understand the mechanistic
metabolic consequences of rotenone exposure.
Interestingly, many of the medium-chain lipids such as octanoate, are able to enter
mitochondria independently of the carnitine shuttle system and can therefore bypass the
major regulatory actions of malonyl-CoA. For this reason, medium-chain fatty acids can
serve as important metabolic precursors for energy production and indeed, the decrease in
medium chain-CoAs observed in response to rotenone indicates that they might be an
important nutrient source in response to complex I inhibition.
Previous studies have shown up-regulation of fatty acid import as an important
adaptive response to hypoxia in order to sustain the structural stability of membrane
content (125), coinciding with a concomitant switch from glucose to glutamine derived
acetyl-CoA for de novo lipid synthesis. In agreement with this finding rotenone mimics
many of the effects observed in hypoxia, including decreased glycolytically-derived
acetyl-CoA (26), increased glutaminolysis for lipogenic purposes (Figure 5.5), as well as
increased fatty acid import (Figure 5.6). However, here we show for the first time that
fatty acids are also utilized as a critical compensatory metabolic nutrient for energetic
purposes in times of impaired complex I function (Figure 5.2).
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It is noteworthy that seven molecules of FADH2 (from the action of acyl-CoA
dehydrogenase) arise for each molecule of palmitate that undergoes oxidation to βHBCoA (Figure 5.3). FADH2 is utilized by complex II of the electron transport chain. In this
setting, cycling of lipids could help maintain ATP production through continued
respiration by utilizing complex II when complex I is inhibited. In addition to the
formation of FADH2, each step of β-oxidation also produces one molecule of NADH.
Upon complex I inhibition, NADH is expected to build up and would thus prevent
oxidation of fatty acids due to the high NADH:NAD+ ratio. However, reductive
carboxylation of α-ketoglutarate is a NADPH dependent process and therefore provides
an outlet for regeneration of NAD+ whereby reducing equivalents are shuttled between
NAD(H) and NADP(H) by the nicotinamide nucleotide transhydrogenase (NNT) (126).
Reductive metabolism of glutamine offers a potential mechanism for the generation of
NADP+, and ultimately NAD+, which would then be reduced to NADH during fatty acid
β-oxidation. This means that reductive glutamine metabolism might provide a critical
metabolic component required for sustained fatty acid catabolism.
Acetyl-CoA lies at a critical intersection of glucose and fatty acid metabolism and
is known to play an important role throughout a diverse range of cellular processes
including protein acetylation, ketogenesis, mitochondrial energy production, and
cholesterol synthesis. Alterations in acetyl-CoA levels, therefore, would likely impact a
wide range of biological functions. Our study has also shown that fatty acids play an
important compensatory role in the maintenance of acetyl-CoA levels in response to
rotenone. While acetyl-CoA is maintained in the SH-SY5Y neuronal cell model, the
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dramatic decrease in succinyl-CoA could have important biochemical implications.
Lysine succinylation has been identified as a widely occurring post-translational
modification (127). In particular, metabolic enzymes such as IDH are succinylated (127).
The functional role of many of these post-translational modifications have not yet been
identified but are likely to play important regulatory roles in a similar fashion to
acetylation of metabolic enzymes by acetyl-CoA. Regulation of metabolic enzymes by
metabolic intermediates is rapidly becoming recognized as an important regulatory
mechanism and is undoubtedly altered in times of cofactor depletion (15,128).
It should be noted that findings in the present study do not distinguish between
intracellular compartmentalization of metabolite pools such as mitochondrial and
cytosolic acetyl-CoA. Characterizing alterations specific to these two cellular
compartments would offer an improved understanding of the metabolic alterations
resulting from rotenone exposure. For example, identifying differences between IDH1
(cytosolic) and IDH2 (mitochondrial) may shed additional light on mechanistic changes
to reductive glutamine metabolism. Various mitochondrial transporters including the
citrate and malate shuttle, likely play an important role in maintaining bioenergetic
homeostasis in times of complex I inhibition. Interrogation of these subcellular-specific
metabolic activities remains to be performed in our model.
Using SH-SY5Y neuroblastoma cells, we have identified previously unknown
metabolic abnormalities in response to rotenone. Future efforts should aim to further
elucidate a causal mechanistic understanding of how such metabolic adaptations could be
protective or pathogenic. Finally, these findings should be verified in a non-transformed
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cell line, as well as with in vivo models. Utilizing isolated primary dopaminergic neurons
will clarify the relevance of our findings in terms of clear adaptations with pathogenic
relevance to PD.

5.6 Conclusion
Quantitative stable isotope dilution LC-SRM/MS analysis revealed that rotenone
decreased the absolute levels of medium-chain acyl-CoAs in neuronal cells. However,
acetyl-CoA and palmitoyl-CoA levels were maintained. Using isotopologue analysis, it
was established that the maintenance of acetyl-CoA was accomplished through increased
fatty acid β-oxidation, as well as by reductive glutamine metabolism. Palmitoyl-CoA
levels were maintained through increased glutamine metabolism as well by import of
palmitoyl-carnitine. These findings support the hypothesis that rotenone causes metabolic
pathway modulation and induction of compensatory mechanisms to preserve critical
metabolite levels. Disruptions to these compensatory pathways in specific neurons such
as by reduced lipid uptake and metabolism (121) could then contribute to cell death
observed in PD. Cell death could also be mediated by decreased glutamate
dehydrogenase activity (129) and/or by reduced glutaminase-mediated conversion of
glutamine to glutamate (Figure 5.3) (130). In keeping with this latter possibility, CSF
concentrations of glutamine are increased almost two-fold in PD, whereas glutamate
concentrations are decreased three-fold compared with controls subjects (111). Finally,
the finding that fatty acid β-oxidation is a compensatory mechanism during complex I
inhibition could have implications for the development of glutaminase inhibitors as anti119

cancer agents (131). Fatty acid metabolism and import of lipids could provide escape
mechanisms for cancer cells “addicted” to glutamine when they are treated with
glutaminase inhibitors (114,131).
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Chapter 6: Rotenone stereospecifically increases (S)-2-hydroxyglutarate in SHSY5Y neuronal cells
6.1 Abstract
The α-ketoglutarate metabolite 2-hydroxyglutarate (2-HG) has emerged as an
important mediator in a subset of cancers and rare inherited inborn errors of metabolism.
Due to potential enantiospecific metabolism, chiral analysis is essential for determining
the biochemical impacts of altered 2-HG metabolism. I have developed a novel
application of chiral liquid chromatography-electron capture/atmospheric pressure
chemical ionization/mass spectrometry, which allows for the quantification of both (R)-2HG (D-2-HG) and (S)-2-HG (L-2-HG) in human cell lines. This method avoids the need
for chiral derivatization, which could potentially distort enantiomer ratios through
racemization during the derivatization process. The study revealed that the pesticide
rotenone (100 nM), a mitochondrial complex I inhibitor, caused a significant almost
threefold increase in the levels of (S)-2-HG, (107.0 ± 7.5 ng/106 cells) when compared
with the levels of (R)-2-HG (32.7 ± 1.2 ng/106 cells) in the SH-SY5Y neuronal cells, a
widely used model of human neurons. Stable isotope tracers and isotopologue analysis
revealed that the increased (S)-2-HG was derived primarily from L-glutamine.
Accumulation of highly toxic (S)-2-HG occurs in the brains of subjects with reduced L-2HG dehydrogenase activity that results from mutations in the L2HGDH gene. This
suggests that the observed stereospecific increase of (S)-2-HG in neuronal cells is due to
rotenone-mediated inhibition of L-2-HG dehydrogenase but not D-2-HG dehydrogenase.
The high sensitivity chiral analytical methodology that has been developed in the present
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study can also be employed for analyzing other disruptions to 2-HG formation and
metabolism such as those resulting from mutations in the isocitrate dehydrogenase gene.
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6.2 Introduction
Mitochondrial dysfunction is widely recognized as a causal factor in a range of
diseases including cancer (132), cardiovascular disease (133), and neurodegeneration (6).
The pathological link between mitochondria and disease states is likely a combination of
oxidative stress and perturbations to central energy metabolism (134). Recent studies
have demonstrated that altered cellular metabolism can be a driving force in disease
pathogenesis as opposed to merely an adaptation (3). Cofactor dependence of enzymes,
metabolic feedback inhibition, and metabolite-driven post-translational modifications are
important physiological examples of how biochemical processes can be modulated
through altered metabolite levels (135-137). Consequently, characterization of metabolic
abnormalities in conjunction with mitochondrial dysfunction might implicate previously
unidentified mechanisms in the pathogenesis of many diseases.
2-Hydroxygutarate (HG) is closely linked with mitochondrial metabolism and the
Krebs cycle (Figure 6.1) and its biosynthesis is susceptible to the effects of mitochondrial
perturbations. For example, deficiencies in the mitochondrial citrate transporter result in
(D/L)-2-HG aciduria (138). The pesticide rotenone is a known inhibitor of mitochondrial
complex I, which induces a Parkinsonian phenotype in rodents (94). Furthermore,
occupational exposure to rotenone is associated with the increased incidence of PD in
human populations (92). Recently identified metabolic defects that occur in response to
rotenone implicate compensatory metabolic alterations that maintain bioenergetic
homeostasis in times of impaired complex I activity. The resulting biochemical changes
could account in part for the neurological defects resulting from rotenone exposure
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Figure 6.1: Schematic of the Krebs cycle. Abbreviations: α-KGD,: α-ketoglutarate
dehydrogenase; AT, aspartate transaminase; CS, citrate synthase; L2HGDH, L-2hydroxyglutarate dehydrogenase; MD, malate dehydrogenase; MutIDH, mutated
isocitrate dehydrogenase; SCS, succinyl-CoA synthase; SD, succinate
dehydrogenase.
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(19,26). Importantly, an increase in glutaminolysis into the Krebs cycle suggested that 2HG might be susceptible to changes in response to complex I inhibition (Figure 6.1) (19).
For this reason we sought to identify the effects of rotenone on 2-HG metabolism.
Both enantiomers of 2-HG (Figure 6.1) have been linked to the induction of
oxidative stress in animal models (139,140). Additionally, 2-HG has been identified as a
biomarker in a subset of cancers with mutations in the gene coding for the metabolic
enzyme, isocitrate dehydrogenase (IDH). In particular, cancers harboring IDH mutations
exhibit large increases in the levels of (R)-2-HG (D-2-HG or D-α-HG) (141-144). The
oncogenic effects of (R)-2-HG are thought to arise through competitive inhibition of αketoglutarate dependent enzymes (145). For example, inhibition of α-ketoglutarate
dependent dioxygenases and demethylases can lead to modified responses to hypoxia as
well as epigenetic alterations due to hypermethylation of DNA (142). Conversely, (S)-2HG (L-2-HG or L-α-HG) has more commonly been associated with the rare
neurometabolic disorder of L-2-HG acidurea resulting from a defect in the L2HGDH
gene, which encodes the enzyme L-2-HG dehydrogenase (146-149). These patients
exhibit a severe neurodegenerative phenotype with hypertonia, tremors, and
leukoencephalopathy, which increases their susceptibility to brain tumors (150,151). (S)2-HG can also competitively inhibit α-ketoglutarate-dependent enzymes and in some
cases is even more potent than the (R)-enantiomer (152).
In view of the stereospecific biochemical effects of 2-HG, it is critical to have
sensitive and specific chiral methodology available for the separation and quantification
of the individual enantiomers. Liquid chromatography-selected reaction monitoring/mass
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spectrometry (LC-SRM/MS) serves as the gold standard for quantification of metabolites
from complex biological matrices (20). However, robust quantification of low molecular
weight, polar, chiral metabolites is often problematic due to poor retention with typical
reversed phase LC-MS systems, ion suppression, interference from isobaric species, as
well as poor ionization efficiency leading to inadequate sensitivity. We have employed
chiral LC-electron capture atmospheric pressure chemical ionization (ECAPCI)/SRM/MS
(106,107) for the quantification of the 2-HG enantiomers in SH-SY5Y neuronal cells, a
widely used model of human neurons (153). Analytes were first converted to bispentafluorobenzyl (PFB) ester derivatives in order to facilitate the ECAPCI process
(106). Normal phase chiral chromatography, which provides excellent resolution of chiral
lipids, was then used for the separation of the 2-HG-bis-PFB enantiomers (107).
6.3 Materials and methods
6.3.1 Materials
Rotenone, L-[13C515N2]-glutamine, PFBBr, diisopropylethylamine (DIPEA), (R)2-HG, (S)-2-HG, and dimethyl sulfoxide (DMSO) were purchased from Sigma-Aldrich
(St. Louis, MO). [13C515N1]-glutamate was purchased from Cambridge Isotopes
(Tewksbury, MA). Optima LC-MS grade methanol (MeOH), 2-propanol (IPA), hexanes,
and water were purchased from Fisher Scientific (Pittsburgh, PA). DMEM:F12 media
(with and without glutamine), fetal bovine serum (FBS), streptomycin, and penicillin
were purchased from Invitrogen (Carlsbad, CA). SH-SY5Y cells were obtained from the
laboratory of Dr. David Lynch at the Children’s Hospital of Philadelphia.
6.3.2 Cell culture
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SH-SY5Y cells were maintained in 1:1 DMEM:F12 media, supplemented with
10% fetal bovine serum, 2 mM L-glutamine, penicillin and streptomycin. Cells were
incubated at 37 °C and 95% humidity with 5% CO2. Cells were treated with either freshly
prepared rotenone in DMSO (100 nM final concentration) or 1% DMSO vehicle control
when cells had reached approximately 80% confluence. For glutamine labeling
experiments, cells were treated with glutamine-free media supplemented with 2 mM
unlabeled or L-[13C515N2]-glutamine.
6.3.3 2-HG extraction and derivatization
Cells were lifted gently with a cell scraper, centrifuged at 500 x g for 5 min and
resuspended in 750 µL/10 cm2 plate of ice cold methanol/water (4:1; v/v) containing 1 µg
[13C515N1]-glutamate internal standard for extraction. Samples were pulse sonicated on
ice for 30 s with a probe sonicator, followed by centrifugation at 16,000 x g for 10 min.
The supernatant was then transferred to a clean tube and evaporated to dryness under
nitrogen. Dried samples were derivatized with 100 µL diisopropylethylamine (DIPEA) in
acetonitrile (ACN, 1:99; v/v) and 50 µL PFBBr in ACN (1:4; v/v) at 60 °C overnight.
Derivatized samples were evaporated to dryness under nitrogen and resuspended in 100
µL hexanes/ethanol (95:5; v/v) prior to LC-MS/MS analysis.
6.3.4 Liquid chromatography-mass spectrometry
Bis-PFB ester derivatives of the 2-HG enantiomers were separated using a
Chiralpak AD-H column (250 × 4.6 mm i.d., 5 μm; Daicel Chemical Industries, Ltd.,
Tokyo, Japan) at a flow rate of 1 mL/min. Solvent A was hexanes and solvent B was
IPA/MeOH (1:1; v/v). The linear gradient was as follows: 1% B for 3 min, increased to
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60% B over 32 min and held for 4 min, down to 1% B over 1 min prior to a 5 min
equilibration. The separation was performed at 30 °C and a post-column addition (0.75
mL/ min MeOH) was used. MS analysis was conducted on a Thermo Scientific TSQ
Quantum Ultra AM mass spectrometer (Thermo Scientific, San Jose, CA, USA) equipped
with an APCI source operating in negative mode. The TSQ Quantum operating
conditions were as follows: vaporizer temperature, 350 °C; heated capillary temperature,
300 °C; corona discharge needle, 30 μA. The sheath gas (nitrogen) and auxiliary gas
(nitrogen) pressures were 35 and 10 (arbitrary units), respectively. Collision-induced
dissociation used argon as the collision gas at 1.5 mTorr.

6.4 Results
6.4.1 Chiral analysis of 2-HG derivatives by LC-ECAPCI/tandem MS (MS/MS)
Overnight derivatization of 2-HG resulted in bis-PFB 2-HG which, after
undergoing ECAPCI in the source of the MS, yielded mono-PFB 2-HG (Figure 6.2)
resulting from the typical loss of a PFB moiety from the molecule (M). Mono-derivatized
2-HG was not observed (data not shown), indicating the derivatization went to
completion in the reported conditions. LC-MS/MS of the resulting [M-PFB]- parent ion
(m/z = 327) yielded a product ion spectrum consistent with the structure of 2-HG (Figure
6.3). Furthermore, derivatization of (R)-2-HG and (S)-2-HG separatelyand in
combination allowed specific separation of each bis-PFB-enantiomer to be conducted by
normal-phase chiral LC-MS (Figure 6.4). Finally, LC-SRM/MS analysis utilizing
[13C515N1]-glutamate as the internal standard yielded a linear standard curve, which made
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Figure 6.2: Formation of 2-HG-bis-PFB followed by
LC-ECAPCI/MS/MS.
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Figure 6.3: Product ions derived from LC-ECAPCI/MS/MS analysis of [M-PFB]- at
m/z 327 derived from 2-HG-bis-PFB.
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it possible to conduct accurate and precise absolute quantification of both (R)- and (S)-2HG by chiral LC-ECPCI/MS (Figure 6.5). Furthermore, validation of the method
revealed excellent accuracy and precision (Table 6.1), with a limit of detection of 3 pg on
column and a limit of quantification of 10 pg on column for both (R)- and (S)-2-HG.
6.4.2 Rotenone-mediated stereoselective increase in (S)-2-HG
To investigate the impact of rotenone on 2-HG metabolism SH-SY5Y cells were
treated with either 1, 10, 100 nM rotenone or vehicle DMSO for 6 h. Cellular metabolism
was then quenched with ice cold methanol/water (4:1; v/v); and analytes were extracted
and derivatized overnight prior to analysis. Absolute quantification revealed that (S)-2HG levels rose significantly from 53.4 ± 11.7 ng/106 cells (mean ± SEM) in the vehicle
control to 71.5 0 ± 7.5 ng/106 cells (p=0.041) after treatment with 10 nM rotenone and to
107.0 ± 7.5 ng/106 cells (p=0.008) after treatment with 100 nM rotenone (Figure 6.7).
There was no increase in (S)-2-HG levels when cells were treated with only 1 nM
rotenone (Figure 6.7). In contrast, there was no significant difference in the control level
of (R)-2-HG (28.6 ± 4.0 ng/106 cells) when compared with the level of (R)-2-HG after
rotenone treatment (32.7 ± 1.2 ng/106 cells, p = 0.128) at all three doses of rotenone.
Therefore, rotenone induced a stereospecific increase in (S)-2-HG while (R)-2-HG levels
remained unaltered (Figure 6.7).
6.4.3 Glutamine supports (S)-2-HG levels in response to rotenone
To assess the metabolic source of (S)-2-HG the same experiment was performed
for isotopologue analysis in cells treated in the presence of 2 mM L-[13C515N2]-glutamine.
Glutamine can enter the Krebs cycle via α-ketoglutarate, which can then be reduced to
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Figure 6.4: Chromatographic separation of (R)-2-HG
from (S)-2-HG using normal-phase chiral LCECAPCI/MS.
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Figure 6.5: Calibration curves for (R)-2-HG and (S)-2-HG. (R)-2-HG: y =
0.0021x + 0.0056, r2 = 0.995. (S)-2-HG: y = 0.0022x + 0.0046, r2 = 0.988.
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Table 6.1: Accuracy and precision of 3-day validation study. LLOQ,
lower limit of quantification, LQC, low quality control, MQC, medium
quality control, HQC, high quality control.
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form either enantiomer of 2-HG (Figure 6.1). This direct conversion does not include any
loss of carbon atoms and should therefore produce M+5 labeled 2-HG as all 5 labeled
carbons are derived from glutamine. Indeed, treatment with labeled L-glutamine yielded
M+5 labeled (S)-2-HG. Importantly, the M+5 enrichment in (S)-2-HG was approximately
doubled in the rotenone treated samples (Figure 6.8B). This finding suggests that the
increase in (S)-2-HG is derived primarily from L-glutamine directly, as any oxidative
metabolism through the Krebs cycle would involve a decarboxylation of α-ketoglutarate
to form succinyl-CoA (Figure 6.1) and would therefore no longer result in M+5 labeled
2-HG. In agreement with the absolute quantification, L-glutamine labeling into (R)-2-HG
was not significantly altered in response to 100 nM rotenone (Figure 6.8A).
6.5 Discussion
A novel application of chiral LC-ECAPCI/SRM/MS was used to identify a
stereospecific alteration in 2-HG levels in response to rotenone in SH-SY5Y cells.
Inhibition of mitochondrial complex I results in a significant increase of (S)-2-HG while
(R)-2-HG levels remain unchanged (Figure 6.7). Furthermore, utilizing stable isotope
tracer methodology, we have shown that L-glutamine is an important metabolic source
for the increased (S)-2-HG pool (Figure 6.8B), though our results do not exclude the
possibility of other precursors also serving a similar purpose. Given the known
biochemical consequences of increased (S)-2-HG levels, the observed increase could
have critical downstream consequences. Importantly, our findings bring light to the
concept that therapeutics targeting mitochondrial metabolism may have unidentified
impacts on 2-HG metabolism.
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Figure 6.6: Separation of (R)-2-HG and (S)-2-HG from SH-SY5Y neuronal cells
using normal-phase chiral LC-ECAPCI/MS. The cells were treated with (A) DMSO
and (B) 100 nM rotenone for 6 h.
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Figure 6.7: Rotenone induces stereospecific
increases in (S)-2-HG. Student's two-tailed t-test
against vehicle control: * p<0.05, *** p<0.001 (n=4).
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Rotenone causes increased utilization of both fatty acids and L-glutamine as a
compensatory mechanism in response to decreased glycolytic production of acetyl-CoA
(19,26). In addition to maintaining acetyl-CoA levels; a proposed mechanism for this
shift includes the generation of NADH and FADH2 via β-oxidation of fatty acids to
maintain complex II activity (Figure 6.1). The mitochondrial form of malate
dehydrogenase converts malate to oxaloacetate. However, there is a cytosolic form,
which is known to convert α-ketoglutarate into (S)-2-HG using NADH as a co-factor
(Figure 6.1) (154). In the presence of rotenone, this could potentially lead to increased
(S)-2-HG as a result of the increased NADH co-factor availability from increased fatty
acid β-oxidation (Figure 6.1). Normally, the (S)-2-HG would be reduced back to αketoglutarate by L-2-HG dehydrogenase. Therefore, the observed increase in (S)-2-HG
most likely arose through a rotenone-dependent inhibition of L-2-HG dehydrogenase.
This would result in a phenotype similar to that observed in (S)-2-HG aciduria, in which
there is also an accumulation of (S)-2-HG. In contrast, (R)-2-HG is formed primarily
from mutated IDH (in an NADPH-dependent process), and a separate dehydrogenase
exists for the oxidation of (R)-2-HG to α-ketoglutarate (155,156). Consequently, the lack
of any effect of rotenone on (R)-2-HG levels is in keeping with our proposed mechanism
for increased (S)-2-HG in the neuronal cells. This proposal is supported by the
observation that glutamine is an important metabolic source of the increased (S)-2-HG
(Figure 6.8B). The formation of (S)-2-HG would occur through glutaminase-mediated
formation of glutamate followed by the action of glutamate dehydrogenase to give α-
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ketoglutarate followed by NADH-dependent cytosolic malate dehydrogenase-mediated
reduction of α-ketoglutarate into (S)-2-HG (Figure 6.1).
(S)-2-HG and (R)-2-HG have both been linked to control of the methylation status
of DNA as well as histone proteins. The two enantiomers inhibit α-ketoglutarate
dependent enzymes including the ten-eleven translocation (TET)1 and TET2 5methylcytosine hydroxylases, HIF asparaginyl hydroxylase FIH1, and the lysine-specific
demethylase (KSDM) 4D (JMJD2D), a histone demethylase (152,157). (S)-2-HG was
found to be a more potent enzyme inhibitor (152), although aspects of this finding remain
controversial. In contrast, activity of the 2-HG enantiomers on Egg-laying defective nine
(EGLN) prolyl hydroxylases is quite distinct. (R)-2-HG is an activator of EGLN1,
EGLN2, and EGLN3 causing depletion of HIF1α; whereas (S)-2-HG is an inhibitor
(157). Furthermore, increased production of (R)-2-HG by tumor derived mutant IDH1
R132H (141,158), coupled with concomitant depletion of α-ketoglutarate is associated
with the promotion of leukemogenesis (144). It is noteworthy that there is evidence to
suggest that HIF activation inhibits myeloid leukemia, suggesting that depletion of HIF1α
would be pro-leukemogenic (144). The function of (S)-2-HG is less clear, although
elevated levels of (S)-2-HG have been reported in renal cancer (137), where unlike
leukemia, HIF activation supports tumorigenesis (159). In addition, the severe neurologic
phenotype of (S)-2-HG aciduria suggests that altered brain physiology is an important
pathological consequence resulting from elevated levels of (S)-2-HG (150). This is in
keeping with the role of disrupted methylation during neurodevelopment that occurs in
genetic disorders such as Rett’s syndrome, where there is a mutation in the methyl CpG
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binding protein gene (MECP)2 gene (160). Elevated levels of (S)-2-HG can also increase
susceptibility to brain tumors (161).
The sensitivity and chiral separation offered by this new chiral LC-ECAPCI/MS
method will be useful in discovery and validation of biomarkers for 2-HG aciduria,
mitochondrial dysfunction, and IDH-mutation related cancers. Partial loss of
differentiation block against erythropoietin in late passage leukemia cells transiently
transfected with mutant IDH1 was dose-dependent on (R)-2-HG, which suggests that
prognostic monitoring of (R)-2-HG might be informative in this setting (144). 2-HG is a
normal constituent of human urine (162), thus non-invasive screening of 2-HG
enantiomers should be feasible. There are previous reports on the analysis of 2-HG by
chiral derivatization and GC-MS analysis (163-165). In addition, Rashed et al. reported
chiral analysis of 2-HG by LC-MS without derivatization (166), which was used to
confirm the diagnosis of (S)-2-HG aciduria using urine from a small number of patients.
Gross et al. described the accumulation of 2-HG in acute myeloid leukemia carrying
IDH1/2 mutations without chiral analysis (167), and Wang et al. have investigated the
increase of 2-HG in AML, but also failed to resolve (R)- and (S)-2-HG (168,169). Fan et
al. recently reported chiral analysis of 2-HG derivatization with (R)-butanol coupled with
achiral LC-MS (170) and Struys et al. have reported a sensitive chiral derivatization
method also coupled with achiral LC-MS (171). However, there is always a concern that
racemization at the chiral center and/or enantioselective derivatization can occur during
these chemical reactions (172), which would artifactually distort the enantiomer ratios.
Such potential artifacts cannot arise from the LC-ECAPCI/MS method because
141

derivatization does not occur at the chiral center, but rather on the two carboxylate
moieties; the derivatization is used simply to facilitate electron capture and increase
sensitivity. Although the product ion at m/z = 129 was the most intense signal observed
during MS/MS analysis (Figure 6.3), the background for the m/z = 101 channel was
lower when subsequent LC-SRM/MS analyses were conducted. Therefore, this product
ion was chosen for the quantitative LC-SRM/MS analyses and collision energies were reoptimized to ensure maximum sensitivity. Base-line separation of the 2-HG-bis-PFB
enantiomers was readily achieved using a normal-phase chiral LC column (Figure 6.4)
(107). It is noteworthy that the synthesis of [13C]-(R)-2-HG has been reported (157). This
means that [13C]-(R/S)-2-HG analogs could be used as internal standards in the future,
rather than the [13C515N1]-glutamate internal standard used in the present assay, which
could further improve the precision, accuracy, sensitivity, and specificity of the LCECAPCI method (20).

6.6 Conclusion
In summary, a novel application of chiral LC-ECAPCI/SRM/MS, which allows
for the quantification of both (R)-2-HG and (S)-2-HG has been developed. Use of this
methodology revealed that rotenone induced a stereospecific increase in (S)-2-HG in the
SH-SY5Y neuronal cell line. This suggests that in addition to mutated enzymes,
pharmacological modulation of mitochondrial metabolism can have unexpected impacts
on 2-HG metabolism. The increased (S)-2-HG observed in the SH-SY5Y neuronal cells
is most likely to occur through a rotenone-mediated decrease in the activity of L-2-HG
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dehydrogenase, which results in a phenotype similar to that observed in patients with
mutations in the L2HGDH gene. Current efforts are underway to obtain models with
known disruptions of 2-HG metabolism such as mutations in IDH in an attempt to further
characterize and potentially modulate these systems.
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Chapter 7: Platelet biomarkers of metabolic disturbances in Friedreich’s ataxia
7.1 Abstract
Friedreich’s ataxia (FRDA) is an autosomal recessive disease characterized by
neurodegeneration and cardiomyopathy, with metabolic abnormalities proposed to have a
crucial role in disease pathogenesis. Despite this knowledge, the inability to access the
highly affected neuronal and cardiac tissues has hampered metabolic evaluation and
biomarker development. Since inherited metabolic diseases often affect metabolism
globally, we reasoned that platelets could serve as a surrogate diagnostic tissue for
inherited metabolic diseases such as FRDA if these pathways are utilized in platelets.
Using a liquid chromatography-mass spectrometry-based method to determine whether
platelets isolated from patients with FRDA exhibit differentiable metabolism compared
with healthy controls. Isotopologue analysis enables evaluation of metabolic pathway
activity, as isotopic labeling of a metabolite pool reveals the relative contribution of
specific enzymes and pathways. We tested two isotopic tracers ([13C6]-glucose and
[13C16]-palmitate) that indicate metabolic variations in FRDA by analysis of isotopic
enrichment in various acyl-coenzyme A (CoA) thioesters spanning multiple metabolic
pathways. Isotopologue analysis of acyl- CoA thioesters showed a marked decrease in
glucose incorporation with a concomitant increase in palmitate-derived acyl-CoA
thioesters in FRDA platelets compared with controls. This is consistent with a
combination of increased fatty acid β-oxidation and decreased glycolysis in FRDA. Our
findings demonstrate that platelets can be used as a surrogate tissue for in vivo biomarker
studies to monitor new therapeutic approaches for the treatment of FRDA. Studies of
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platelet metabolism may also lend insight into metabolic defects in heritable metabolic
diseases.
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7.2 Introduction
Friedreich’s ataxia (FRDA) is the most commonly inherited ataxia affecting 1 in
29,000 Caucasians (173). It is an autosomal recessive genetic disorder, with a mean ±
standard deviation (SD) age at onset of 10 ± 7.4 years, and no known effective treatment
(174). The main sites of pathology in FRDA are the dorsal root ganglia, posterior
columns of the spinal cord, corticospinal tracts, and the heart (173,175). Most FRDA
individuals develop dysarthria and are wheelchair-bound by a mean age ± SD of 15.5 ±
7.4 years after disease onset (173). The genetic basis of 98% of FRDA cases is a guanineadenine-adenine (GAA) triplicate nucleotide expansion in intron 1 of the FXN (176) gene
leading to a deficiency of the protein frataxin, thought to be involved in the assembly of
iron-sulfur clusters (177). The remaining cases arise from point mutations in the FXN
gene (173,178). A range of cellular processes depend on iron-sulfur clusters for proper
biological functions (179), such as the electron transferring components of the
mitochondrial electron transport chain and the metabolic enzyme aconitase (180).
Frataxin is localized to the mitochondria, which suggests that altered mitochondrial
function plays a role in FRDA (181,182). Previous studies utilized antioxidants in an
attempt to improve mitochondrial function (183,184); however, in addition to
antioxidants, it seems likely that supplementation of highly consumed metabolic
precursors could have a positive synergistic effect (185). Therefore, further
characterization of metabolic abnormalities associated with FRDA could reveal
additional therapeutic targets in this poorly understood disease.
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Liquid chromatography-selected reaction monitoring/mass spectrometry (LCSRM/MS) offers a highly sensitive and specific platform for performing metabolic
studies (20). While absolute quantification of metabolites provide insight into the
metabolic state of a system, it is possible for compensatory metabolic actions to occur
that maintain a metabolite pool by altering the utilization of other precursors (19,26).
Thereby, shifts in metabolism may go unnoticed with absolute quantification as the only
indicator of the metabolic state of a system. For this reason it is important to assess the
utilization of metabolic precursors (21). Isotopologue analysis enables evaluation of
metabolic pathway activity, as isotopic labeling of a metabolite pool reveals the relative
contribution of specific enzymes and pathways (186). Here, we have tested two isotopic
tracers ([13C6]-glucose and [13C16]-palmitate) that indicate metabolic variations in FRDA
by analysis of isotopic enrichment in various acyl-coenzyme A (CoA) thioesters spanning
multiple metabolic pathways (Figure 7.1). Glycolysis results in the incorporation of
[13C6]-glucose directly into Krebs cycle metabolites through its conversion to [13C2]acetyl-CoA, which then proceeds through the Krebs cycle (Figure 7.2). Conversely,
[13C16]-palmitate is converted primarily into acetyl-CoA, β-hydroxybutyryl (HB)-CoA,
and 3-hydroxy-3-methylglutaryl (HMG)-CoA during short-term incubations in platelets
(Figure 7.2). We report the use of isotopologue analysis for the characterization of [13C6]glucose and [13C16]-palmitate incorporation into acyl-CoA thioesters in the platelets of
patients with FRDA, a comparison with unaffected controls, and the utility of this
methodology as a biomarker for FRDA.
7.3 Patients, materials, and methods
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Figure 7.1: Metabolic incorporation of [13C6]-glucose and [13C16]-palmitate isotopic
tracers into acyl-CoA thioesters.
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7.3.1 Participants
Ten FRDA patients and ten controls were entered into the study. There were no
significant differences between the two groups in the mean age (FRDA, control), and the
mean ± SD GAA repeat length among patients (476 ± 149.8). The GAA repeat lengths
indicated that the FRDA was of moderate severity (Table 7.1). Blood samples were
obtained from the participants who were enrolled in an ongoing Friedreich’s Ataxia
Research Alliance study at the Children’s Hospital of Philadelphia (IRB # 01-002609).
7.3.2 Materials
Glucose, [13C6]-glucose, sodium chloride (NaCl), potassium chloride (KCl),
sodium bicarbonate (NaHCO3), calcium chloride (CaCl2), magnesium chloride (MgCl2),
5-sulfosalacylic acid (SSA), ammonium acetate, and trichloroacetic acid (TCA) were
purchased from Sigma-Aldrich (Saint Louis, MO, USA). [13C16]-palmitate was purchased
from Cambridge Isotope Laboratories, Inc. (Cambridge, MA, USA). Acid-citratedextrose Vacutainer® tubes (8.5 mL; Sol A) were purchased from BD Biosciences
(Franklin Lakes, NJ, USA). All solvents for LC-MS were Optima grade purchased from
Fisher Scientific (Pittsburgh, PA, USA).
7.3.3 Platelet isolation and treatment
Whole blood was drawn into 8.5 mL acid-citrate-dextrose Vacutainer® tubes,
transferred to 15-mL polypropylene tubes, and spun at 175 × g for 15 min with no brakes.
The upper platelet-rich layer was then transferred to a new tube and spun at 400 × g for
10 min. The resulting platelet pellet was resuspended in 1 mL pre-warmed Tyrode’s
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Table 7.1: Characteristics of subjects who donated platelets for the
study.
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solution (139 mM NaCl, 3 mM KCl, 17 mM NaHCO3, 3 mM CaCl2, and 1 mM MgCl2)
at 37°C containing 5 mM [13C6]-glucose or 5 mM glucose with 100 µM [13C16]-palmitate
and transferred to a 1.5 mL microcentrifuge tube. Samples used for isotopic correction
were treated with Tyrode’s containing only 5 mM glucose. Suspended platelets were
incubated with tracers for 1 hour at 37°C prior to quenching and acyl-CoA extraction.
7.3.4 Acyl-CoA extraction
The extraction and LC-MS analysis have been described in detail previously
(15,74). Briefly, treated platelets were pelleted by centrifugation at 1,000 x g for 2 min
and resuspended in 1 mL of ice-cold 10% TCA followed by pulse-sonication for 30 s on
ice using a sonic dismembranator (Fisher), followed by a 10 min centrifugation at 15,000
x g. The supernatant was transferred to a fresh tube, and the pellet was discarded. The
supernatant was purified by solid-phase extraction as follows: Oasis HLB 1 cm3 (30 mg)
SPE columns (Waters) were conditioned with 1 mL of methanol followed by 1 mL of
water. The collected supernatant was applied, washed with 1 mL of water, and finally
eluted using three subsequent applications of 0.5 mL of methanol containing 25 mM
ammonium acetate. Eluted compounds were evaporated to dryness under nitrogen and
resuspended in 50 μL of 5% SSA in water. Injections of 20 μL were made for LCMS/MS analysis.
7.3.5 Liquid chromatography-mass spectrometry
Acyl-CoAs were separated using a reversed-phase HPLC Phenomenex Luna C18
column (2.0 mm × 150 mm, particle size 5 μm) with 5 mM ammonium acetate in water
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as solvent A, 5 mM ammonium acetate in 95:5 ACN/water (v/v) as solvent B, and
80:20:0.1 (v/v/v) ACN/water/formic acid as solvent C as previously described (19,74).
Gradient conditions were as follows: 2% B for 1.5 min, increased to 25% B over 3.5 min,
increased to 100% B in 0.5 min and held for 8.5 min, washed with 100% C for 5 min,
before equilibration for 5 min. The flow rate was 200 μL/min. Samples were analyzed
using an API 4000 triple-quadrupole mass spectrometer (Applied Biosystems, Foster
City, CA) in the positive electrospray (ESI) mode. Samples (20 μL) were injected using a
Leap CTC autosampler (CTC Analytics, Zwingen, Switzerland) where they were
maintained at 4°C, and data was analyzed with Analyst 1.4.1 software. The column
effluent was diverted to the mass spectrometer from 8 to 18 min and to waste for the
remainder of the run. The mass spectrometer operating conditions were as follows: ion
spray voltage (5.0 kV), nitrogen as curtain gas (15 units), ion source gas 1 (8 units), gas 2
(15 units), and collision-induced dissociation (CID) gas (5 units). The ESI probe
temperature was 450 °C, the declustering potential was 105 V, the entrance potential was
10 V, the collision energy was 45 eV, and the collision exit potential was 15 V.
7.3.6 Statistical analysis
Descriptive statistics were calculated. Unless otherwise specified, data are
expressed as means ± standard errors of the means (SEM). Normality of the data was
examined by Shapiro-Wilk W test. Comparison of the labeling between patients with
FRDA and unaffected controls were made by a two sample t-test with equal variance
assumption (or unequal variance when appropriate).

All tests were two-sided. To

evaluate combination of M+2 labeling from [13C6]-glucose for acetyl-CoA and M+2
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labeling from [13C16]-palmitate for βHB-CoA, a logistic regression analysis was
performed. Sensitivity and specificity was computed at each possible cut-off values based
on the predictive score estimated from the logistic model, and a ROC curve was
generated. The area under the receiver operating characteristic (ROC) curve was
computed to measure the ability of the combined biomarkers in correctly classifying
those with and without FRDA. A higher area under the curve (AUC) value for the ROC
indicated better discrimination. Statistical analyses were conducted using GraphPad
Prism v 6.0 for Mac OS X and STATA v13.0 for Windows.
7.4 Results
7.4.1 Glucose labeling
There was significant labeling in the isotopologue of acetyl-CoA 2 Da higher in
mass (M+2) than the endogenous acetyl-CoA (M+0) in platelets treated with [13C6]glucose (5 mM) that were obtained from both FRDA and unaffected controls (Figure
7.3A). This resulted from the action of pyruvate dehydrogenase on pyruvate derived from
[13C6]-glucose (Figure 7.2). FRDA platelets exhibited significantly reduced M+2 labeling
in acetyl-CoA (mean ± SEM: 7.0 ± 1.2%; p < 0.05) when compared with acetyl-CoA
labeling (12.3 ± 1.8%) in control platelets (Figure 7.3A, 7.3E). This finding is consistent
with decreased utilization of [13C6]-glucose for the pyruvate dehydrogenase-mediated
formation of acetyl-CoA (Figure 7.2). The FRDA platelets also showed decreased M+2
labeling of succinyl-CoA (6.3 ± 1.92%; p < 0.05) when compared with control platelets
(10.8 ± 0.7%) (Figure 7.3B, 7.3E). These levels of incorporation were very similar to
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Figure 7.3: [13C6]-glucose labeling was decreased in FRDA platelets. (A) Acetyl-CoA.
(B) Succinyl-CoA. (C) βHB-CoA. (D) HMG-CoA. (E). Boxplots depicting significantly
different enrichments from glucose. Mean percent labeling plotted with SEM, *p<0.05
for 10 patients with FRDA and 10 controls.
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those observed for acetyl-CoA (Figure 7.3A) as might be expected from its role as a
Krebs cycle intermediate (Figure 7.2). The formation of βHB-CoA and HMG-CoA can
arise through two different pathways. The first pathway involves thiolase-mediated
formation of acetoacetyl-CoA followed by the 3-hydroxy-CoA dehydrogenase-mediated
conversion of acetoacetyl-CoA to βHB-CoA, or HMG-CoA synthase-mediated
conversion of acetoacetyl-CoA to HMG-CoA (Figure 7.2). The second pathway, which
we recently demonstrated to occur in neuronal cells (19), involves conversion of
palmitate to butyryl-CoA, which then serves as a precursor for the formation of βHBCoA and HMG-CoA (Figure 7.2). The first pathway should lead to the formation of M+2
isotopologues of βHB-CoA and HMG-CoA from [13C6]-glucose; whereas the second
pathway should only be observed in these short-term incubations through the formation
of M+4 isotopologues from the metabolism of [13C]-labeled palmitate (Figure 7.2). In
keeping with these concepts, both βHB-CoA and HMG-CoA exhibited substantial
labeling in their M+2 isotopologues but not in their M+4 isotopologues after a 1 h
incubation with [13C6]-glucose (Figure 7.3C, 7.3D). The M+2 labeling of HMG-CoA in
both FRDA (10.3 ± 2.3%) and control (16.7 ± 1.5%) platelets (Figure 7.3D) was
significantly higher than that observed for acetyl-CoA in FRDA (7.0 ± 1.2%) and control
(12.3 ± 1.8%) platelets (Figure 7.3A), suggesting that the HMG-CoA pool size could be
smaller than the other analytes. M+2 labeling in FRDA platelets from [13C6]-glucose for
both βHB-CoA (5.1 ± 0.8%; p < 0.01) and HMG-CoA (10.3 ± 2.3%; p < 0.05) was
significantly lower than the M+2 labeling of βHB-CoA (8.5 ± 0.9%) and HMG-CoA
(16.7 ± 1.5%) in control platelets (Figure 7.3C-7.3E).
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7.4.2 Palmitate labeling
To determine if fatty acid metabolism is affected in FRDA, platelets were treated
with 100 µM [13C16]-palmitate for 1 h (Figure 7.1). This also made it possible to monitor
the butyryl-CoA pathway for the formation of M+4 isotpologues of βHB-CoA and HMGCoA (Figure 7.2). Analysis of [13C]-isotopic enrichment in acyl-CoAs revealed that
labeling from [13C16]-palmitate into the Krebs cycle occurred as we had shown previously
(74). In control platelets, the M+2 incorporation into acetyl-CoA was 22.0 ± 1.9% and for
succinyl-CoA was 20.6 ± 2.0%. However, unlike incorporation from [13C6]-glucose into
these Krebs cycle acyl-CoA thioesters there was no significant difference in
incorporation of [13C16]-palmitate between FRDA and control platelets (data not shown).
Direct thiolase-mediated formation of HMG-CoA from acetyl-CoA (Figure 7.2) resulted
in substantial incorporation of [13C16]-palmitate into M+2 for both βHB-CoA (14.9 ±
0.7%) and HMG-CoA (23.4 ± 1.6%) in control platelets (Figure 7.4A, 7.4B). In contrast
to the [13C6]-glucose results, there was a significant increase rather than a decrease in
M+2 labeling from [13C16]-palmitate for βHB-CoA (21.6 ± 1.4%; p < 0.001) compared
with controls (Figure 7.4A, 7.4C). There was also increased incorporation of [13C16]palmitate into M+2 of HMG-CoA (29.8 ± 4.1%), although this did not reach statistical
significance when compared with controls (23.4 ± 1.6%) (Figure 7.4B). There was also
significant incorporation of [13C16]-palmitate into M+4 of βHB-CoA (18.5 ± 2.2%) and
HMG-CoA (4.8 ± 0.8%) in control platelets (Figure 7.4B, 7.4C), through the second
pathway involving intermediate formation of [13C4]-butyryl-CoA (Figure 7.2).
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Interestingly, incorporation of [13C16]-palmitate into M+4 for HMG-CoA in
FRDA platelets (13.3 ± 1.5%; p < 0.001) was significantly increased when compared
with controls (4.8 ± 0.8%) (Figure 7.4B, 7.4C). However, the incorporation of [13C16]palmitate into M+4 of βHB-CoA in FRDA platelets (18.5 ± 2.2%) was almost identical
with that observed for controls (Figure 7.4A). This unexpected finding suggests that there
is compartmentalization of some of the metabolites and that the pool sizes of these
individual compartments dictate the actual incorporation.
7.4.3 Correlation with GAA repeat length
The decrease in M+2 acetyl-CoA labeling from [13C6]-glucose in FRDA platelets
showed a negative correlation (r2 = 0.39; r = 0.625; p = 0.054) with GAA repeat length
(Figure 7.5A), a genetic marker of disease severity for FRDA (187). Analogously, the
increased labeling into βHB-CoA (M+2) from [13C16]-palmitate demonstrated a positive
correlation (r2 = 0.51; r = 0.717; p = 0.020) with GAA repeat length (Figure 7.5B).
7.4.4 Sensitivity and specificity
Generation of a ROC curve by combining decreased M+2 labeling into acetylCoA from [13C6]-glucose and increased M+2 labeling into βHB-CoA from [13C16]palmitate revealed an area under the curve of 0.89 (95% CI; 0.73-1.00) (Figure 7.6). This
combination of biomarkers gave high sensitivity and specificity (> 80%) under a wide
range of scenarios as a result of the precision and accuracy with which the isotopologue
analyses could be conducted. A sensitivity of 80% and specificity of 100% was observed
at the optimal cut-off value for the current samples. These data provide confidence that
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the methodology will provide a useful biomarker reflecting the biochemical abnormalities
of FRDA and the potential response of dysfunctional metabolic pathways to therapy.
7.5 Discussion
We have recently shown that isolated human platelets can serve as a platform for
metabolic studies (74). Platelets have been used previously to assess the activity of
serotonin selective reuptake inhibitors (188) as well as a model for assaying glutamate
uptake in PD (189). Several studies have also used platelets to assay the activity of the
electron transport chain in multiple neurological diseases (190). In addition to the benefit
of a relatively non-invasive sample collection and isolation, platelets are mitochondriarich and maintain metabolic activity if properly isolated (74,191). Since inherited
metabolic diseases often affect metabolism globally, we reasoned that platelets could
serve as a surrogate diagnostic tissue for inherited metabolic diseases such as FRDA if
these pathways are utilized in platelets. Furthermore, isolated platelets allow for more
complex metabolic challenges than are possible in other in vivo assays (74).
In the present study, we have shown that FRDA platelets exhibit differential
mitochondrial metabolism when compared to healthy controls. Many biomarker studies
focus on absolute quantification of analytes to monitor phenotypic differences. A critical
shortcoming of such approaches is the need for external normalization, which often
introduces a significant degree of variability. While LC-MS analysis utilizing stable
isotope internal standards controls for variability introduced during sample processing
and analysis (20), either volume, cell count, protein quantity, or factor normalization is
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required for biological normalization. Isotopologue analysis of samples treated with
isotopic tracers circumvents the need for external standardization because the relative
levels of isotopic incorporation are normalized to the total analyte signal within a given
sample. Thus, the ability to conduct isotopologue assays, which do not require external
normalization, simplifies the workflow and removes steps that can introduce high levels
of variation. Working with isolated platelets reduces the potential of diluting the isotopic
purity of a tracer by highly abundant and variable endogenous metabolites such as blood
glucose. This approach is particularly relevant to promising strategies that systemically
increase frataxin levels as it can provide a biomarker showing that frataxin increases are
biologically active through normalization of the Krebs cycle and related metabolic
pathways.
The decreased conversion of glucose to acetyl-CoA (Figure 7.3A) is consistent
with studies that have shown diminished pyruvate oxidation in FRDA (192). The lack of
a compensatory pathway to acetyl-CoA from fatty acid β-oxidation suggests that
decreased histone acetylation could occur in FRDA through decreased co-factor
availability similar to our recent observation in tumor cells (9). This finding is also
consistent with epigenetic silencing of frataxin expression that occurs in FRDA (193) as a
result of the GAA expansion (176,194), which results in increased DNA (195,196) and
histone methylation (197) at the expense of histone acetylation. Decreased glucose
utilization in FRDA platelets also results in decreased labeling of succinyl-CoA,
suggesting that without some compensatory metabolic change there could be downregulation of protein succinylation in FRDA through decreased co-factor availability. The
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exact biochemical consequences of decreased protein succinylation have yet to be
determined, although isocitrate dehydrogenase, an important Krebs cycle enzyme, is
succinylated (127). The decreased M+2 labeling of acetyl CoA in FRDA platelets (Figure
7.3A) also resulted in decreased incorporation of glucose into βHB-CoA (Figure 7.4A)
and HMG-CoA (Figure 7.4B), important intermediates in the formation of D-βhydroxybutyrate (ketone body), sterols, and prenylated proteins. It appears that the
increased β-oxidation of fatty acids can overcome these defects but cannot compensate
for the reduction in acetyl-CoA and succinyl-CoA formation. Based on our results,
multiple metabolic pathways dysregulated in FRDA can be monitored using platelets
from affected patients as biomarkers. Two of the isotopologue biomarkers, percent M+2
labeling of acetyl-CoA from [13C6]-glucose and percent M+2 labeling of βHB-CoA from
[13C16]-palmitate, correlated with the severity of the disease (Figure 7.5A, 7.5B).
Importantly, the ROC curve obtained by combining two of these biomarkers had an AUC
of 0.89 (Figure 7.6).
The β-oxidation of fatty acids results in the removal of contiguous two carbon
units from the fatty acyl substrate and produces one molecule of FADH2 together with
one molecule of NADH (19). These reduced cofactors can be utilized to maintain the
electrochemical gradient across the inner mitochondrial membrane required for ATP
production. Therefore, the increased lipid metabolism observed in the FRDA could play
an important role in cellular homeostasis in times of mitochondrial dysfunction. Taken
together, these results suggest FRDA platelets exhibit a diminished capacity for oxidative
phosphorylation, as decreased glucose labeling into acetyl-CoA occurs in response to
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pharmacologic inhibition of mitochondrial complex I (26). Cell culture studies have
shown increased β-oxidation of lipids in response to diminished complex I activity (19),
supporting the notion that lipid breakdown plays an important compensatory role in times
of mitochondrial dysfunction. It is also consistent with the loss of mitochondrial complex
I function that has been identified in FRDA (180). Here, we have shown that there is a
shift in metabolism toward production of βHB-CoA and HMG-CoA from palmitate in
FRDA platelets.
Cardiac muscle is highly dependent on fatty acids for its energy needs (198), and
would therefore likely be one of the most susceptible tissues to alterations in lipid
metabolism in FRDA. Cardiovascular events (173,175) are among the most serious lifelimiting conditions in patients with FRDA. Therefore, pharmacologic or dietary
interventions to help amend such metabolic abnormalities could have therapeutic
benefits. For example, medium-chain fatty acids (MCFAs) are able to enter mitochondria
independently of the carnitine shuttle system (199), making them readily available in
times of metabolic stress. In addition to increased lipid oxidation, complex I inhibition
also induces a dramatic decrease in medium-chain acyl-CoAs (19). Up-regulation of the
medium-chain acyl-CoA dehydrogenase has been implicated in FRDA (200), suggesting
a possible connection with MCFA metabolism. It remains to be seen if MCFAs play a
defining role in energy metabolism in FRDA, as other metabolic pathways are likely
influenced in FRDA.
Patients with FRDA have variable numbers of GAA repeats in intron 1 of the
frataxin gene, which causes epigenetic silencing that results in decreased frataxin mRNA
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and protein expression (194). One pathway of epigenetic silencing arises through upregulation of histone lysine methyltransferases resulting in increased methylation of
specific lysine residues on histone tails (e.g., H3K9) and inhibition of frataxin gene
transcription (197). Co-silencing of the nrf-2 gene might occur in FRDA through a
similar mechanism, which would explain the paradoxical reduction of nrf-2 expression in
FRDA (197). The reduction in nrf-2 protein expression in FRDA suggests that there
would be a reduced ability to mount an antioxidant response. However, urinary 8-oxo-2’deoxyguanosine (201) and isoprostane F2α (202), which are the best validated in vivo
biomarkers of oxidative stress (203,204), are indistinguishable between patients with
FRDA and unaffected controls. Furthermore, the antioxidant therapies that have been
tested to date have not significantly improved outcomes in FRDA (205). These findings,
coupled with the reduced levels of frataxin in patients with FRDA, have stimulated an
alternative strategy to overcome epigenetic silencing of the frataxin gene, which has
involved the use of interferon γ, erythropoietin, nicotinamide, and histone deacetylase
inhibitors (174,205,206). Consequently, methods for quantifying frataxin protein and
mRNA expression have been developed as biomarkers to monitor these new therapeutic
approaches (207,208). Other biomarkers of FRDA to monitor the efficacy of novel
therapeutic strategies, such as iron chelation with deferiprone (209), include MRI (210),
glucose tolerance (211), and ataxia rating scales with performance measures (201). None
of these likely has the sensitivity of the approaches tested here.
7.6 Conclusion

166

In summary, we have shown that treatment of isolated platelets with isotopic
tracers coupled with isotopologue analysis by LC-MS can be used to characterize
metabolic alterations that are central to cellular metabolism. Platelets from patients with
FRDA exhibited metabolic abnormalities that fit with the suspected phenotype of
impaired mitochondrial function. Importantly, our findings suggest that in addition to the
Krebs cycle, shifts in lipid metabolism may be an important mechanism implicated in
FRDA. The biomarker methodology developed here will be useful in future studies of
novel therapeutic agents designed to up-regulate frataxin protein as an important
complement to the protein and mRNA biomarker analyses that have already been
developed. Finally, the concept of using platelets as metabolic biomarkers is not limited
to FRDA, but may be useful for disease detection for inborn errors of metabolism as well
as for other diseases of mitochondrial dysfunction.
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Chapter 8: Summary and future directions

8.1 Summary
This thesis research has resulted in new LC-MS methodology enabling a more
complete and rigorous view of cellular metabolism than was previously possible. In
particular, an ion-exchange based SPE cleanup allows for profiling of short, medium, and
long chain acyl-CoA species. Further, a novel application of PFB derivatives coupled
with LC-ECAPCI-MS/MS analysis enables enantiomer-specific quantification of 2-HG.
In addition to these improvements by both extraction and chemical derivatization, our
group has successfully generated a panel of isotopically labeled acyl-CoAs at high
efficiency, which greatly enhances the reliability of acyl-CoA thioester analysis, a
previously challenging endeavor in the field.
By utilizing these tools in cell culture models, I have identified formerly unknown
metabolic adaptations in response to the mitochondrial complex I inhibitor rotenone. βoxidation of fatty acids was shown to support acetyl-CoA levels in times of decreased
glucose utilization. Furthermore, glutamine was shown to support acetyl-CoA levels for
lipogenic purposes through both oxidative and reductive metabolism. An important note
is that these metabolic adaptations identified here are suggested to serve a compensatory
role and may therefore represent a novel target for therapeutic approaches through
approaches such as dietary supplementation of highly consumer precursors. Although
less well understood, the observed increased levels in (S)-2-HG in response to rotenone
are likely to have important downstream biochemical impacts, though elucidating these
factors is beyond the scope of the work presented here.
168

In addition to the cell culture studies, I have also developed and employed a novel
platelet assay (based on the analytical advances that I have contributed to) for detecting
metabolic abnormalities in FRDA, an inherited genetic disease. Excitingly, the findings
from our clinical approach are in agreement with our rotenone work, whereby increased
lipid oxidation seems to compensate for decreased glucose utilization. This agreement
indicates that diminished complex I activity may be a factor in FRDA, a concept that is
supported by data in the literature.
8.2 Future directions
Our ability to use a biological system to generate isotopically labeled complex
metabolites to be used as internal standards has greatly improved the analytical capacity
of our group. It is important to note that although this work is currently limited to CoAs
derived from pantothenic acid, in principle other classes of compounds can be
manipulated in the same fashion. For example, carnitine is derived from the amino acids
lysine and methionine, affording the opportunity to supplement these precursors in an
isotopically labeled form. In this manner it should be possible to generate panels of
isotopically enriched acyl-carnitines, which might lend further insight into cellular
metabolism. The carnitine shuttle is the primary mechanism for fatty acid import into
mitochondria for subsequent oxidation and likely plays a role in times of mitochondrial
dysfunction. Although our group does not specialize in working with yeast, it should be
possible to obtain lines engineered such that they are dependent on any range of external
nutrient supplies which can then be exploited. Our work therefore lays the groundwork
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for many other potential products, which could eventually generate libraries of internal
standards for MS analysis.
Although the focus of these studies has been on rotenone and its link with PD,
there are other xenobiotics that can be used to address similar questions. For example,
studies have shown that paraquat is also able to induce a Parkinsonian phenotype and
selective dopaminergic cell death. Although generally thought to act by redox cycling
and inducing oxidative damage, it is possible that paraquat may induce similar metabolic
phenotypes as rotenone. If so, identifying a common metabolic link between these two
compounds independent of ROS generation would further support a metabolic
component to PD. It is noteworthy that paraquat (and some toxicologically similar
compounds) are thought to require an activation step, whereby it is first metabolized to
the active toxicological entity by monoamine oxidase, present in only dopaminergic
neurons. In this situation a true neuronal dopaminergic model may be required to assess
relevant metabolic adaptations.
Use of a true dopaminergic neuronal model will afford the opportunity to study
other important metabolic pathways in a more relevant system. First, one phenomenon
observed in models of PD is increased dopamine turnover. As dopamine is a catecholcontaining molecule, chronically up-regulated levels may induce oxidative stress,
especially with co-occurring metabolic lesions that reduce endogenous anti-oxidant
capacity. Second, the first step of dopamine synthesis occurs by the enzyme tyrosine
hydroxylase. Thus, tyrosine (or phenylalanine, which is an essential amino acid) serves as
the precursor for all dopamine synthesis, and may exist in competition for substrates with
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other pathways involved in neuronal maintenance and function. Lastly, an alternative
pathway of tyrosine metabolism results in the production of fumarate and acetoacetate
from a single molecule of tyrosine. Therefore, eight carbons can be incorporated into the
Krebs cycle for energetic purposes, making tyrosine a high energy-yielding substrate in
times of increased energetic demand. It is possible then that in times of impaired
mitochondrial function tyrosine oxidation leading to the Krebs cycle serves an important
compensatory role in the same manner that palmitate does (Figure 5.2B). If this were the
case, dopamine synthesis would likely be impacted, and one response may be the
observed increased dopamine turnover. Therefore, interrogating alterations to tyrosine
metabolism and dopamine synthesis in response to rotenone may prove very informative.
If this model is proven to be correct, supplementation of high levels of tyrosine in the diet
may prove beneficial, not unlike the administration of L-dopa, a downstream
intermediate in dopamine synthesis, as is the current regimen for PD patients.
I have identified previously unknown metabolic defects in FRDA. Although
promising, the data generated thus far is limited in sample size (n=10). Current efforts are
underway to expand the cohort within the study in hopes of validating my findings across
a larger group of patients. In addition to characterizing metabolic abnormalities relative
to controls, our group is now part of an ongoing clinical trial with Reata Pharmaceuticals
in an attempt to assess the biochemical impacts of a nrf-2 activator. This entails
performing the platelet labeling in patients before and after a twelve-week regimen in an
attempt to detect differences resulting from up-regulated antioxidant responses. In
addition to expanding the study groups themselves, we are also in the process of testing
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additional isotopic tracers to add to our current panel. Specifically, preliminary data
indicates that isoleucine catabolism is drastically up-regulated in FRDA, offering another
novel pathway to target in an effort to ameliorate symptoms. Finally, given the decrease
in medium chain acyl-CoA species in response to rotenone (Figure 5.1), we feel
interrogating medium chain fatty acid metabolism in models of FRDA may be an
important future aspect to this project.
As discussed previously, there is a clear link between mitochondrial dysfunction
and neuronal cell death, ultimately leading to neurodegenerative diseases. A shared
connection in this process is likely oxidative damage. However, as proposed and
demonstrated in this work, mitochondrial metabolism also seems to play a role. Because
mitochondrial dysfunction is not specific to any single neurodegenerative disease, it
seems that some metabolic phenotype may be central to this process. An interesting point
to consider in this framework is the biogenesis of CoA itself. Although the emphasis of
chapters 2 and 3 of this thesis were focused on generating isotopically labeled CoA
species with pantothenic acid, this pathway itself may be an important component to
metabolic deficiencies leading to neuronal cell death.
Although it is not the focus of this thesis, preliminary data from our group
indicates that the generation of CoA from pantothenic acid itself may be susceptible to
defects leading to disease pathogenesis. As described in the introduction, acyl-CoA
species are crucial to mitochondrial metabolism (Figure 1.1). Any defects in a biological
system in its ability to generate CoA would therefore have a detrimental impact on
cellular metabolism. This common connection across so many metabolic pathways may
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therefore account in part for the seemingly universal link between mitochondrial
dysfunction and subsequent neurodegeneration.
To support this concept, a very rare disease known as Hallervorden-Spatz
syndrome (HSS) is characterized by aberrations in the gene encoding the protein
pantothenate kinase (PANK2), which catalyzes the first and rate-limiting step of CoASH
biosynthesis via the phosphorylation of pantothenic acid. HSS manifests as an extremely
severe neurological phenotype, as would be expected from deficiencies in such a central
metabolic process. Although preliminary, utilizing the same model as chapters 5 and 6,
we have shown that rotenone inhibits the biosynthesis of CoA directly via isotopic
labeling from pantothenic acid (Figure 8.1). Specifically, M+4 labeling into multiple
acyl-CoA species from pantothenic acid is diminished in response to rotenone. This
unknown mechanism may be responsible in part for the neurodegenerative phenotypes
resulting from chronic rotenone exposure.
Unraveling the role of pantothenic kinase in neurodegeneration is being actively
pursued by our group. Current efforts are focused on synthetically generating the
commercially unavailable phosphorylated intermediates that make up CoA biosynthetic
precursors. Once available, a LC-MS method will be developed which will allow for the
full characterization of the impacts rotenone has on CoA biosynthesis. In addition, (R)hopantenate, a known inhibitor of pantothenate kinase, is also being synthesized, the
availability of which will allow us to characterize metabolic defects resulting from a
diminished capacity to generate CoA. Finally, to test if this mechanism is relevant in
multiple neurodegenerative models we are planning to utilize pantothenic acid as an
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additional tracer in our platelet studies with FRDA. It is worth noting that our group has
successfully labeled CoA species in platelets previously by employing the proposed
model.
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Figure 8.1: Rotenone decreases pantothenic acid labeling into acyl-CoA species.
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